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CHAPTER 1: INTRODUCTION 
 
1.1 BRCA Mutation Associated Cancers  
 
BRCA-1 (breast cancer gene 1) and BRCA-2 (breast cancer gene 2), found in human 
genes, are responsible in producing tumor suppressor proteins. These normal genes play 
important role in repairing DNA double-strand breaks via homologous recombination 
(HR), a mechanism that perfectly repairs any damaged DNA. The cytogenic locations 
of BRCA-1 (Figure 1.1) and BRCA-2 (Figure 1.2) are at 17q21 (Hall et al., 1990; Miki 
et al., 1994) and 13q12.3, respectively (Wooster et al., 1994, 1995). Mutations and 
alterations in the genes may result in genetic modifications that lead to increased risk of 
cancer development, such as breast cancer, ovarian cancer, prostate cancer and other 
cancers (Sloots, Ausems, & de Haan, 2002). Mutations in these genes have been logged 
for 30-50% of hereditary breast cancer (HBC) (Passaperuma et al., 2010), about 5-10% 
of other breast cancers (Campeau, Foulkes, & Tischkowitz, 2008), most hereditary 
ovarian cancers especially the high grade serous cancer (HGSC) type, and in 15% of 
prostate cancer in men (Fraser et al., 2014).  
 
Hereditary cancer is a cancer that develops from mutated genes of a biological parent 
to offspring inheritance. Gene mutation is heritable either from a mother or a father that 
is passed on to their sons or daughters, termed as germline mutations. Thus there is a 
50% chance for a child to inherit a mutated gene also makes them susceptible to 
develop colon cancer and pancreatic cancer (Judson & Van Le, 1998). As reported by 
the University of Cambridge in 2002, British women with BRCA-1 mutations aged 
above 70 have 36% and 28% are at risk in developing breast cancer and ovarian cancer. 
Similarly, a 69% chance of breast cancer development and a 17% chance for ovarian 
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cancer were reported for those who had BRCA-2 mutations. This figure is notably 
higher when compared with women of the same age group without BRCA mutation, 
with who are at 5% risk of developing breast cancer. This shows that individuals who 
are carriers of BRCA-1 and BRCA-2 mutations have a higher risk of developing breast 
and ovarian cancers relative to the general population (Antoniou et al., 2002). 
 
 
Figure 1.1. Cytogenic location of BRCA-1 (Försti et al., 2001). 
 
 
 
Figure 1.2. Cytogenic location of BRCA-2 (Försti et al., 2001). 
 
In men, carriers of the BRCA-2 mutations are more likely to have a higher risk for 
prostate cancer compared to carriers of BRCA-1 mutations. In addition, environmental 
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elements, non-genetic and genetic modifiers can also affect and promote this occurrence 
(Chung, 1996; Levy-Lahad & Friedman, 2007). In normal cells, homologous 
recombination (HR) pathway remains the primary mechanism for DNA repair. 
However, in tumor cells that contain dysfunctional BRCA, the PARP expression related 
to base excision repair (BER) mechanism is enhanced in response to DNA damage 
(Wesierska-Gadek et al., 2012). Evidently, it was shown that mutagenic cells were more 
sensitive towards PARP-1 inhibitors, compared to normal cells (Gandhi et al., 2010; 
Giannini et al., 2014). Judging from the mechanism and findings, synthetic lethality 
tactic would be a novel approach in cancer therapy. This is because single-strand breaks 
(SSBs), induced by accumulation of PARP inhibitors, increase double-strand breaks 
(DSBs) that would subsequently lead to cell death in tumor cells (Glendenning & Tutt, 
2011). 
 
 
1.2 Poly (Adenosine Diphosphate-ribose) Polymerase 
 
Poly (adenosine diphosphate-ribose) polymerase, PARP, discovered by Chambon 
and co-workers (Chambon, Weill, & Mandel, 1963), is a family of proteins involved in 
a number of cellular processes, including modulation of chromatin structure, 
transcription, replication, recombination and DNA repair. It comprises 18 putative 
members that have potential PARP activity (Figure 1.3). Per unit polymer, PARP 
proteins are made of 2 phosphates and 2 ribose moieties, where PARP-1 is the best 
understood protein (Weil & Chen, 2011). The main roles of PARP are in the DNA 
repair mechanism and regulation of transcription. Notably, PARP activity increases 
when DNA is damaged cause due to induced-radiation and DNA damaging agents 
(Morales et al., 2014). Normal cells use PARP to repair itself to maintain normal life 
4 
cycle. Unfortunately, cancer cells also act in a similar manner as normal healthy cells in 
using PARP to repair the damaged DNA. However, unlike normal cells, this makes the 
growth in cancer cells become uncontrollable. The NAD+ ADP-ribosyltransferase 1 
(PARP-1) and PARP-2 (Figure 1.4) are the only PARP family members that contain 
DNA-binding domains with PARP-1 as the main family member (Ame, Spenlehauer, & 
de Murcia, 2004). This would clinically be useful for the treatment of several cancers, 
especially breast, ovarian and prostate cancer  (Gagne, Rouleau, & Poirier, 2012).  
 
There are three structural domains that control the activity of PARP: DNA binding 
domain of N-terminal, which contains two zinc fingers that bind to the damaged DNA; 
an auto-modification domain containing BRCT protein-protein interaction and the C-
terminal catalytic region that contains the active site (Sodhi, Singh, & Jaggi, 2010). 
PARP-1 is an enzyme that is mainly involved in sensing, it assisting in repairing single-
strand breaks (SSBs) and is found to be active in the homodimer form. When DNA 
damage occurs, especially during single-strand breaks, the enzyme recognizes it and 
binds to the site of damage. Binding to the damaged site stimulates PARP-1 to catalyze 
the synthesis of polymers of the ADP-ribose (linear and branched) by using 
nicotinamide adenine dinucleotide (NAD+) as the substrate with the release of 
nicotinamide. The synthesized polymers are then transferred to acceptor proteins, which 
can be found in the PARP-1 itself or on other proteins mainly involved in the DNA 
repair (White et al., 2000). 
 
Through the base excision repair pathway (BER), PARP-1 signals and recruits other 
DNA repair proteins, such as the X-Ray cross complementing gene 1 (XRCC1), DNA 
ligase III (Lig III), DNA polymerase beta (pol β), and kinase to participate in the single-
strand break repair machinery (El-Khamisy et al., 2003; Ame, Spenlehauer, & de 
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Murcia, 2004; Penning et al., 2010). In normal and healthy cells, homologous 
recombination (HR) overpowers the DNA reparation, whereby this mechanism is 
potentially an error-free repair mechanism in conjunction with BRCA genes (BRCA1 
and BRCA2) (Rehman, Lord, & Ashworth, 2010). 
 
 
Figure 1.3. Structure of PARP (Source: Schreiber et al., 2006). 
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Figure 1.4. Structure of human PARP-1 and PARP-2 (Source: Kim, Zhang, & Kraus, 
2005). 
 
 
1.3 Dihydroorotate Dehydrogenase 
 
Dihydroorotate dehydrogenase (DHODH), is a mitochondrial enzyme that plays a 
crucial part in the de novo biosynthesis of pyrimidine bases (Fritzson et al., 2010). 
Through redox process, the enzyme catalyzes the oxidation conversion of 
dihydroorotate to orotate with the aid of the prosthetic group, flavin mononucleotide 
(FMN), and ubiquinone (CoQ) as co-factors (Evans & Guy, 2004; McLean et al., 2010) 
(Figure 1.5).  
 
 
Figure 1.5. Role of DHODH in the inner mitochondrial membrane. Reprinted with 
permission (Velez et al., 2013). 
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In the DNA and RNA syntheses, rapid proliferation of human T cells require the de 
novo biosynthesis of pyrimidines in strand-break repair, biosynthesis of membrane-lipid 
as well as in protein glycosylation (Liu et al., 2000). DHODH consists of two families, 
a cytosolic enzyme encoded in family 1, and an enzyme associated within the inner 
membrane of the mitochondrial, encoded as family 2. Family 1 DHODHs use fumarate 
and NAD as electron acceptors. In contrast, the family 2 DHODHs consist of the human 
DHODH (HsDHODH), and P. falciparum DHODH (PfDHODH) that rely on the 
respiratory chain function, and ubiquinone as the direct electron acceptor (Zameitat et 
al., 2007). Mutations in this gene cause Miller Syndrome, but it is unclear how the signs 
and symptoms lead to this phenomenon (Ng et al., 2010). 
 
 
1.4 PARP inhibitors 
 
PARP inhibitors are drugs that were designed to prevent the reparation of DNA 
damaged cancer cells by PARP proteins (Ame, Spenlehauer, & de Murcia, 2004). 
Evidently, PARP inhibitors showed both in vitro and in vivo anticancer effects in cells 
deficient of breast cancer associated genes (BRCA-1 and BRCA-2) at high sensitivity 
(Liu, Konstantinopoulos, & Matulonis, 2014; Powell et al., 2010). Furthermore, 
anticancer activities were also observed in prostate cancer (Castro et al., 2013; Levy-
Lahad & Friedman, 2007) and ovarian high-grade serous cancer (Liu, 
Konstantinopoulos, & Matulonis, 2014). In addition, therapeutic benefits of PARP 
inhibitors were also reported for many other diseases, such as in ischemic kidney 
disease, ischemic liver disease, ischemic-reperfusion disorder, myocardial infarction, 
hemorrhagic shock, inflammatory lung disease, stroke, spinal cord trauma, and colitis 
(Graziani & Szabo, 2005; Lord et al., 2009).  
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By inhibiting base excision repair with PARP inhibitors, reparation of single strand 
breaks, caused by cytotoxic chemotherapy and ionizing radiation is halted. Therefore, 
formation of double strand breaks occurs, as DNA replication at the forks of single 
strand breaks is stalled. Subsequent repair of the accumulative double strand breaks is 
also stunted due to faulty homologous recombination (HR) pathway in the mutated 
BRCA cells leads to cell death, creating synthetic lethality effect (Scarpelli et al., 2010; 
Weil & Chen, 2011; Liu, Konstantinopoulos, & Matulonis, 2014). 
 
An alternative DNA repair pathway that exerts anticancer mechanism is called non-
homologous end joining (NHEJ), an error prone repair mechanism. Homologous 
recombination (HR) cell death is increased by phosphorylation of catalytic subunit 
enzyme known as DNA-dependent protein kinase (Park et al., 2009; Peng et al., 2014). 
Trapping PARP-1 and PARP-2 in the PARP enzyme with PARP inhibitors producing 
DNA-PARP complexes showed potential DNA replication disturbance (Murai et al., 
2012). The use of PARP inhibitors as competitive inhibitors is through blocking the 
NAD+ in the active site of the PARP enzyme to obtain 90% inhibition, is ideal for DNA 
reparation obstruction (Scarpelli et al., 2010; Weil & Chen, 2011; Giannini et al., 
2014).  
 
It is discovered that PARP inhibitors can be used as a single agent, or in combination 
therapies (Giannini et al., 2014). As a result of its potential therapeutic effect, these 
small molecule inhibitors sparked interest in various organisations to fight cancer at the 
DNA level (Tong et al., 2009). Classical PARP inhibitors, such as nicotinamide (Clark, 
Ferris, & Pinder, 1971) and 3-aminobenzamide (Cosi, 2002) were tested and reported to 
be low in potency, limited cellular resistance time and cell uptake, and showed non-
specific effects. Thus, newer versions of PARP inhibitors, consists of benzimidazole 
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core, primary amide and lactam components, were disclosed by Alex W. White and co-
workers (White et al., 2000) with relatively small scaffold and high intrinsic potency 
(Peninng et al., 2008). This was mainly due to the network of hydrogen bond 
interactions and π–stacking that structurally mimics the binding mode of nicotinamide 
inside the binding site of PARP-1 (Tong et al., 2009). These inhibitors showed 
improvement in inhibition in terms of potency and specificity. One example is veliparib 
(ABT-888), which has a carboxamide attached to a benzimidazole (Sodhi et al., 2010), 
that will be described in the following section. 
 
 
1.5 DHODH inhibitors 
 
DHODH inhibitors are a class of drugs that exhibit immunosuppressant (Lolli et al., 
2012) and anti-proliferative effects on rapidly dividing cells for the treatment of cancer, 
rheumatoid arthritis and multiple sclerosis (Sutton & Clardy, 2006; Erra et al., 2009; 
McLean et al., 2010) as well as for the prevention of transplant rejection (Breedveld & 
Dayer, 2000). The effects of these inhibitors were shown to be the most pronounced 
during thymus cell (T-cell) proliferation, (Leban et al., 2004; Baumgarnet et al., 2009; 
Davies et al., 2009). DHODH inhibitors were designed and developed responsibly to 
block the pyrimidine biosynthesis that converts dihydroorotate to orotic acid through 
oxidation process, resulting in the depletion of pyrimidine nucleotides. This would lead 
to the inhibition of DNA and RNA syntheses, as well as arresting cell proliferation 
(Herrmann, Schleyerbach, & Kirschbaum, 2000). During proliferation, approximately 8 
folds of pyrimidine pool in activated lymphocytes are expanded, while an increase for 
purine pools is only 2 folds. The demand for both de novo and salvage pathways 
increases as the requirement for nucleotides increases, subsequently suppressing the 
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immune system (Breedveld & Dayer, 2000). There are several DHODH inhibitors that 
reached clinical development such as Brequinar, Leflunomide and its active metabolite 
Teriflunomide, but failed in clinical trials due to its inadequate therapeutic evidence 
(Lolli et al., 2012).  
 
 
1.6 Veliparib 
 
Veliparib (ABT-888) is one of the well known PARP inhibitors that inhibits PARP-1 
and PARP-2 at Ki = 5.2 nM and 2.9 nM, respectively. It was discovered and developed 
by Abbot Laboratories (Scheme 1.1) and has a decent oral bioavailability where the 
efficacy and potency of the drug were shown both in vivo and in vitro (Zhu et al., 2006). 
 
 
Scheme 1.1. Synthesis of Veliparib. 
 
Furthermore, this compound penetrated the blood-brain barrier in rat under 
pharmacokinetic (PKs) studies (Weil & Chen, 2011). In syngeneic and xenograft tumor 
models, veliparib potentiates a number of DNA damaging agents such as 
termozolomide, chemotherapy and radiation. On top of these, veliparib has interestingly 
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been reported to potentially act as a single-agent activity inhibitor. With these wide 
ranging therapeutic potentials, veliparib has entered Phase I and II clinical trials for 
various malignant solid tumors (Donawho et al., 2007; Palma et al., 2008; Weil & 
Chen, 2011). 
  
 
1.7 Brequinar 
 
Brequinar was first synthesized by DuPont Merck Pharmaceuticals by using 5-
flouroindoline-2,3-dione and 1-(2'-fluoro-[1,1'-biphenyl]-4-yl)propan-1-one as the 
starting materials, using Pfitzinger condensation method (Scheme 1.2) (Batt et al., 
1995).   
 
 
Scheme 1.2. Synthesis of Brequinar. 
 
It is a small molecular weight inhibitor for DHODH, which has gone through clinical 
development with an IC50 of 12 nM (Erra et al., 2011). Reports showed that brequinar 
has two major contributions in the binding of the family-2 DHODH at the highly 
variable tunnel of N-terminus site, which is polar and hydrophobic (Hurt et al., 2006). 
Originally, organ transplant rejection therapy was the main cause of the drug 
development, but directions towards cancer therapy were then pursued as brequinar 
showed potential immunosuppressive and antiproliferative activities by inhibiting 
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DHODH (Allison, 2000). Other potential applications exhibited by brequinar are for the 
treatment of rheumatoid arthritis (RA) and psoriasis (Batt et al., 1998). Unfortunately, 
this compound failed in clinical trials due to its narrow therapeutic window, where oral 
administration leads to toxic effects (Baumgartner et al., 2006).  
 
 
1.8 Benzimidazole 
 
Generally, benzimidazole (Figure 1.6) is an organic bicyclic hetero compound that is 
made up from the fusion of a benzene connected to 4th and 5th position of an imidazole 
ring (Tonelli et al., 2010). It is classified as amphoteric substance with its acid 
dissociation constant (pKa) value at 12.8 for benzimidazole and 5.6 for conjugate acid. 
It is also known as 1,3-benzodiazole that has both basic and acidic characteristics, 
whereby the presence of free NH group serves as both a strong acid and a weak base. 
Another feature of this benzimidazole is its capability of forming salt formation 
(Wright, 1951). 
 
 
Figure 1.6. Structure of benzimidazole. 
 
The first benzimidazole synthesis was discovered by Hobrecker in 1872 (Hobrecker, 
1872) where he obtained tautomers of 2,5- and 2,6-dimethylbenzimidazole, b, by 
reducing 2-nitro-4-methylacetanilide, a (Scheme 1.3), and found this scaffold to be a 
pre-eminent structure (Gaba, Singh, & Mohan, 2014). 
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Scheme 1.3. Synthesis of benzimidazole by Hobrecker in 1872. 
 
The hydrogen that is attached to the nitrogen at the first position is readily 
tautomerised as shown in Figure 1.7, where certain derivatives may appear, as isomers 
but are actually tautomers in reality. Isomeric form exists when larger groups compared 
to hydrogen are present, attached to the first position of the nitrogen. In addition, the 
hydrogen at the first position seems to be acidic enough to give N-metal benzimidazole 
compound which was first reported by Bamberger and Lorenzen and later by various 
other organizations with various metals (Wright, 1951).  
 
 
Figure 1.7. Tautomerisation of benzimidazole. 
 
In nature, N-ribosyl-dimethylbenzimidazole exists as the most prominent compound 
that serves as an axial ligand for cobalt in vitamin B12 (Ramanpreet et al., 2011). A 
general method for obtaining benzimidazole compounds is by reacting 1,2-
diaminobenzenes with carbonyl-containing compounds, such as aldehyde, carboxylic 
acid and others under strong acidic condition such as polyphosphoric acid, hydrochloric 
acid, p-toluenesulfonic acid or boric acid (Scheme 1.4). The use of Lewis acids, mineral 
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acids, or even inorganic clays in this reaction improved yield, as well as purity (Ingle & 
Magar, 2011).  
 
 
Scheme 1.4. General reaction of benzimidazole. 
 
The emergence of benzimidazole and its derivatives in medicinal chemistry may be 
accounted by their significantly privileged structures due to the diversity of the 
compounds in various therapeutic applications (Gong et al., 2014), such as antitumor 
(Wang et al., 2014), antiviral, anticancer, antimicrobial (Seenaiah et al., 2014), 
antihypertensive (Yang et al., 2014), anxiolytic (Chen et al., 2014), antihistaminic 
agents (Tonelli et al., 2010) and others. 
 
 
1.9 In-silico Design for PARP-1 and DHODH Enzymes Inhibitors 
 
Various organizations have independently reported extensive in-silico design for 
both PARP-1 and DHODH enzyme inhibitors. Back in the 1980’s, 3-aminobenzamide 
(IC50 = 30 µM), synthesized by Purnell and Whish, along with nicotinamide (IC50 = 210 
µM) as basic competitive inhibitor gave insights into the modern pharmacophore 
improvisation techniques for designing more potent PARP-1 inhibitors (Purnell & 
Whish, 1980). More refined work was further done by others, demonstrating that 
potency of PARP-1 inhibition would be beneficial by restricting the degree of freedom 
of amide moiety (Banasik & Ueda, 1994). Later on, imidazole and benzoxazole 
carboxamide were introduced by Griffin and Golding where intramolecular hydrogen 
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bond formed between the primary amide and the nitrogen of the imidazole, created a 
‘pseudo-ring’ (Griffin et al., 1995) benzimidazole carboxamide core, exhibiting 
improved potency (IC50 = 95 nM) (White et al., 2000). Langlier and Pascal reported on 
the role of PARP-1 to a damaged DNA by utilising the zinc fingers as detectors, based 
on crystal structure (Langelier & Pascal, 2013). X-ray co-crystal structure of PARP-1 
with known PARP inhibitors, such as nicotinamide, 3-aminobenzamide and veliparib 
(ABT-888), showed similar H-bond networks as the substrate of NAD+ in the 
nicotinamide binding pocket, as shown in Figure 1.8 (Zhu et al., 2013). 
 
 
Figure 1.8. Interactions of NAD+ in the active site of PARP-1 enzyme. Hydrogen bonds 
are shown in dashed lines.  
 
The key interaction is the three hydrogen bonds donors-acceptors, formed between 
the carboxamide group of the inhibitor core and two amino acids designated Ser-904 
and Gly-863, in the catalytic domain of PARP-1 (Ferraris et al., 2003). In addition, π- π 
stacking interaction with Tyr-907 was also involved (Penning et al., 2008). In some 
cases, conserved water molecule may or may not act as a H-bond mediator between 
Glu-988 and inhibitor (White et al., 2000; 2004). Increment of the inhibitor potency was 
due to a certain location of the heteroatom in the benzimidazole scaffold, creating 
network with the residue (Ferraris et al., 2010). Another interesting feature of the NAD+ 
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binding pocket is the advantageous adenine-ribose binding site. It is a large hydrophobic 
pocket that is adjacent to the nicotinamide binding site where improvement in 
solubility, potency and other pharmacology properties can be further exploited for 
improvement (Kinoshita et al., 2004). 
 
In the case of DHODH, particularly for human DHODH (HsDHODH), brequinar, 
leflunomide and teriflunomide (A771726) exhibited immunosuppressive and 
antiproliferative activities (Kim, Na, & Löffler, 2003; Cowen et al., 2010). Later on, 
these compounds were further developed for use as cancer therapy. However, they 
failed in clinical trials due to limited therapeutic potentials (Davies et al., 2009). 
Nonetheless, leflunomide has been marketed for more than 10 years for the treatment of 
rheumatoid arthritis treatment (Munier-Lehmann et al., 2013). Brequinar, however is a 
known non-competitive inhibitor for DHODH (Breedveld & Dayer, 2000).  
 
The first co-crystallization of HsDHODH complexed with brequinar analogue 
inhibitor, was reported in August 2000 (Liu et al., 2000). The HsDHODH consist of 
two domains, a small N-terminal and a C-terminal that are connected by an extended 
loop. The location of brequinar and its analogue in the HsDHODH were located in the 
ubiquinone binding site where polar and hydrophobic predominant promotes to the 
binding (Fritzson et al., 2010). The head-group structure of brequinar, 6-flouro-3-
methyl-4-quinoline carboxylic acid binds deep in the polar region and the aromatic 
rings, the tail-end extends out in the hydrophobic region of the binding site (Liu et al., 
2000). The key interaction between the inhibitor and the enzyme is the carboxylate 
group of the quinoline, creating well oriented H-bonds to Arg-136 residue. In addition, 
hydrogen bond between Gln-47 and the carboxylate were also found. Hydrophobic 
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contacts between nine residues and the biphenyl ring of the inhibitor were also observed 
in Figure 1.9 (Baumgartner et al., 2006). 
 
 
Figure 1.9. Brequinar analogue binding mode in human DHODH showing the 
contributing residues in the binding site. Cyan residues show electrostatic interaction, 
Green stick residues represent hydrophobic interactions and light blue indicates 
aromatic stacking. 
 
The inhibitor binding site shows amphipathic features. Entrance of the cavity mostly 
consists of hydrophobic amino acids and polar surroundings at the inner end of the 
cavity with Val-143 and Val-134 forming small hydrophobic pocket (Baumgartner et 
al., 2006; Hurt et al., 2006). The natural substrate, ubiquinone, also binds in the same 
region that the head group very well overlays each other, thus showing a similar binding 
mode (Liu et al., 2000). 
 
In this work, in-silico design has been proposed and carried out by Aurigene 
Discovery Technologies Limited, Bangalore, India. Using veliparib and brequinar as 
reference for PARP-1 and DHODH inhibitors, respectively, Aurigene has developed a 
series of compounds that retains the benzimidazole as basic scaffold, and generated new 
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pharmacophore features at the second, fourth and sixth position of the scaffold, essential 
for inhibition improvement. Starting from 2-([1,1'-biphenyl]-4-yl)-1H-benzoimidazole-
4-carboxamide, I1 (Thunuguntla et al., 2010), the compound was docked with the 
binding mode resemblance to brequinar (Figure 1.10) and an IC50 value of 0.75 µM. 
 
 
Figure 1.10. Binding mode of compound I1 in DHODH (pdb ID: 41GH) showing 
interactions with Arg-136 and Gln-47. Also a water mediated interaction with Thr-360 
is observed. 
 
This result postulates the consistency of what other organizations have proposed and 
reported. The latter (compound I1) were then optimized for better potency and drug 
properties for both PARP-1 and DHODH. 
 
 
1.10 Scope and objective of this thesis 
 
Due to its vast prominent features in medical treatment in various diseases, 
benzimidazole based compounds have been the object of many studies for more than 
three decades. Amongst the activities shown by these compounds are included 
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anticancer, antihypertensive and immunosuppressive effects. Nonetheless, other 
scaffolds also showed potential therapeutic benefits towards the same goal. Known 
compounds have reached clinical trials but failed due to limited therapeutic window, 
and there are no natural products, which are reported as potent inhibitors for PARP and 
DHODH enzymes. The aim and objectives of this study are as follow: 
 
I. Design and synthesis would be an alternative way to explore new compounds to 
generate hits-to-lead since treatment at the level of DNA would notably be worth 
investigating.  
II. No reports up to now showed dual inhibition of these two enzymes. Thus, the aim 
is to develop compounds with better potency to enhance the drug properties.  
III. The objective of present study is to design and synthesise a series of 
benzimidazole compounds as dual inhibitors of PARP-1 and DHODH enzymes 
and to investigate their therapeutic activities. 
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CHAPTER 2: SYNTHESIS OF BENZIMIDAZOLE 
 
2.1 Introduction to Benzimidazole Synthesis 
 
As described in the earlier chapter, benzimidazole shows a wide range of therapeutic 
effects in other applications, such as fungicide-pesticide (Ma, Yoshimura, & 
Michailides, 2003; Boubaker, 2008; Malandrakis, Markoglou, & Ziogas, 2011), and as 
anthelmintic (Baliharová et al., 2003; Ancheta et al., 2004). Hence, there are many 
works that have been carried out by various organisations to develop more potent and 
diversified benzimidazole derivatives. 
 
The first benzimidazole compound was synthesised by Hobrecker (Hobrecker, 
1872). Currently, there are several methods that are commonly used to produce 
benzimidazole; condensation reaction between 1,2-diaminobenzene as starting material 
with a carboxylic acid or an aldehyde, Schiff bases, pseudo bases and others (Wright, 
1951).  
 
Unfortunately, condensation reaction between 1,2-diaminobenzene as starting 
material with either a carboxylic acid or an aldehyde had their disadvantages. For the 
coupling of 1,2-diaminobenzene with a carboxylic acid, strong acidic condition and 
high temperature are required. While condensation of 1,2-diaminobenzene with 
aldehyde involves dehydration, requires stoichiometric amount of oxidising agent. 
Often, regioisomers and disubstituted side products are obtained from this reaction 
(Kim et al., 2011). Over the years, the synthesis of benzimidazole have evolved and 
expanded with little modification to produce higher product yield, shorter reaction time 
and better selectivity of the scaffold. 
21 
Scheme 2.1 shows a reported one-pot synthesis of 2H-benzimidazole derivatives, 
using heterocyclic 2-nitroamines as substrate, and iron as the reductant (Hanan et al., 
2010). 
 
 
Scheme 2.1. General method for a one-pot synthesis of aromatic and heteroaromatic 2-
nitroamines to bicyclic 2H-imidazoles (Hanan et al., 2010). 
 
In this method, formic acid, in combination with isopropanol was used as the solvent 
and the formic acid acts also as the source of methylene for Phillips cyclisation to occur. 
Optimum condition were established using 10 equivalents of iron and 10 equivalents of 
ammonium chloride, as additive to reduce the nitro group, to produce more than 95% 
pure product, following an aqueous workup with no further purification (Hanan et al., 
2010). 
 
Nannapaneni and co-workers reported the synthesis of benzimidazole using 
ammonium chloride, an inexpensive and commercially available compound as catalyst, 
in the condensation of 1,2-diaminobenzene and an aldehyde to give excellent yield 
under ambient temperature as shown in Scheme 2.2 (Nannapaneni et al., 2010). 
 
 
Scheme 2.2. Synthesis of 2-arylbenzimidazole catalyzed by ammonium chloride. 
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Solvent and catalyst-free redox reaction between aliphatic amine and ortho-
amine/mercaptan/hydroxyl anilines were developed by Nguyen Thanh Binh and co-
workers in their effort to develop a “green” condition to produce benzazoles. Here, 
elemental sulfur was used as traceless oxidising agent under moderate temperature 
(Scheme 2.3) (Nguyen et al., 2012). 
 
 
Scheme 2.3. Benzazole general reaction with elemental sulfur as traceless oxidising 
agent. 
 
Sulfur was chosen as the oxidising agent in place of oxygen due to its low reactivity 
at ground state, as well as for being non-toxic, readily available, and stable under 
normal conditions with low explosion rate. In addition, chemoselectivity was observed 
in the reaction although no metal catalyst was involved. This oxidative coupling 
reaction to form benzimidazole provided moderate to excellent yield (70-92% isolated 
yield) which is advantageous for large scale synthesis, presumably with lower 
environmental pollution (Nguyen et al., 2012). 
 
Jinsong Peng and co-workers (Peng et al., 2011) developed an intramolecular N-
arylation reaction to construct the benzimidazole scaffold through a C-N cross coupling 
reaction catalysed by copper instead of the more expensive palladium, or the highly 
toxic nickel as the catalyst. Five mol percent of catalyst loading in combination with 
1,2-bis(methylamino)ethane (DMEDA), and 2 equivalents potassium carbonate in water 
at 100oC was found to be optimum to produce the benzimidazole in relatively good 
yield (Scheme 2.4). 
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Scheme 2.4. Copper catalyzed benzimidazole formation in base-aqueous condition. 
 
The use of water in this reaction, along with the cheap copper catalyst provides 
environmental and economical advantages for the production of large number of 
benzimidazole libraries (Peng et al., 2011). 
 
Another convenient method to produce benzimidazole was reported by Penning and 
co-workers, Tong and co-workers and Xue and co-workers through a peptide coupling 
reaction. Reaction of the 2,3-diaminobenzamide with carboxylic acid and 1,1'-
carbonyldiimidazole (CDI) as the coupling reagent, followed by acid-promoted 
cyclisation under reflux (Scheme 2.5), gave good to excellent yield of the 
benzimidazole product (Penning et al., 2008, 2009, 2010; Tong et al., 2009; Xue et al., 
2011). 
 
 
Scheme 2.5. Benzimidazole synthesis from peptide coupling. 
 
In a similar approach, benzimidazole was synthesised by Jufang H. Barkalow and co-
workers (Scheme 2.6), by reacting 1,1'-carbonyldiimidazole (CDI) with 1-methyl-2-
pyrrolidone (NMP) and piperidine acid to produce acylimidazole, which was 
subsequently combined with 2,3-diaminobenzamide under moderate heat to give the 
H
N
NH
R1
X
R2
H
N
R1R2
N
5% mol Cu2O
10% mol DMEDA
K2CO3, H2O
100oC, 30 h
X = Cl, Br, I
CONH2
NH2
NH2
HOOC R1
CONH2
NH2
N
H
O
R1
CONH2
N
N
H
R1
CDI
DMF:Pyr
AcOH
reflux
24 
hydrochloride salt amide intermediate with excellent yield and high purity. The salt then 
underwent cyclisation under water-acetic acid condition to give the succinate salt of 
benzimidazole which was then crystallized with isopropyl acetate-methanol (Barkalow 
et al., 2007). 
 
 
Scheme 2.6. Synthesis of 2-(1-Propyl-4-piperidinyl)-1H-benzimidazole-4-carboxamide 
Succinate Salt via the acylimidazole route (Barkalow et al., 2007). 
 
In another approach, acylation of methyl 2,3-diaminobenzoate with an acid chloride 
in the presence of tertiary amine and 4-dimethylaminopyridine (DMAP) as the catalyst 
provides the intermediate A, which subsequently underwent cyclisation under acidic 
condition with acetic acid to give the desired benzimidazole B (Scheme 2.7) (White et 
al., 2000). However, this method was found to be inefficient and not applicable as a 
general route. 
 
 
Scheme 2.7. Acylation reaction towards benzimidazole synthesis. 
 
It was later modified by Weidenhagen using either 2,3-diaminobenzoic acid or 2,3-
diaminobenzamide with an aryl aldehyde as starting material and copper (II) acetate as 
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catalyst to give the benzimidazole product, as illustrated in route I in Scheme 2.8 (White 
et al., 2000). 
 
Scheme 2.8. General strategy for the syntheses of benzimidazole scaffold. 
  
As outlined in route II of Scheme 2.8, White and co-workers discovered that heating 
2,3-diaminobenzamide with the aryl halide in N,N-dimethylacetamide (DMA) and 
sodium hydrogen sulfite (NaHSO3) also produced the desired benzimidazole derivatives 
(White et al., 2004). Route III (Scheme 2.8) illustrates the synthesis of benzimidazole 
compounds from 2,3-diaminobenzamide and pyridine-containing aryl aldehyde 
catalyzed by palladium-on-carbon (Pd/C) catalyst (Penning et al., 2010), while in route 
IV (Scheme 2.8), 2,3-diaminobenzoic acid was heated in dimethylformamide (DMF) 
with the aldehyde to furnish the benzimidazole intermediate in which the carboxylic 
acid head group was converted into the carboxamide with EDCI.HCl / HOBt as the 
desired product (Xue et al., 2011). 
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Apart from the main skeleton of benzimidazole, various substituents at the second 
position of the benzimidazole ring also play critical role in determining the bioactivity 
of the benzimidazole compounds. Benzimidazole side-chain preparation have been 
abundantly reported, some of which will be described in the next section.  
 
 
2.2 Boronic acid and Miyaura Borylation  
Borylation reaction is a reaction that converts an activated carbon-hydrogen bond, 
both aliphatic and aromatic, to a carbon-boron bond, usually catalysed by transition 
metal catalyst (Hartwig, 2011). Boronic acids (Figure 2.1) (Wu, Neumann, & Beller, 
2010) and boronate esters, mainly bis(pinacolato)diboron (Figure 2.2), are common 
compounds extensively used as the source of boron in Suzuki coupling reactions. These 
boronic compounds are used mainly due to the ease of transmetalation particularly with 
organopalladium compounds (Miyaura & Suzuki, 1995). 
 
 
Figure 2.1. General structure of boronic acid. 
 
 
Figure 2.2. Structure of bis(pinacolato)diboron. 
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2.3 Miyaura-Suzuki Coupling 
Miyaura-Suzuki Coupling is considered to be one of the recognized reactions in 
chemistry, which provides carbon-carbon bond formation, that serves as key steps in 
building many complex molecules (Suzuki, 1992, 2002). As illustrated in Scheme 2.9, 
this reaction can be performed either by using (4-(methoxycarbonyl)phenyl)boronic 
acid with tert-butyl 2-chloro-1H-pyrrole-1-carboxylate, or methyl 4-bromo-2-
fluorobenzoate with (1-(tert-butoxycarbonyl)-1H-pyrrol-2-yl)boronic acid in the 
presence of palladium as catalyst and base (Ishida et al., 2006; Penning et al., 2010). 
 
 
Scheme 2.9. Carbon-carbon bond formation via Suzuki coupling reaction. 
Boronate ester serves as an alternative boron source in the Suzuki coupling reaction 
where bis(pinacolato)diboron is widely used in a palladium complex-catalysed reaction 
(Scheme 2.10) (Miyaura & Suzuki, 1979, 1995; Miyaura, Yamada, & Suzuki, 1979).  
 
 
Scheme 2.10. Boronate ester used as starting materials in Suzuki Coupling. 
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2.4 Amide Coupling Reaction 
 
Amides and peptides compounds are common features in natural products as well as 
in many bioactive synthetic compounds. Carboxamide in particular, appears to be 
important in functional group in bioactive compounds due to its stability, neutrality and 
hydrogen-bond donor acceptor capability (Montalbetti & Falque, 2005). Thus, methods 
and strategies towards amide formation reaction have been growing tremendously to 
enhance its applications and addressing its challenges (Han & Kim, 2004). 
 
One general distinctive amide coupling reaction involves activation of a carboxylic 
acid moiety and an amine moiety, as shown in Scheme 2.11 (Valeur & Bradley, 2009).  
 
 
Scheme 2.11. Amide bond formation via coupling reagent reaction. 
 
Carboxamide can also be produced in high yield from carboxylic acid through a 
reaction with ammonium chloride and EDCI with HOBt as additive in the presence of 
Hunig’s base, as shown in Scheme 2.12 (Wang & McMurray, 1999; Gruver et al., 2008; 
Kalgutkar et al., 2008). 
 
 
Scheme 2.12. Conversion of carboxylic acid moiety to carboxamide. 
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There is an abundance of coupling reagents to generate amide bonds ranging from 
aminiums, carbodiimides, phosphoniums, uroniums, and others reported such as 
dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC) (Valeur & 
Bradley, 2009), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI.HCl) 
(Nakajuma & Ikada, 1995), 1-hydroxybenzotriazole (HOBt) (Carpino, 1993), and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro 
phosphate (HATU) (Figure 2.3) (Albericio, 2004). 
 
 
Figure 2.3. Common coupling reagents available in amide bond reaction. 
 
 
2.5 Nitro Reduction 
 
Arylnitro compounds can be reduced to arylamine compounds. Countless methods 
have been reported on this reduction process. Mild nitro reduction conditions with high 
yield reaction have been employed by Kroemer and co-workers using zinc dust in 
aqueous medium, as illustrated in Scheme 2.13 (Kroemer et al., 2006). 
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Scheme 2.13. Aryl nitro reduction to aryl amine. 
 
In a similar manner, as shown in Scheme 2.14, Gamble and co-workers reported an 
attractive approach to aryl nitro reduction by ultrasonic irradiation using iron as 
reducing agent under acidic condition. The desired aryl amine was obtained in a shorter 
reaction time (Gamble et al., 2007).  
 
 
Scheme 2.14. Aryl nitro reduction via sonication reaction. 
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CHAPTER 3: DESIGN OF HITS-TO-LEAD BENZIMIDAZOLE 
 
3.1 Molecular Docking 
 
Veliparib and brequinar are two drugs that work independently on PARP-1 and 
DHODH enzymes, respectively. Using information on these two drugs such as their 
interactions with residues of both enzymes would be viable in designing a new drug that 
can act as a dual inhibitor towards both the PARP-1 as well as the DHODH enzymes. 
The approach that we have taken in our attempt to design a compound that could be a 
potential inhibitor for both DHODH and PARP-1 involves molecular docking, synthesis 
of the compounds and subsequent screening for their activities, as depicted in Figure 
3.1. 
 
 
Figure 3.1. Workflow of project for PARP-1 and DHODH dual inhibitors. 
 
3.2 Molecular Docking Methodology 
 
The molecular docking studies of PARP-1 and DHODH were done at Aurigene 
Discovery Technologies Ltd, Bangalore, India. Here, 2D structures of the ligands were 
sketched using ChemBioDraw Ultra 12.0 program and then converted into their 3D 
format with the LigPrep utility of Schrodinger Software Suite 2014-1. Similarly the 
protein-ligand complexes, obtained from the Protein Data Bank in the pdb format (pdb 
ID: 4IGH for DHODH and 4HHZ for PARP-1), were prepared using the Protein 
Preparation Wizard utility of the software. The hydrogen atoms were added, bond 
32 
orders assigned, missing side-chains filled, and water molecules outside the active site 
deleted. Restrained minimization was done on the structures to relieve the strain and 
steric clashes that may occur in the protein-ligand complexes.  
 
Using the Glide module of the Schrodinger Software, the active site was defined by 
constructing a receptor grid spanning amino acid residues within a distance of around 
10Å from the co-crystallized ligand in the protein complexes. Some key hydrogen-
bonding constraints (like with residues Gln-47 & Arg-136 in DHODH and with Gly-
202 & Ser-243 in PARP-1) were also defined while generating the receptor grid to be 
employed in the protein-ligand docking.  
 
The prepared ligands (in sdf format) and protein structures (as receptor grids) were 
supplied as input to the Glide module of the software for docking. During Glide 
docking, extra precision (XP) mode was employed. The protein was kept as rigid, while 
the ligands were given full flexibility in addition to sampling nitrogen inversions and 
ring conformations. However, the amide torsions were restricted to the trans-
conformation only. Other parameters include adding Epik state penalties to docking 
score, rewarding intramolecular hydrogen bonds, and enhancing planarity of the 
conjugated pi groups. The docking protocol was set to report at least 10 poses per 
ligand, which were finally viewed and analyzed within the protein active site for desired 
interactions, using the maestro viewer of the Schrodinger Software Suite, or PyMol. 
 
3.3 Molecular Docking Results on Known Inhibitors 
 
Initial studies were conducted with known PARP inhibitors to obtain some structural 
insights. Eight known PARP inhibitors (Kinoshita et al., 2004; Iwashita et al., 2005; 
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Ishida et al., 2006; Barkalow et al., 2007; Donawho et al., 2007; Miyashiro et al., 2009; 
Gandhi et al., 2010; Penning et al., 2010) shown in Figure 3.2, were chosen and docked 
onto PARP-1 enzyme (pdb ID: 4HHZ), as illustrated in Figure 3.3 and Figure 3.4. 
 
 
Figure 3.2. Structures of known PARP-1 inhibitors. 
 
 
Figure 3.3. X-Ray co-crystal of compounds 1-4 overlaid on PARP-1 enzyme. 
N
H
N
CONH2
N
H
N
CONH2O
NH
N
H
N
CONH2
N
N
H
N
CONH2 F
HN
NH
N
O
N
F
CONH2
N
N
Cl
N
H
NO
F
O
N
N
N
NH
O
Ki = 5 nM (PDB ID: 3GN7) Ki = 8 nM (PDB ID: 2RCW)
IC50 = 8-16 nM (PDB ID: 1UK0)
Ki = 33 nM (PDB ID: 3L3L)
Ki = 6 nM (PDB ID: 3L3M) IC50 = 60 nM (PDB ID: 1UKL)
IC50 = 33 nM (PDB ID: 1WOK) Ki = 5 nM (PDB ID: 3GJW)
1 2
5
3
4 6
7 8
34 
 
Figure 3.4. X-Ray co-crystal of compounds 5-8 overlaid on PARP-1 enzyme. 
 
As for DHODH inhibitors, brequinar and compound 4Sc, shown in Figure 3.5 
(Leban et al., 2004, 2005, 2006) were selected and docked inside DHODH enzyme (pdb 
ID: 4IGH) and superpositioned to one another as preliminary studies, as shown in 
Figure 3.6. 
 
 
Figure 3.5. Selected structures of known DHODH inhibitors of compound 4Sc and 
brequinar. 
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Figure 3.6. Binding mode of brequinar (cyan) and compound 4Sc (orange) 
superimposed in DHODH enzyme (pdb ID: 4IGH). 
 
 
3.4 Molecular Docking Discussion on Known Inhibitors 
 
From the illustrations of Figure 3.3 depicted above, each compound 1-4 showed 
similar binding pose in the binding site of PARP-1 enzyme where the carboxamide of 
the benzimidazole scaffold creates three hydrogen bonds between two key amino acid 
residues Ser-243, (C=O to H-O Ser-243) and Gly-202 backbone, (C=O to N-H Gly-202 
and N-H to C=O Gly-202) in the nicotinamide binding site. Also observed was π-π 
stacking interaction with Tyr-246 residue. Compounds 5-8 in Figure 3.4 showed only 
two hydrogen bonds with the amide backbone of Gly-202 amino acid residue, and π-π 
stacking interaction with Tyr-246 residue with each compound, demonstrating different 
poses in the catalytic site. A consensus pharmacophore has been disclosed in relation to 
become PARP-1 inhibitor (Costantino et al., 2001; Tonelli et al., 2004; Jagtap & Szabo, 
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2005; Zhu et al., 2008; Refaat, 2010; Curtin & Szabo, 2013; Steffen et al., 2013; Zhu et 
al., 2013), as shown in Figure 3.7. 
 
 
Figure 3.7. A consensus pharmacophore query for PARP-1 inhibitor. 
 
Three key features were found to be optimal for PARP-1 binding, restricting the 
rotation of a carboxamide group attached at C-4 position with one NH locked achieved 
by intramolecular hydrogen bond, an aromatic ring and side-chain extended towards the 
hydrophobic region. 
 
As in the binding mode of brequinar (discussed in previous section, Chapter 1), 
compound 4Sc also adopts the “brequinar-like” conformation where carboxylic acid of 
the thiophene ring interacts with Arg-136 and Gln-47 residue side chains (Figure 3.7). 
However, it is likely that compound 4Sc is capable of displaying a “nonbrequinar-like” 
conformation whereby hydrogen bond interaction with Tyr-356 and a water molecule 
mediated with Tyr-147 was observed when the thiophene ring were rotated at 180o 
(Figure 3.8). This seems to suggest that compound 4Sc exhibits a dual binding mode 
(Baumgartner et al., 2006). In nature interactions between protein and ligand, 
identification of subsites can be explored. Each subsite (Figure 3.8) consists of specific 
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functional groups responsible, and could potentially be a stabiliser for interactions 
occurring with each functional group introduced by plausible inhibitor. 
 
 
Figure 3.8. Five subsites of a DHODH inhibitor binding site. Black dotted lines in 
subsite one are mainly responsible for hydrophobic interactions where two more 
remotely hydrophobic site are located at subsite four of the binding pocket. Plausible 
hydrogen bond interactions are shown in black dashed lines found in subsite two and 
three. Subsite five is polar in nature anchored by hydroxyl group of Tyr-38 and Leu-62. 
Other alternative binding mode of the inhibitor is coded in green. Reprinted with 
permission (Baumgartner et al., 2006). 
 
 
From the information obtained, three important pharmacophores were outlined 
(Hansen et al., 2004; Das et al., 2013). They are; (i) free carboxylic acid of the 
quinolone/aromatic ring as the head group, (ii) potential electron withdrawing-donating 
effect on the quinolone/aromatic ring and (iii) side-chain extension towards the 
hydrophobic pocket. 
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Compound I1 (Figure 3.9), developed by Aurigene Discovery Technologies Ltd. 
were then docked with DHODH enzyme (pdb ID: 4IGH) and the interactions were 
studied.  
 
 
Figure 3.9. Binding mode of compound I1 on DHODH enzyme (pdb ID: 4IGH). 
 
Our findings demonstrate that the binding mode of compound I1 substantially 
possess a ‘brequinar-like’ interactions and is located at the ubiquinone binding site with 
an IC50 value of 750 nM. The carboxylic acid head group of the inhibitor makes 
hydrogen bond interactions towards the back bone of Arg-136 and Glu-47 amino acid 
residues. Additional interactions with one water molecule were also observed, depicted 
as red circle in Figure 3.9.  
 
As we come closer in understanding and obtaining better insights of the 
pharmacophores discussed, some similarities and close relationship between the PARP-
1 and DHODH inhibitor pharmacophores can be observed. Both enzymes seem to be in 
need of electron rich aromatic ring and side-chain that extends out to the hydrophobic 
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pocket while only the head group either carboxamide in Veliparib or carboxylic acid in 
Brequinar differs in each particular inhibitor, respectively. With all the information 
gathered, the compounds, as depicted in Table 3.1, are proposed to serve as hits-to-lead 
in order to achieve our objective in searching for a dual inhibitor for PARP-I and 
DHODH. The compounds proposed to be synthesised and screened for their biological 
activity. 
 
Table 3.1. Proposed compounds to be synthesised. 
Entry Compound Structure 
1 9aa 
 
2 9b 
 
3 9cb 
 
4 9d 
 
5 9eb 
 
6 9f 
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Table 3.1 continued 
7 9g 
 
8 9h 
 
9 9i 
 
10 9j 
 
11 10aa 
 
12 10b 
 
13 10c 
 
14 10da 
 
15 10e 
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Table 3.1 continued 
16 10f 
 
17 10g 
 
18 10h 
 
19 11a 
 
20 11d 
 
21 11c 
 
22 11d 
 
23 11e 
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Table 3.1 continued 
25 7b 
 
26 7c 
 
27 7d 
 
28 7e 
 
29 7f 
 
30 7g 
 
aCompounds reported by Tong and group (Tong et al., 2009).  
bCompounds reported by White and group (White et al., 2000). 
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CHAPTER 4: SYNTHESIS OF BENZIMIDAZOLE DERIVATIVES 
 
4.1 General 
 
Chemicals that were used in all syntheses were purchased from Merck, Sigma-
Aldrich and/or provided by Aurigene Discovery Technologies Limited. All melting 
points were taken on a Stuart Melting Point SMP 30 melting point apparatus. NMR 
spectra were obtained from Bruker AVN 400, JEOL Lambda 400, JEOL ECA 400 and 
JEOL 270. Semi-preparative HPLC was performed on Waters Binary Pump 1525, 
Waters Photodiode Array Detector 2998 with Merck Chromolith® Performance 
Reverse-phase C-18 column (100-4.6mm). High Resolution Mass Spectrometry was 
recorded with Agilent 1200 Series / Agilent Technologies 6530 Q-TOF (ESI) with 
Agilent Zorbax C-18 column. 1H, 13C and MS analyses were used to characterize all the 
target compounds. Thin Layer Chromatography (TLC) was carried out by using 
aluminium sheets TLC silica 60 F254 purchased from Merck. Flash Column 
Chromatography using silica gel (40-60 µm) were purchased from Merck, Mallinckrodt 
and Analisa Resources Sdn. Bhd. Anhydrous tetrahydrofuran (THF) used were purified 
through the PureSolv solvent purification system and dichloromethane (CH2Cl2) were 
distilled from CaH2 prior to use. Other anhydrous solvents and also reagents used were 
purchased from Merck and Sigma-Aldrich. 
 
4.2 Retrosynthetic Analysis 
 
The approach involved making a series of compounds containing benzimidazole 
scaffold with various functional groups at three different positions (C-2, C-4 and C-6) 
of the benzimidazole, as illustrated in Figure 4.1. Initially work is to focus on the 
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preparation of various side chains that is eventually connected to the tail-end of the 
benzimidazole core as shown in Figure 4.1 (in blue). 
 
 
Figure 4.1. Three positions functional group variation on the benzimidazole scaffold. 
 
Scheme 4.1 describes the retrosynthetic analysis of the benzimidazole ring 
construction. Two routes have been employed in order to accomplish the benzimidazole 
ring formation. The retrosynthesis analysis on the right hand side in Scheme 4.1 shows 
a functional group interconversion from a carboxylic acid (D) to the target amide (E). 
Functional group interconversion of the ester (C) presumably will lead to the carboxylic 
acid (D). Retrosynthesis of the ester (C) shows a disconnection of the imidazole ring, 
which could be achieved through intramolecular cyclisation of ester (B). The ester (B) 
could be obtained from the diaminobenzoate (A). 
 
Retrosynthesis on the left hand side illustrates a shorter route involving a 
intramolecular cyclisation of the amide (F) to form the target amide (G). The amide (F) 
could be prepared from an amide coupling reaction between the diamine (E) and the 
carboxylic acid (2). 
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Scheme 4.1. Retrosynthesis of benzimidazole. 
 
 
4.3 Synthesis of Benzimidazole Derivative Side Chains 
 
As mentioned in Chapter 3, 30 different benzimidazole derivatives have been 
designed for biological testing. The differences in these compounds lie mainly in the 
carboxyl substituent on the C-2 position of the benzimidazole scaffold. These carboxyl 
substituents were prepared from carboxylic acids (2), where different groups were 
placed at the ortho, meta, and para-position. The carboxylic acids (2) were, in turn, 
prepared by saponification of the corresponding ester (1) (Figure 4.1), as shown in 
Table 4.1 (Compounds 2a-x). 
46 
Table 4.1. Side chain compounds. 
 
Entry Structure Entry Structure 
2a 
 
2m 
 
2b 
 
2n 
 
2c 
 
2o 
 
2d 
 
2p 
 
2e 
 
2q 
 
2f 
 
2r 
 
2g 
 
2s 
 
2h 
 
2t 
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Table 4.1 continued 
2i 
 
2u 
 
2j 
 
2v 
 
2k 
 
2w 
 
2l 
 
2x 
 
 
Eleven carboxylic acid side chains (Figure 4.2), used in this work (Compounds 2a, 
2b, 2c, 2d, 2e, 2f, 2g, 2o, 2w), were provided by Aurigene Discovery Technologies Ltd. 
 
 
Figure 4.2. Compounds provided by Aurigene Discovery Technologies Ltd. 
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Table 4.2. List of starting materials used in the synthesis. 
Entry Structure / Name of Molecule Entry Structure / Name of Molecule 
A1  
(4-(Methoxycarbonyl)phenyl) 
boronic acid 
C4  
1-(Bromomethyl)-2-
nitrobenzene 
A2 
 
Pyridin-3-ylboronic acid 
C5  
1-(Bromomethyl)-4-
nitrobenzene 
A3 
 
4-Bromobenzoic acid 
D1 
 
4-Bromo-2-methoxyaniline 
A4 
 
5-Bromonicotinic acid 
D2 
 
4-Bromophenol 
A5 
 
5-Bromopicolinic acid 
D3  
Pyrrolidine 
 
BHO OH
COOMe
Br
NO2
N
B
OHHO
NO2
Br
Br
COOH NH2
OMe
Br
N
Br
COOH
Br
OH
N
Br
COOH
H
N
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Table 4.2 continued 
A6 
 
Phenylboronic acid 
D4  
Piperidine 
B1 
 
4-Bromo-3-nitrobenzoic acid 
D5  
2-Bromoethanol 
B2 
 
4-Bromo-2-fluorobenzoic acid 
D6 
 
3-Bromopropan-1-ol 
B3  
Cyclopropanecarboxylic acid 
E1 
 
Methyl 2,3-diaminobenzoate 
B4  
Propionic acid 
E2  
Methyl 2,3-diamino-5-
methylbenzoate 
C1 
 
5-Bromopyridin-2-amine 
E3 
 
2,3-Diaminobenzamide 
 
 
BHO OH HN
COOH
NO2
Br
Br
OH
COOH
F
Br
Br OH
HO
O COOMeNH2
NH2
HO
O
COOMe
NH2
NH2
N
Br
NH2
CONH2
NH2
NH2
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Table 4.2 continued 
C2 
 
4-Bromoaniline 
E4  
Methyl 2,3-diamino-5-
fluorobenzoate 
C3 
 
4-Bromo-3-fluoroaniline 
F1  
Bis(pinacolato)diboron 
*Starting materials were obtained from Aurigene Discovery Technologies Ltd. (India). 
 
 
The remaining carboxylic acids (Compounds 2h, 2i, 2j, 2k, 2l, 2m, 2n, 2p, 2q, 2r, 
2s, 2t, 2u, 2v, 2x), shown in Table 4.1, were synthesised using various methods. Prior to 
the synthesis, the compounds were categorized into groups according to similarities in 
the functional groups, as illustrated in Figure 4.3 (Refer to appendix A1 for spectra). 
This was done since the synthetic strategies being carried out were presumed to be the 
same for the compounds within the same group. With the exception of Group 1 
(provided by Aurigene), the synthetic strategies for the preparation of Groups 2-6 
compounds are described below; 
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Figure 4.3. Carboxylic acid side chains divided into groups. 
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4.3.1 Synthesis of Carboxylic Acids in Group 2 
 
 
Figure 4.4. Compounds of Group 2. 
 
4.3.1.1  Synthesis of 4-(pyridin-3-yl)benzoic acid, 2i 
 
 
 
Procedure: 
(i) Pd(PPh3)2Cl2 (0.28 g, 0.40 mmol) was taken into the mixture of 1,4-dioxane (30 
mL) and water (10 mL) and then degassed with N2 gas for 10 minutes. 4-
bromobenzoic acid (A3) (1.00 g, 4.03 mmol) and pyridin-3-ylboronic acid (A2) 
(0.59 g, 4.83 mmol) was added to the reaction mixture and again degassed for 
another 10 minutes before adding CS2CO3 (4.26 g, 12.07 mmol), then the 
resulting mixture was degassed for 5 minutes and heated to 80°C for 4 hours. 
After completion of the reaction, which was monitored by TLC, it was filtered 
through celite pad, and the filtrate was concentrated to remove 1,4-dioxane. The 
COOHCOOH
N
N
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N
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i
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Br
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B OHHO
N
COOH
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residue was diluted with water and washed with EtOAc. Acidifying the aqueous 
phase with 10% HCl to pH 2 resulted solids that were filtered and dried under 
vacuum to obtain 4-(pyridin-3-yl)benzoic acid (2i) as light yellow solid in 59% 
yield (0.47 g, 2.38 mmol), and used without further purification. Rf 
(EtOAc:Hex; 1:1; v/v) 0.0. 1H NMR (400 MHz, DMSO-d6): δ 8.97 (s, 1H), 
8.64 (d, J=8.0, 1H), 8.07 (d, J=8.5, 2H), 7.88 (d, J=8.5, 2H), 7.53 (dd, J=4.8, 
7.5, 1H). 
 
4.3.1.2  Synthesis of methyl 4-(6-aminopyridin-3-yl)benzoate, 1j-1 
 
 
 
Procedure 
(i) To a solution of 1,4-dioxane (20 mL) and water (5 mL), was added CS2CO3 
(3.06 g, 8.67 mmol) and left to stir through N2 gas bubbling for 10 minutes. (4-
(methoxycarbonyl)phenyl)boronic acid (A1) (0.62 g, 3.47 mmol) and 5-
bromopyridin-2-amine (C1) (0.50 g, 2.89 mmol) were then added to the mixture 
and allowed to dissolve completely, followed by Pd(PPh3)2Cl2 (0.41 g, 0.58 
mmol) and stirred for additional 10 minutes. The reaction mixture was set to 
reflux at 100°C for about 3 hours. After completion of the reaction (monitored 
by TLC), 1,4-dioxane was removed in vacuo. The residues were extracted with 
EtOAc, washed with water and brine followed by drying over MgSO4 and 
concentrated. The crude residue was then purified by column chromatography 
N
Br
NH2BHO OH
COOMe COOMe
N
NH2
A1 C1
1j-1
i
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(CH2CL2:MeOH; 9:1; v/v) to afford the desired product methyl 4-(6-
aminopyridin-3-yl)benzoate (1j-1) as yellow solid in 54% yield (0.36 g, 1.56 
mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.20. 1H NMR (400 MHz, DMSO-d6): δ 8.36 
(s, 1H), 7.97 (d, J= 8.5, 2H), 7.79 (dd, J=2.4, 8.5, 1H), 7.73 (d, J=8.5, 2H), 
6.54 (d, J=8.5, 1H), 6.25 (s, NH2), 3.86 (s, 3H). 
 
4.3.1.3  Synthesis of 4-(6-aminopyridin-3-yl)benzoic acid, 2j 
 
 
 
Procedure 
(ii) Compound 1j-1 (0.36 g, 1.56 mmol) was dissolved in MeOH:THF (6 mL; 1:1; 
v/v), followed LiOH (0.11 g, 4.79 mmol) dissolved in water (3 mL) were added 
and the reaction mixture was stirred for 24 hours. The reaction mixture progress 
was monitored by TLC. Upon reaction completion, solvents were removed in 
vacuo. The pH of the resulting mixture was adjusted to 2 with 10% HCl to 
obtain the desired product 4-(6-aminopyridin-3-yl)benzoic acid (2j) as light 
brown solid in 95.5% yield (0.32 g, 1.49 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.0. 
1H NMR (400 MHz, DMSO-d6): δ  8.42 (s, 1H), 8.35 (dd, J=1.9, 9.3, 1H), 8.27 
(bs, NH2), 8.02 (d, J=8.3, 2H), 7.81 (d, J=8.3, 2H), 7.13 (d, J=9.3, 1H). 
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4.3.1.4  Synthesis methyl 4-(6-acetamidopyridin-3-yl)benzoate, 1k-1 
 
 
 
Procedure 
(i) To a stirred solution of compound 1j-1 (0.40 g, 1.75 mmol) in dichloromethane 
(25 mL), triethylamine (0.70 mL, 5.25 mmol) was added and the mixture was 
cooled to 0°C. Acetyl chloride (AcCl, 0.18 mL, 2.62 mmol) was then added 
dropwise and the reaction was brought to room temperature while stirring (about 
4 hours). Progress of the reaction was monitored by TLC. Water was added to 
quench the reaction and the mixture was extracted with dichloromethane. The 
organic phase was then washed with water, brine and dried over MgSO4. The 
reaction proceeded to the next step without further purification. Crude 
compound containing methyl 4-(6-acetamidopyridin-3-yl)benzoate (1k-1) 
obtained was 0.62 g. Rf (EtOAc:Hex; 3:7; v/v) 0.3.  1H NMR (400 MHz, 
CDCl3): δ  8.53 (d, J=2.2, 1H), 8.31 (d, J=8.7, 1H), 8.29 (s, NH), 8.13 (d, 
J=8.3, 2H), 7.95 (dd, J=2.2, 8.8, 1H), 7.63 (d, J=8.5, 2H), 3.95 (s, 3H), 2.25 (s, 
3H). 
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4.3.1.5  Synthesis of 4-(6-acetamidopyridin-3-yl)benzoic acid, 2k 
 
 
 
Procedure 
(ii) Compound 1k-1 (0.62 g, 2.27 mmol) was dissolved in MeOH:THF (6 mL, 1:1; 
v/v), followed by the addition of LiOH (54 mg, 2.25 mmol) in water (3 mL), and 
the reaction mixture was allowed to stir overnight. Progress of the reaction was 
monitored by TLC. Upon completion reaction, solvents were removed in vacuo. 
The resulting aqueous mixture was adjusted to pH 2 with 10% HCl to obtain the 
desired product 4-(6-acetamidopyridin-3-yl)benzoic acid (2k), as light brown 
powder in 69% yield (0.41 g, 1.58 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.0. 1H 
NMR (400 MHz, DMSO-d6): δ  10.65 (s, 1H), 8.70 (s, 1H), 1.88-1.86 (s, 2H 
overlap), 8.01 (d, J=8.5, 2H), 7.83 (d, J=8.3, 2H), 2.11 (s, 3H). 
 
 
Compound 2i was synthesised in one-step through a Suzuki coupling reaction of the 
pyridinylboronic acid (A2) and the 4-bromocarboxylic acid (A3) in 59% yield (Scheme 
4.2). 
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Scheme 4.2. Synthesis strategy for compound 2i. 
 
As shown in Scheme 4.3, Suzuki coupling of the phenylboronic ester (A1) with the 
5-bromopyridin-2-amine (C1) gave the intermediate compounds (1j-1).  Saponification 
of 1j-1 gave the compounds 2j, while compound 2k was obtained after N-acetylation 
and subsequent saponification of 1j-1 in decent yields (approximately 51.6%). 
 
 
Scheme 4.3. Synthetic strategy for compounds 2j and 2k. 
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4.3.2 Synthesis of Carboxylic Acids in Group 3 
 
 
Figure 4.5. Compounds of Group 3. 
 
4.3.2.1  Synthesis of 4-bromo-3-nitrobenzoate, B1a 
 
 
 
Procedure 
(i) 4-Bromo-3-nitrobenzoic acid (B1) (0.50 g, 2.03 mmol) was added to a solution 
of MeOH (50 mL) dissolved with EDCI (0.51 g, 2.64 mmol). Afterwards, 
DiPEA (0.53 mL) was added and left to stir at room temperature for 2 hours. 
Upon completion of reaction, MeOH was removed in vacuo and the solids were 
washed with water, filtered and dried to afford methyl 4-bromo-3-nitrobenzoate 
(B1a) as light yellow solid in 77% yield (0.41 g, 1.56 mmol), and used for next 
step with no further purification. Rf (EtOAc:Hex; 3:7; v/v) 0.4. 1H NMR (400 
MHz, CDCl3): δ  8.47 (d, J=1.9, 1H), 8.07 (dd, J=1.9, 8.5, 1H), 7.84 (d, J=8.2, 
1H), 3.97 (s, 3H). 
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4.3.2.2  Synthesis of 3-amino-4-bromobenzoate, B1b 
 
 
 
Procedure 
(ii) To a mixture of acetic acid/ethanol/water (5 mL, 2:2:1, v/v), was added 
compound B1a (0.10 g, 0.38 mmol). Reduced iron powder (0.11 g, 1.92 mmol) 
was introduced and the resulting mixture was sonicated at 30°C for 15 minutes, 
with TLC analysis monitoring to assess the reaction progress. The reaction 
mixture was filtered through celite and washed with EtOAc. The filtrate was 
treated with saturated aqueous NaHCO3, where the basic layer was further 
extracted with EtOAc (3x), washed with water, brine, dried under MgSO4 and 
concentrated to give methyl 3-amino-4-bromobenzoate (B1b) as yellow solid in 
85% (0.08 g, 0.03 mmol), which was used without purification. Rf (EtOAc:Hex; 
3:7; v/v) 0.38. 1H NMR (400 MHz, CDCl3): δ  7.37 (d, J=8.2, 1H), 7.34 (d, 
J=1.7, 1H), 7.16 (dd, J=1.9, 8.3, 1H), 4.18 (bs, NH2), 3.79 (s, 3H). 
 
4.3.2.3  Synthesis of methyl 2-amino-[1,1'-biphenyl]-4-carboxylate, 1u-1 
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Procedure 
(iii) To a solution of 1,4-dioxane (20 mL) and water (5 mL) was added CS2CO3 
(0.66 g, 1.87 mmol), and left to stir with bubbling (degassed) under N2 gas for 
10 minutes. Phenylboronic acid (A6) (0.17 g, 1.41 mmol) and compound B1b 
(0.22 g, 0.94 mmol) were then added to the mixture and allowed to dissolve 
completely followed by addition of Pd(PPh3)2Cl2 (0.13 g, 0.19 mmol) and 
stirring for additional 10 minutes. The reaction mixture was set to reflux at 
100°C for about 2 hours. Upon completion of reaction monitored by TLC, 1,4-
dioxane was removed in vacuo and extracted with EtOAc, washed with water, 
brine followed by drying over MgSO4 and concentration. The crude residue was 
then purified by column chromatography (EtOAc:Hex; 3:1; v/v) to afford the 
desired product methyl 2-amino-[1,1'-biphenyl]-4-carboxylate (1u-1), as yellow-
orange liquid in 77% yield (0.16 g, 0.72 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 
1H NMR (400 MHz, CDCl3): δ  7.48-7.43 (m, 7H), 7.17 (d, J=7.8, 1H), 3.90 
(s, 3H), 3.87 (bs, NH2). 
 
4.3.2.4  Synthesis of methyl 2-acetamido-[1,1'-biphenyl]-4-carboxylate, 1u-2 
 
 
 
Procedure 
(iv) To a stirred solution of compound 1u-1 (0.15 g, 0.54 mmol) in dichloromethane 
(20 mL), triethylamine (0.22 mL, 1.62 mmol) was added and cooled to 0°C. 
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Acetyl chloride (AcCl) (0.09 g, 1.08 mmol) was then added dropwise and the 
reaction was left to stir for additional 2 hours to room temperature. Progress of 
the reaction was monitored by TLC. Water was added to quench the completed 
reaction and extracted with dichloromethane. The organic phase was then 
washed with water, brine and dried over MgSO4 to afford methyl 2-acetamido-
[1,1'-biphenyl]-4-carboxylate (1u-2) as light yellow solid in 95% yield (0.17 g, 
0.63 mmol) which were used without further purification. Rf (EtOAc:Hex; 3:7; 
v/v) 0.3. 1H NMR (400 MHz, CDCl3): δ  8.87 (s, 1H), 7.86 (d, J=4.8, 1H), 7.50 
(d, J=7.6, 2H), 7.46 (d, J=7.2, 1H), 7.37 (d, J=6.8, 2H), 7.32 (d, J=8.4, 1H), 
7.14 (bs, NH), 3.93 (s, 3H), 2.10 (s, 3H). 
 
4.3.2.5  Synthesis of 2-acetamido-[1,1'-biphenyl]-4-carboxylic acid, 2u 
 
 
 
Procedure 
(v) Compound 1u-2 (0.17 g, 0.63 mmol) was dissolved in MeOH:THF (4 mL, 1:1, 
v/v) followed by the addition of LiOH (0.02 g, 0.94 mmol) in water (2 mL) and 
the reaction mixture was allowed to stir overnight. Upon reaction completion, 
solvents were removed in vacuo. pH of the resulting aqueous mixture was 
adjusted to 2 with 10% HCl to obtain the desired product 2-acetamido-[1,1'-
biphenyl]-4-carboxylic acid (2u), as white solid in 81% (0.14 g, 0.54 mmol). Rf 
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(EtOAc:Hex; 3:7; v/v) 0.0. 1H NMR (400 MHz, DMSO-d6): δ  13.03 (bs, 1H), 
9.39 (s, NH), 8.05 (s, 1H), 7.82 (d, J=8.8, 1H), 7.49-7.38 (m, 6H), 1.91 (s, 3H). 
 
 
Compounds 2e, 2f, and 2g in Group 3 were synthesised directly from the 
phenylboronic ester (A1) with the various o-, m- and p-substituted bromoaniline (C6, 
C7 and C8), respectively (Scheme 4.4) (Provided by Aurigene). 
 
Scheme 4.4. Synthetic strategy for compounds 2e, 2f and 2g. 
 
Attempts on Suzuki coupling between phenylboronic acid and 4-bromo-3-
nitrobenzoic acid (B1) did not result in the desired compound 1u-3, as shown in 
Scheme 4.5. 
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Scheme 4.5. Synthetic strategy for compound 1u-3. 
 
Thus, different strategy was used where the carboxylic acid (B1) was first protected 
as an ester, and then subjected to both Suzuki and Ullman coupling, as shown in 
Scheme 4.6 below. However, Suzuki reaction gave less than 10% yield of the desired 
product, while no product was obtained under the Ullman condition. 
 
 
Scheme 4.6. Esterification of B1 followed by Suzuki coupling and Ullman coupling. 
 
Although Suzuki coupling has been reported to work well with many substrates, 
including nitrobenzenes, the reaction did not proceed well when the reaction was 
performed. Thus, B1 was firstly esterified, and then reduce the nitro group to an amino 
group following the procedure of Gamble and co-workers (Gamble et al., 2007). Here, 5 
equivalents of iron powder were added to the methyl 4-bromo-3-nitrobenzoate (B1a) in 
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a mixture of ethanol, glacial acetic acid and water. The reaction mixture was then 
subjected to ultrasonic condition for 15 minutes to give the methyl 3-amino-4-
bromobenzoate (B1b) in quantitative yield. This fast reaction may be due to the high-
energy effects of acoustic cavitation of the ultrasound, with the iron surface 
continuously been cleaned and activated by glacial acetic acid (Gamble et al., 2007). 
Dehalogenation was not observed during the aryl nitro reduction (Scheme 4.7). 
 
The corresponding methyl 3-amino-4-bromobenzoate (B1b) was subjected to Suzuki 
coupling reaction with phenylboronic acid, as shown in Scheme 4.7. This reaction 
proceeded well, producing the methylamino biphenyl carboxylate (1u-1) in 77% yield. 
N-acetylation and saponification of the methylamino biphenyl carboxylate (1u-1) gave 
the desired N-acetyl biphenyl carboxylic acid (2u) in about 59% yield in 3 steps from 
the methylamino biphenyl carboxylate (1u-1). 
 
 
Scheme 4.7. Alternative route in preparing compound 2u. 
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4.3.3  Synthesis of Carboxylic Acids in Group 4 
 
 
Figure 4.6. Compounds of Group 4. 
 
4.3.3.1  Synthesis of (4-bromophenyl)(pyrrolidin-1-yl)methanone, 1h-1 
 
 
 
Procedure 
(i) 4-bromobenzoic acid (A3) (1.00 g, 4.95 mmol), pyrrolidine (D3) (0.53 g, 7.42 
mmol), EDCI (0.94 g, 4.95 mmol) and HOBt (0.67 g, 4.95 mmol) was added to 
a solution of DMF (6 mL) followed by DiPEA (1 mL). The resulting mixture 
was then allowed to stir at room temperature for 3 hours. Upon completion of 
the reaction, water (80 mL) was added to the reaction mixture and solids 
obtained was filtered and dried, affording (4-bromophenyl)(pyrrolidin-1-
yl)methanone (1h-1) as yellow solid in 80% yield (1.01 g, 3.96 mmol). Rf 
(EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR (400 MHz, CDCl3): δ  7.66 (d, J=8.2, 2H), 
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7.18 (d, J=8.2, 2H), 3.53 (t, J=6.9, 2H), 3.32 (t, J=6.3, 2H), 1.88-1.84 (m, 2H), 
1.82-1.77 (m, 2H). 
 
4.3.3.2 Synthesis of methyl 4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-
carboxylate, 1h-2 
 
 
 
Procedure 
(ii) To a solution of 1,4-dioxane (35 mL) and water (10 mL), was added CS2CO3 
(4.15 g, 0.01 mol), and left to stir bubbling (degassed) under N2 gas for 10 
minutes. (4-(methoxycarbonyl)phenyl)boronic acid (A1) (0.84 g, 4.70 mmol) 
and compound 1h-1 (1.00 g, 3.92 mmol) was then added to the mixture and 
allowed to dissolve completely, followed by bis(triphenylphosphine) 
palladium(II)dichloride Pd(PPh3)2Cl2 (0.55 g, 0.78 mmol), and stirred for 
additional 10 minutes. Reaction mixture was set to refluxed at 100°C for about 4 
hours. After completion of the reaction monitored by TLC, 1,4-dioxane was 
removed in vacuo, extracted with EtOAc, washed with water and brine followed 
by drying over MgSO4 and concentrated. The crude residue was then purified by 
column chromatography (EtOAc:Hex; 3:1; v/v) to afford desired product methyl 
4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-carboxylate (1h-2) as light yellow 
solid in 68% yield (0.83 g, 2.66 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H NMR 
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(400 MHz, CDCl3): δ  8.12 (d, J=8.0, 2H), 7.68-7.63 (m, 6H), 3.95 (s, 3H), 
3.68 (t, J=6.4, 2H), 3.49 (t, J=6.8, 2H), 2.00-1.96 (m, 2H), 1.93-1.89 (m, 2H). 
 
4.3.3.3 Synthesis of product 4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-
carboxylic acid, 2h 
 
 
 
Procedure 
(iii) Compound of 1h-2 (0.80 g, 2.58 mmol) was dissolved in MeOH:THF (8 mL; 
1:1; v/v), followed by the addition of LiOH (0.18 g, 7.72 mmol) in water (4 
mL), and the reaction mixture was allowed to stir overnight. Upon reaction 
completion, solvents were removed in vacuo. The resulting aqueous mixture pH 
was adjusted to 2 with 10% HCl to obtain the desired product 4'-(pyrrolidine-1-
carbonyl)-[1,1'-biphenyl]-4-carboxylic acid (2h) as pale yellow solid in 90% 
yield (0.69 g, 2.32 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.0. 1H NMR (400 MHz, 
CDCl3): δ  8.17 (d, J=6.8, 2H), 7.70-7.64 (m, 6H), 3.68 (t, J=6.4, 2H), 3.49 (t, 
J=6.0, 2H), 2.01-1.96 (m, 2H), 1.92-1.89 (m, 2H). 
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4.3.3.4  Synthesis of compound 2l 
 
 
 (i) EDCI, HOBt, DMF, DiPEA; (ii) Pd(PPh3)2Cl2, CS2CO3, 1,4-Dioxane, H2O, 100°C; 
(iii) LiOH/H2O, MeOH/THF. 
 
Procedure 
Compounds 1l-1, 1l-2 and 2l were prepared in a similar fashion as compound 2h. 
 
(a) Spectral data for (5-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone, 1l-1 
 
Yellow solid in 85% yield (1.07 g, 4.21 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR 
(400 MHz, CDCl3): δ  8.64 (dd, J=0.7, 2.3, 1H), 7.93 (dd, J=2.3, 8.4, 1H), 7.78 (dd, 
J=0.7, 8.4, 1H), 3.76 (t, J=6.8, 2H), 3.67 (t, J=7.0, 2H). 1.95-1.91 (m, 4H).  
 
N
Br
COOH
N
Br
ON
H
N
COOMe
B OHHO
N
ON
COOMe
N
ON
COOH
i ii
iii
A5 D3
1l-1 A1
1l-2 2l
N
Br
COOH
N
Br
ON
H
N
COOMe
B OHHO
N
ON
COOMe
N
ON
COOH
i ii
iii
A5 D3
1l-1 A1
1l-2 2l
69 
(b) Spectral data for methyl 4-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)benzoate,  
1l-2 
 
Light yellow solid in 70% yield (0.85 g, 2.74 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H 
NMR (400 MHz, CDCl3): δ  8.84 (dd, J=0.7, 2.3, 1H), 8.16 (d, J=8.5, 2H), 8.03 (dd, 
J=2.3, 8.1, 1H), 7.96 (dd, J=0.7, 8.1, 1H), 7.69 (d, J=8.5, 2H), 3.95 (s, 3H), 3.82 (t, 
J=6.7, 2H), 3.71 (t, J=6.9, 2H), 1.97-1.93 (m, 4H). 
 
(c) Spectral data for 4-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)benzoic acid, 2l 
 
Pale yellow solid in 93% yield, (0.71 g, 2.39 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.0. 1H 
NMR (400 MHz, CH3OD): δ  8.95 (s, 1H), 8.32 (d, J=8.3, 1H), 8.16 (d, J=8.3, 2H), 
7.89 (d, J=8.3, 1H), 7.84 (d, J=7.8, 2H), 3.70-3.65 (m, 4H), 1.97 (m, 4H). 
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4.3.3.5  Synthesis of compound 2m 
 
 
(i) EDCI, HOBt, DMF, DiPEA; (ii) Pd(PPh3)2Cl2, CS2CO3, 1,4-Dioxane, H2O, 100°C; 
(iii) LiOH/H2O, MeOH/THF. 
 
Procedure 
 
Compounds 1m-1, 1m-2 and 2m were prepared in a similar fashion as compound 2h. 
 
(a) Spectral data for (5-bromopyridin-3-yl)(pyrrolidin-1-yl)methanone, 1m-1 
 
Yellow solid in 80% yield (1.01 g, 3.96 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR 
(400 MHz, CDCl3): δ  8.64 (d, J=2.3, 1H), 8.61 (d, J=1.8, 1H), 7.94 (t, J=2.1, 1H), 
3.57 (t, J=6.9, 2H), 3.39 (t, J=6.3, 2H), 1.93-1.82 (m, 4H). 
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(b) Spectral data for methyl 4-(5-(pyrrolidine-1-carbonyl)pyridin-3-yl)benzoate, 
1m-2 
 
Light yellow solid in 68% yield (0.83 g, 2.66 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H 
NMR (400 MHz, CDCl3): δ  8.92 (d, J=2.0, 1H), 8.79 (d, J=1.7, 1H), 8.16 (d, J=8.4, 
2H), 8.10 (t, J=1.6, 1H), 7.68 (d, J=8.4, 2H), 3.69 (t, J=6.8, 2H), 3.95 (s, 3H), 3.52 (t, 
J=6.4, 2H), 2.05-1.91 (m, 4H). 
 
(c) Spectral data for 4-(5-(pyrrolidine-1-carbonyl)pyridin-3-yl)benzoic acid, 2m 
 
Pale yellow solid in 90% yield (0.69 g, 2.32 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.0. 1H 
NMR (400 MHz, CD3Cl + CD3OD): δ 8.99 (d, J=2.1, 1H), 8.86 (d, J=1.8, 1H), 8.21 
(d, J=8.4, 2H), 8.20 (t, J=1.4, 1H), 7.70 (d, J=8.3, 2H), 3.72 (t, J=6.8, 2H), 3.55 (t, 
J=6.4, 2H), 2.04-1.94 (m, 4H). 
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4.3.3.6  Synthesis of methyl 5-bromonicotinate, A4-1 
 
 
 
Procedure 
(i) 5-Bromonicotinic acid (A4) (5.00 g, 0.02 mol) was added to a solution of MeOH 
(50 mL) dissolved with EDCI (4.99 g, 0.03 mol). Afterwards, DiPEA (6 mL) 
was added and left to stir at room temperature for 2 hours. Upon completion of 
reaction, MeOH was removed in vacuo, and the solids were washed with water, 
filtered and dried to afford methyl 5-bromonicotinate (A4-1) as light yellow 
solid in 95% yield, (5.11 g, 0.02 mol). Rf (EtOAc:Hex; 3:7; v/v) 0.4 and 
proceeded to next step without further purification. 
 
4.3.3.7  Synthesis of (5-bromopyridin-3-yl)methanol, A4-2 
 
 
 
Procedure 
(ii) In a round bottom flask equipped with a magnetic stir bar, MeOH (6 mL) and 
compound A4-1 (1.62 g, 7.50 mmol) were added and left to stir for 10 mins. To 
the mixture, a solution of NaBH4 (0.70 g, 0.02 mol) in H2O solution was added 
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dropwise and continued to stir at room temperature, and refluxed for 5 hours. 
Water was added to the reaction mixture was acidified with 10% HCl, followed 
by ethyl acetate extraction and purified with EtOAc:MeOH (10:1; v/v), yielding 
(5-bromopyridin-3-yl)methanol (A4-2) as yellow oil in 48% yield (0.68 g, 3.60 
mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.1. 1H NMR (400 MHz, CDCl3): δ  8.47 (d, 
J=2.4, 1H), 8.39 (d, J=1.4, 1H), 7.88 (s, 1H), 4.68 (s, 2H). 
 
4.3.3.8  Synthesis of 5-bromonicotinaldehyde, A4-3 
 
 
 
Procedure 
(iii) A4-2 (0.68 g, 3.60 mmol) dissolved in dichloromethane (DCM) (10 mL) was 
added to a suspension of Dess-Martin Periodinane (DMP) solution, 15% (11.7 
mL, 5.40 mmol) at 0°C, and the mixture was stirred to room temperature. After 
reaction completion, judged by TLC, sufficient amount of NaHCO3 was added 
to destroy the excess of oxidant. The mixture was diluted with dichloromethane, 
and the aqueous layer was extracted with dichloromethane (3x). Combined 
organic layer extracts were washed with water, brine, dried over MgSO4 and 
concentrated to yield product 5-bromonicotinaldehyde (A4-3) as light yellow 
solid in 84% yield (0.56 g, 3.00 mmol), and used without further purification. Rf 
(EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR (400 MHz, CDCl3): δ  10.08 (s, 1H), 8.99 
(s, 1H), 8.91 (s, 1H), 8.30 (s, 1H).  
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4.3.3.9  Synthesis of methyl 4-(5-formylpyridin-3-yl)benzoate, 1n-1 
 
 
 
Procedure 
(iv) To a solution of 1,4-dioxane (15 mL) in water (2 mL) was added CS2CO3 (3.42 
g, 9.69 mmol) and left to stir bubbling (degassed) under N2 gas for 10 minutes. 
(4-(methoxycarbonyl)phenyl)boronic acid (A1) (0.63 g, 3.52 mmol) and 
compound A4-3 (0.60 g, 3.23 mmol) were then added to the mixture and 
allowed to dissolve completely, followed by Pd(PPh3)2Cl2 (0.23 g, 0.32 mmol) 
and stirred for additional 10 minutes. The reaction mixture was set to reflux at 
100°C for about 5 hours. After completion of reaction, monitored by TLC, 1,4-
dioxane iwas removed in vacuo and extracted with EtOAc, washed with water, 
brine followed by drying over MgSO4 and then concentrated. The crude residue 
was then purified by column chromatography (EtOAc:Hex; 5:1; v/v) to afford 
desired product methyl 4-(5-formylpyridin-3-yl)benzoate (1n-1) as white solid 
in 53% yield (0.42 g, 1.74 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H NMR (270 
MHz, CDCl3): δ  10.10 (s, 1H), 8.99 (s, 2H), 8.27 (s, 1H), 8.06 (d, J=11.9, 2H), 
7.60 (d, J=11.9, 2H). 
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4.3.3.10 Synthesis of methyl 4-(5-(pyrrolidin-1-ylmethyl)pyridin-3-
yl)benzoate, 1n-2 
 
 
 
Procedure 
(v) Compound 1n-1 (1.00 g, 4.15 mmol) and pyrolidine (D3) (0.38 mL, 4.51 mmol) 
were mixed together in 1,2-dichloroethane (DCE) (10 mL), and then further 
treated with sodium triacetoxyborohydride (Na(OAc)3BH) (1.30 g, 6.13 mmol), 
which was stirred for 2 hours at room temperature under N2 gas. The reaction 
mixture was quenched with saturated NaHCO3 aqueous, and extracted with 
EtOAc, washed with water and dried over MgSO4. The organic phase were 
concentrated and purified with EtOAc:Hex (5:1; v/v) to yield the product, 
methyl 4-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)benzoate (1n-2), as brownish 
sticky gel in 45% yield (0.55 g, 1.86 mmol). Rf (EtOAc:Hex; 1:2; v/v) 0.1. 1H 
NMR (270 MHz, CD3OD): δ  8.78 (d, J=2.8, 1H), 8.60 (d, J=2.4, 1H), 8.16 (s, 
1H), 8.04 (d, J=11.9, 2H), 7.73 (d, J=12.3, 2H), 4.04 (s, 2H), 3.87 (s, 3H), 2.90 
(s, 4H), 1.92 (bs, 4H). 
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4.3.3.11 Synthesis of 4-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)benzoic acid, 
2n 
 
 
 
Procedure 
(vi) Compound 1n-2 (0.55 g, 1.86 mmol) was dissolved in MeOH:THF (10 mL, 1:1; 
v/v), followed by the addition of LiOH (0.26 g, 11.15 mmol) in water (5 mL), 
and the reaction mixture was allowed to stir overnight. Upon reaction 
completion, solvents were removed in vacuo. pH of th resulting aqueous was 
adjusted to 2 with 10% HCl to obtain the desired product 4-(5-(pyrrolidin-1-
ylmethyl)pyridin-3-yl)benzoic acid (2n) as light brown solid in 95% yield (0.51 
g, 1.79 mmol), that was filtered, dried and used without further purification. Rf 
(EtOAc:Hex; 3:7; v/v) 0.0. 1H NMR (270 MHz, CD3OD): δ  8.86 (d, J=2.8, 
1H), 8.74 (d, J=2.8, 1H), 8.41 (s, 1H), 7.95 (d, J=12.3, 2H), 7.62 (d, J=12.3, 
2H), 4.55 (s, 2H), 2.13 (bs, 4H), 1.93 (s, 4H). 
 
Compounds 2h, 2l and 2m in Group 4 were synthesised, first through amide-bond 
formation, followed by Suzuki coupling and subsequent saponification, as shown in 
Scheme 4.8. 
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Scheme 4.8. Synthetic strategy for compounds 2h, 2l and 2m. 
 
Compound 2n was obtained in a slightly different manner where, the ester A4-1 was 
reduced to the alcohol A4-2 first. This alcohol was then reoxidised to the aldehyde (A4-
3), which was then subjected to the Suzuki coupling reaction with phenylboronic ester 
(A1). The aldehyde (1n-1) was treated to a reductive amination with pyrrolidine, and 
subsequent saponification of the ester (1n-2) gave the desired product in 26% overall 
yield (Scheme 4.9). 
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Scheme 4.9. Synthetic strategy for compound 2n. 
 
 
4.3.4 Synthesis of Carboxylic Acids in Group 5 
 
 
Figure 4.7. Compounds of Group 5. 
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4.3.4.1  Synthesis of compounds 2p and 2q 
 
 
(i) neat, reflux, 60°C; (ii) MsCl, TEA, DCM, 0°C; (iii) K2CO3, DMF, 60°C; (iv) 
LiOH/H2O, THF. 
Scheme 4.10. Synthetic strategy for compounds 2p and 2q. 
 
4.3.4.2  Synthesis of 3-(piperidin-1-yl)propan-1-ol, D6a 
 
 
 
Procedure 
(i) Piperidine (D4) (2.18 mL, 0.02 mol) was refluxed at 60°C, followed by 
dropwise addition of 2-bromoethanol (D6) (1.00 mL, 0.01 mol) in 1 hour with 
continuous stirring and monitoring by TLC analysis.  The compounds was 
extracted with diethyl ether and concentrated to afford crude compound 3-
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(piperidin-1-yl)propan-1-ol (D6a) as light orange solid in 82% yield (1.30 g, 
9.08 mmol). The compound was further used without any purification. Synthesis 
of 2-(piperidin-1-yl)ethanol (D5a) requires the same procedure by using 3-
bromopropanol (D5) and piperidine (D4) as starting materials. Rf (EtOAc:Hex; 
3:7; v/v) 0.25. 1H NMR (400 MHz, CDCl3): δ  3.73 (t, J=5.1, 2H), 2.49 (t, 
J=5.6, 2H), 2.37 (bs, 4H), 1.62 (q, J=5.3, 2H), 1.50 (q, J=5.6, 4H), 1.36 (bs, 
2H). 
 
(a) Spectral data for 2-(piperidin-1-yl)ethanol, D5a 
 
Light orange powder in 90% yield (1.64 g, 0.01 mol). 1H NMR (400 MHz, CDCl3): δ  
3.61 (t, J=5.2, 2H), 2.48 (t, J=5.6, 2H), 2.41 (bs, 4H), 1.61-1.55 (m, 2H), 1.46-1.45 
(bm, 2H). 
 
4.3.4.3  Synthesis of 3-(piperidin-1-yl)propyl methanesulfonate, D6b 
 
 
 
Procedure 
(ii) To a solution of D6a (1.80 g, 0.01 mol) in dichloromethane (35 mL) was added 
triethylamine (2 mL), followed by dropwise addition of methanesulfonyl 
chloride (MsCl) (0.79 mL, 0.02 mol) at 0°C. The mixture was allowed to stir for 
30 minutes and another additional 1 hour stir at room temperature. The resulting 
mixture was diluted with EtOAc after it was concentrated, washed with water, 
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brine, dried over MgSO4 and concentrated. Flash chromatography of 
EtOAc:Hex (1:5; v/v) elution gave purified compound of 3-(piperidin-1-
yl)propyl methanesulfonate (D6b) as orange liquid in 13% yield (0.37 g, 1.67 
mmol). Synthesis of 2-(piperidin-1-yl)ethyl methanesulfonate (D5b) required 
the same procedure by using D5a as starting material where D5b was then used 
without any purification for the next step. Rf (EtOAc:Hex; 3:7; v/v) 0.3. 1H 
NMR (400 MHz, DMSO-d6): δ  4.12 (t, J=8.2, 2H), 3.39 (bt, J=5.8, 6H – 
Overlap H2O), 2.42 (q, J=8.2, 2H), 2.29 (s, 3H), 1.62 (bm, 4H), 1.41 (m, 2H). 
 
(a) Spectral data for 2-(piperidin-1-yl)ethyl methanesulfonate, D5b 
 
Reaction proceed to next step without purification. 
 
4.3.4.4 Synthesis of methyl 4'-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-
carboxylate, 1q-1 
 
 
 
Procedure 
(iii) In a round bottom flask equipped with a magnetic stirrer, methyl 4'-hydroxy-
[1,1'-biphenyl]-4-carboxylate (F2) (0.35 g, 1.52 mmol) was dissolved in DMF (6 
mL) and K2CO3 (0.42 g, 3.04 mmol) was added to the mixture. Mesylated 
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compound D6b (0.37 g, 1.67 mmol) was later added to the mixture and left to 
stir at 60°C until completion of the reaction. The reaction mixture was then 
extracted with EtOAc. The organic layer was washed with water, brine and dried 
over MgSO4 to obtain the product, methyl 4'-(3-(piperidin-1-yl)propoxy)-[1,1'-
biphenyl]-4-carboxylate (1q-1), as light yellow solid in 63% yield (0.34 g, 0.95 
mmol), which was used without further purification for the next step. To obtain 
methyl 4'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylate (1p-1), the 
same procedure was employed by using D5b as the starting material. Rf 
(EtOAc:Hex; 3:7; v/v) 0.35. 1H NMR (400 MHz, CDCl3): δ  8.04 (d, J=8.3, 
2H), 7.61 (d, J=8.3, 2H), 7.55 (d, J=8.7, 2H), 6.98 (d, J=8.7, 2H), 4.05 (t, 
J=6.3, 2H), 2.49 (t, J=7.8, 2H), 2.41 (bs, 4H), 2.00 (q, J=6.6, 2H), 1.59 (q, 
J=5.6, 4H), 1.44 (bm, 2H). 
 
(a) Spectral data for methyl 4'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4- 
carboxylate, 1p-1 	  
 
Light yellow powder in 60% yield (0.44 g, 1.31 mmol). 1H NMR (400 MHz, CDCl3): 
δ  8.07 (d, J=8.8, 2H), 7.61 (d, J=8.0, 2H), 7.56 (d, J=8.8, 2H), 6.99 (d, J=8.8, 2H), 
4.16 (t, J=6.4, 2H), 2.80 (t, J=6.4, 2H), 2.53 (bs, 4H), 1.65-1.59 (m, 2H), 1.47-1.145 
(bm, 2H). 
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4.3.4.5 Synthesis of 4'-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-
carboxylic acid, 2q 
 
 
 
Procedure 
(iv) Compound 1q-1 (0.30 g, 0.85 mmol) was dissolved in THF:MeOH (6 mL; 1:1; 
v/v), followed by the addition of LiOH (40 mg, 1.69 mmol) in water (3 mL), and 
the reaction mixture was allowed to stir overnight. Upon reaction completion, 
solvents were removed in vacuo. pH of the resulting aqueous mixture was 
adjusted to 2 with 10% HCl to obtain the desired product 4'-(3-(piperidin-1-
yl)propoxy)-[1,1'-biphenyl]-4-carboxylic acid (2q) as white solid in 99% yield 
(0.29 g, 0.84 mmol), and used for next step without further purification. 4'-(2-
(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylic acid (2p) was obtained with 
the same procedure by using 1p-1 as the starting material. Rf (CH2Cl2:MeOH; 
10:1; v/v) 0.0. 1H NMR (400 MHz, DMSO-d6): δ  7.97 (d, J=8.0, 2H), 7.74 (d, 
J=7.9, 2H), 7.68 (d, J=8.3, 2H), 7.05 (d, J=8.3, 2H), 4.10 (t, J=5.8, 2H), 2.96 
(bm, 6H), 2.14 (bs, 2H), 1.72 (bs, 4H), 1.50 (bs, 2H). 
 
(a) Spectral data for 4'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylic acid,  
2p 
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White powder in 97% yield (0.37 g, 1.14 mmol). 1H NMR (400 MHz, CD3Cl): δ  8.17 
(d, J=8.0, 2H), 7.68 (d, J=7.6, 2H), 7.56 (d, J=8.4, 2H), 6.99 (d, J=8.8, 2H), 4.20 (t, 
J=6.0, 2H), 2.89 (t, J=5.2, 2H), 2.64 (bs, 4H), 1.70-1.65 (m, 4H), 1.50 (bm, 2H). 
 
4.3.4.6  Preparation of compounds 2v and 2x 
 
(i) Pd(PPh3)2Cl2, CS2CO3, 1,4-Dioxane, H2O, 100°C; (ii) K2CO3, DMF; (iii) Zn, NH4Cl, 
THF, H2O; (iv) AcCl, DCM, TEA, 0°C; (v) LiOH/H2O, THF. 
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4.3.4.7  Synthesis of methyl 4'-hydroxy-[1,1'-biphenyl]-4-carboxylate, F2 
 
 
 
Procedure 
(i) To a solution of 1,4-dioxane (60 mL) and water (15 mL) was added CS2CO3 
(13.58 g, 0.04 mol) and left to stir bubbling (degassed) under N2 gas for 10 
minutes. (4-(methoxycarbonyl)phenyl)boronic acid (A1) (5.00 g, 0.03 mol) and 
4-bromophenol (D2) (5.76 g, 0.03 mol) was then added to the mixture and 
allowed to dissolve completely followed by addition of Pd(PPh3)2Cl2 (0.39 g, 
0.56 mmol) and stirring for additional 10 minutes. Reaction mixture was set to 
reflux at 100°C for about 4 hours. After reaction completion monitored by TLC, 
1,4-dioxane was removed in vacuo and extracted with EtOAc, washed with 
water, brine followed by drying over MgSO4 and concentrated to afford crude 
residue (5.28 g), which was recrystallized in acetone-methanol solution to obtain 
product of methyl 4'-hydroxy-[1,1'-biphenyl]-4-carboxylate (F2) as white 
powder in 70% yield (4.44 g, 0.02 mol). Rf (EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR 
(400 MHz, CDCl3): δ  8.07 (d, J=8.4, 2H), 7.61 (d, J=7.9, 2H), 7.52 (d, J=8.8, 
2H), 6.93 (d, J=8.8, 2H), 3.93 (s, 3H).  
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4.3.4.8 Synthesis of methyl 4'-((4-nitrobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylate, 1x-1 
 
 
 
Procedure 
(ii) In a round bottom flask equipped with a magnetic stir bar, compound F2 (0.80 
g, 3.51 mmol) was dissolved in DMF (10 mL) and K2CO3 (1.00 g, 7.24 mmol) 
was added to the mixture. 1-(bromomethyl)-4-nitrobenzene (C5) (0.76 g, 3.50 
mmol) was later added to the mixture and left to stir at room temperature for 2 
hours. Water was added upon reaction completion to obtain methyl 4'-((4-
nitrobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate (1x-1) as white powder in 99% 
yield (1.26 g, 3.46 mmol) which was filtered and used without further 
purification. To obtain methyl 4'-((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylate (1v-1), the exact procedure was employed by using 1-
(bromomethyl)-2-nitrobenzene (C4) as the starting materials. Rf (EtOAc:Hex; 
3:7; v/v) 0.35. 1H NMR (400 MHz, CDCl3): δ  8.26 (d, J=8.5, 2H), 8.08 (d, 
J=8.5, 2H), 7.63 (d, J=7.9, 2H), 7.61 (d, J=8.2, 2H), 7.58 (d, J=8.8, 2H), 7.05 
(d, J=8.0, 2H), 5.23 (s, 2H), 3.93 (s, 3H). 
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(a) Spectral data for methyl 4'-((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate,   
1v-­‐1	  
 
 
White solid in 98% yield (1.25 g, 3.44 mmol). 1H NMR (400 MHz, CDCl3): δ  8.12 (d, 
J=8.3, 1H), 8.01 (d, J=8.7, 2H), 7.86 (d, J=9.3, 1H), 7.63 (t, J=8.8, 1H), 7.55 (d, 
J=8.5, 2H), 7.52 (d, J=9.0, 2H), 7.44 (t, J=8.0, 1H), 7.01 (d, J=8.7, 2H), 6.87 
(impurities), 5.48 (s, 2H), 3.86 (s, 3H). 
  
4.3.4.9 Synthesis of methyl 4'-((4-aminobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylate, 1x-2 
 
 
 
Procedure 
(iii) To a solution of tetrahydrofuran (100 mL) mixed with water (10 mL) was added 
ammonium chloride (0.88 g, 0.16 mol), compound 1x-1 (0.60 g, 1.65 mmol), 
followed by excess amount of zinc powder (0.54 g, 8.25 mmol). Reaction 
mixture was stirred at room temperature overnight. Water was added after 
reaction was completed, filtered through celite and dried over MgSO4. Organic 
phase was concentrated to afford the desired product of methyl 4'-((4-
aminobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate (1x-2) as pale yellow powder 
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O
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in 99% yield (0.54 g, 1.63 mmol) with no further purification. To obtain methyl 
4'-((2-aminobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate (1v-2), the exact 
procedure was employed by using 1v-1 as the starting materials. Rf (EtOAc:Hex; 
3:7; v/v) 0.0. 1H NMR (400 MHz, DMSO-d6 + MeOD): δ  7.98 (d, J=8.5, 2H), 
7.74 (d, J=8.5, 2H), 7.65 (d, J=8.7, 2H), 7.09 (d, J=8.3, 2H), 7.06 (d, J=8.8, 
2H), 6.55 (d, J=8.3, 2H), 4.90 (s, 2H), 3.84 (s, 3H). 
 
(a) Spectral data for methyl 4'-((2-aminobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate, 
1v-2 
 
White solid in 99% yield (0.820 g, 2.459 mmol).  
Reaction proceeded to next step without purification based on similar TLC profile as 
compound 1x-2. 
 
4.3.4.10 Synthesis of methyl 4'-((4-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylate, 1x-3 
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Procedure 
(iv) To a stirred solution of compound 1x-2 (0.62 g, 1.86 mmol) in dichloromethane 
(25 mL), triethylamine (0.78 mL, 5.58 mmol) was added and cooled to 0°C. 
Acetyl chloride (AcCl) (0.26 mL, 3.72 mmol) was then added dropwise and the 
reaction was left to stir for additional 2 hours to room temperature. Progress of 
the reaction was monitored by TLC. Water was added to quench the completed 
reaction and extracted with dichloromethane. The organic phase was then 
washed with water, brine and dried over MgSO4. Flash chromatography of 
CH2Cl2:MeOH (9:1, v/v) elution gave purified compound methyl 4'-((4-
acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate (1x-3) as light yellow solid 
in 85% yield (0.59 g, 1.58 mmol). The same procedure was followed for 
compound methyl 4'-((2-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylate 
(1v-3) by using 1v-2 as the starting material. Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H 
NMR (400 MHz, DMSO-d6): δ  9.98 (s, NH), 7.98 (d, J=7.0, 2H), 7.77 (d, 
J=8.3, 2H), 7.68 (d, J=8.9, 2H), 7.58 (d, J=7.3, 2H), 7.37 (d, J=8.0, 2H), 7.10 
(d, J=8.7, 2H), 5.07 (s, 2H), 3.85 (s, 3H), 2.02 (s, 3H). 
 
(a) Spectral data for methyl 4'-((2-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylate, 1v-3 
 
Light yellow solid in 85% yield (0.77 g, 2.04 mmol). 1H NMR (400 MHz, CDCl3): δ  
8.01 (d, J=8.8, 2H), 7.97 (t overlap, J=7.6, 1H), 7.53 (t overlap, J=7.6, 4H), 7.32 (t, 
MeOOC
O
N
H
O
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J=8.0, 1H), 7.28 (d, J=7.2, 1H), 7.08 (t, J=8.0, 1H), 7.02 (d, J=8.8, 2H), 5.06 (s, 2H), 
3.86 (s, 3H), 2.10 (s, 3H).   
 
4.3.4.11 Synthesis of 4'-((4-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-
carboxylic acid, 2x 
 
 
 
Procedure 
(v) Compound 1x-3 (0.30 g, 0.80 mmol) was dissolved in THF (20 mL) followed by 
the addition of LiOH (0.96 g, 4.00 mmol) in water (10 mL) and the reaction 
mixture was allowed to stir overnight. Upon reaction completion, solvents were 
removed in vacuo. pH of the resulting aqueous mixture was adjusted to 2 with 
10% HCl to obtain the desired product 4'-((4-acetamidobenzyl)oxy)-[1,1'-
biphenyl]-4-carboxylic acid (2x), as light yellow powder in 95% yield (0.28 g, 
0.76 mmol), and proceeded to next step without further purification. The same 
procedure was followed for compound 4'-((2-acetamidobenzyl)oxy)-[1,1'-
biphenyl]-4-carboxylic acid (2v) by using 1v-3 as the starting material. Rf 
(EtOAc:Hex; 3:7; v/v) 0.0. 1H NMR (400 MHz, DMSO-d6): δ  10.03 (s, NH), 
7.88 (d, J=8.4, 2H), 7.60 (d, J=4.4, 2H), 7.58 (d, J=4.0, 2H), 7.51 (d, J=8.4, 
2H), 7.37 (d, J=8.4, 2H), 7.06 (d, J=8.8, 2H), 5.05 (s, 2H), 2.03 (s, 3H). 
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(a) Spectral data for 4'-((2-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-carboxylic acid, 
2v 
 
White solid in 92% yield (0.62 g, 1.72 mmol). 1H NMR (400 MHz, DMSO-d6): δ  8.38 
(bs, NH), 7.99 (d, J=8.3, 2H), 7.74 (t, J=7.3, 1H), 7.51 (t overlap, J=8.8, 4H), 7.32-
7.27 (m, 2H), 7.10 (t, J=6.8, 1H), 7.00 (d, J=8.3, 2H), 5.05 (s, 2H), 2.08 (s, 3H). 
 
Group 5 compounds consisted of 2p, 2q, 2v, 2w and 2x. For compounds 2p and 2q, 
initial alkylation of piperidine under neat thermal condition gave the substituted 
piperidinyl compounds D5a and D6a, respectively. Protection of the hydroxyl group 
with methanesulfonyl chloride, followed by Williamson synthesis and saponification 
with lithium hydroxide furnished the desired carboxylic acid 2p and 2q (Scheme 4.10). 
Some decomposition was encountered in the preparation of compound D5b. This may 
be due to the low carbon number in the alkyl chain making the mesylated compound 
unstable, which decomposed during the acidic workup. Thus, in the preparation of 
compound 1p-1, the Williamson ether synthesis was carried through without isolation 
of the mesylated intermediate. 
 
As for compounds 2v, 2w and 2x, Suzuki coupling reaction of phenylboronic ester 
(A1) with 4-hydroxybromobenzene (D2) gave the methyl 4-hydroxy biphenyl 
carboxylate (F2). Williamson ester synthesis of the methyl 4-hydroxy biphenyl 
carboxylate (F2) with o-, m-, and p-bromomethylnitrobenzene gave the compounds 1v-
1, 1w-1 and 1x-1, respectively. Reduction of the nitro group using zinc dust in a mixture 
HOOC
O
N
H
O
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of ammonium chloride, tetrahydrofuran and water on compounds 1v-1, 1w-1 and 1x-1, 
followed by N-acetylation and saponification gave the desired compounds 2v, 2w and 
2x, as shown in Scheme 4.11. 
 
 
Scheme 4.11. Synthetic strategy for compounds 2v, 2w and 2x. 
 
4.3.5 Synthesis of Carboxylic Acids in Group 6 
 
Figure 4.8. Compounds of Group 6. 
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4.3.5.1 Synthesis of product Methyl 4'-amino-[1,1'-biphenyl]-4-carboxylate,  
1r-1 
 
 
 
Procedure 
(i) To a solution of 1,4-dioxane (30 mL) and water was added CS2CO3 (6.4 g, 18.00 
mmol), and left to stir bubbling (degassed) under N2 gas for 10 minutes. (4-
(methoxycarbonyl)phenyl)boronic acid (A1) (1.00 g, 6.00 mmol) and 4-
bromoaniline (C2) (0.83 g, 4.80 mmol) were then added to the mixture and 
allowed to dissolve completely, followed by addition of Pd(PPh3)2Cl2 (0.42 g, 
0.60 mmol) and stirring for an additional 10 minutes. The reaction mixture was 
set to reflux at 100°C for about 2-4 hours. After completion of the reaction 
monitored by TLC, 1,4-dioxane was removed under reduced pressure and 
extracted with EtOAc (3x) and washed with water, brine followed by drying 
over MgSO4 and then concentrated. The crude residue was then purified by 
column chromatography (EtOAc:Hex; 3:1; v/v) to afford the desired product, 
methyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (1r-1), as yellow solid in 50% 
yield, (0.55 g, 2.42 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.3. 1H NMR (400 MHz, 
CDCl3): δ  8.05 (d, J=8.5, 2H), 7.59 (d, J=8.5, 2H), 7.46 (d, J=8.5, 2H), 6.76 
(d, J=8.7, 2H), 3.92 (s, 3H), 3.81 (bs, NH2). 
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4.3.5.2 Synthesis of methyl 4'-propionamido-[1,1'-biphenyl]-4-carboxylate, 
1r-2 
 
 
 
Procedure 
(ii) To a round bottom flask equipped with a magnetic stirrer, was added compound 
1r-1 (0.46 g, 2.02 mmol), propionic acid (B4) (1.53 mL, 2.02 mmol) and HATU 
(1.00 g, 2.63 mmol), dissolved in DMF (6 mL) and stirred under N2 gas 
atmosphere. Afterwards, DiPEA (2 mL) was added to the mixture and the 
reaction mixture was left to stir for 3 hours. Water (100 mL) was then added to 
the reaction mixture, filtered and dried to afford methyl 4'-propionamido-[1,1'-
biphenyl]-4-carboxylate (1r-2) as light yellow solid in 80% yield (0.46 g, 1.62 
mmol), which were used for the next step without purification. Rf (EtOAc:Hex = 
3:7; v/v) 0.15. 1H NMR (400 MHz, CDCl3): δ  8.08 (d, J=8.0, 2H), 7.64-7.53 
(m, 6H), 7.21 (bs, NH), 3.93 (s, 3H), 2.43 (dd, J=7.9, 15.5, 2H), 1.27 (t, J=7.2, 
3H).  
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4.3.5.3 Synthesis of methyl 4'-propionamido-[1,1'-biphenyl]-4-carboxylic 
acid, 2r 
 
 
 
Procedure 
(iii) Compound 1r-2 (0.46 g, 1.62 mmol) was dissolved in THF (40 mL), followed 
by the addition of LiOH (0.19 g, 8.11 mmol) in water (20 mL) and the reaction 
mixture was allowed to stir overnight. Upon completion of reaction, solvents 
were removed in vacuo. pH of the resulting aqueous mixture was adjusted to 2 
with 10% HCl to obtain the desired product, 4'-propionamido-[1,1'-biphenyl]-4-
carboxylic acid (2r) as pale brown solid in 93% yield (0.41 g, 1.52 mmol) and 
used without purification for next step. Rf (EtOAc:Hex; 2:1; v/v) 0.0. 1H NMR 
(400 MHz, DMSO-d6): δ  10.02 (s, NH), 7.98 (d, J=8.3, 2H), 7.65 (d, J=8.3, 
2H), 7.72 (d, J=9.3, 2H) 7.67 (d, J=8.5, 2H), 2.34 (dd, J=7.5, 15.1, 2H), 1.08 
(t, J=7.6, 3H). 
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4.3.5.4 Synthesis of 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline, D1a 
 
 
 
Procedure 
(i) To a solution of 1,4-dioxane (30 mL) was added [1-1’-
bis(diphenylphosphino)ferrocene]dichloropalladium (Pd(dppf)Cl2) (0.40 g, 0.49 
mmol) and degassed for 10 minutes, followed by the addition of KOAc (0.97 g, 
9.89 mmol). 4-bromo-2-methoxyaniline (D1) (1.00 g, 4.95 mmol) and 
bis(pinacolato)diboron (1.89 g, 7.42 mmol) was added to the mixture, degassed 
for another 10 minutes and then refluxed at 80°C. The reaction mixture was 
filtered through celite and extracted with EtOAc, washed with water, brine, 
dried over MgSO4 and concentrated to afford the crude product, which was 
purified by flash column chromatography with EtOAc:Hex (3:7; v/v) to yield 
product of 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
(D1a) as brown liquid in 88% yield (1.08 g, 4.35 mmol). Rf (EtOAc:Hex; 3:7; 
v/v) 0.3. 1H NMR (400 MHz, CDCl3): δ  7.33 (d, J=7.9, 1H), 7.24 (s, 1H), 6.72 
(d, J=7.6, 1H), 3.91 (s, 3H), 1.36 (s, 12H). 
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4.3.5.5  Synthesis of methyl 4-bromo-2-fluorobenzoate, B2a 
 
 
 
Procedure 
(ii) 4-Bromo-2-fluorobenzoic acid (B2) (1.00 g, 4.56 mmol) was added to a solution 
of MeOH (100 mL) dissolved with EDCI (0.92 g, 4.82 mmol). Afterwards, 
DiPEA (1.20 mL, 5.94 mmol) was added and left to stir at room temperature for 
2 hours. Upon completion of the reaction, MeOH was removed in vacuo and the 
solids were washed with water, filtered and dried to afford methyl 4-bromo-2-
fluorobenzoate (B2a) as light yellow solid in 67% (0.71 g, 3.06 mmol). This was 
used for the next step without purification. Rf (EtOAc:Hex; 3:7; v/v) 0.4. 1H 
NMR (400 MHz, CDCl3): δ  7.82-7.77 (m, 1H), 7.35-7.29 (m, 2H), 3.89 (s, 
3H). 
 
4.3.5.6 Synthesis of methyl 4'-amino-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-
carboxylate, 1s-1 
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Procedure 
(iii) To a solution of 1,4-dioxane (30 mL) and water (10 mL), was added CS2CO3 
(3.79 g, 0.01 mol) and left to stir bubbling (degassed) under N2 gas for 10 
minutes. Compound D1a (0.89 g, 3.58 mmol) and compound B2a (1.00 g, 4.29 
mmol) were then added to the mixture and allowed to dissolve completely 
followed by addition of Pd(PPh3)2Cl2 (0.25 g, 0.36 mmol) and stirred for an 
additional 10 minutes. Reaction mixture was set to reflux at 100°C for about 4.5 
hours. After reaction completion, monitored by TLC, 1,4-dioxane was removed 
in vacuo and extracted with EtOAc, washed with water, brine followed by 
drying over MgSO4 and concentration. The crude residue was then purified by 
column chromatography (EtOAc:Hex; 3:7; v/v) to afford the desired product 
methyl 4'-amino-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-carboxylate (1s-1) as 
yellow solid in 60% yield (0.59 g, 2.14 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H 
NMR (400 MHz, CDCl3): δ  7.88 (t, J=8.0, 1H), 7.31 (dd, J=2.0, 8.4, 1H), 7.23 
(dd, J=2.0, 12.8, 1H), 7.02 (dd, J=2.0, 8.0, 1H), 6.96 (d, J=2.0, 1H), 6.70 (d, 
J=8.4, 1H), 3.92 (bs, NH), 3.86 (s, 6H). 
 
4.3.5.7 Synthesis of methyl 4'-(cyclopropanecarboxamido)-3-fluoro-3'-
methoxy-[1,1'-biphenyl]-4-carboxylate, 1s-2 
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Procedure 
(iv) To a round bottom flask equipped with a magnetic stirrer was added compound 
1s-1 (0.50 g, 1.82 mmol), cyclopropanecarboxylic acid (B3) (0.14 mL, 1.82 
mmol), and HATU (0.90 g, 2.36 mmol) dissolved in DMF (6 mL) and stirred 
under N2 gas atmosphere. Afterwards, DiPEA (2 mL) was added to the mixture 
and reaction mixture was left to stir for 3 hours. Water (100 mL) was added to 
the reaction mixture, filtered and dried to afford methyl 4'-
(cyclopropanecarboxamido)-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-carboxylate 
(1s-2) as light yellow solid in 90% yield (0.56 g, 1.63 mmol) which was used 
without further purification. Rf (EtOAc:Hex; 3:7; v/v) 0.3. Reaction proceed to 
next step without purification. 
 
4.3.5.8 Synthesis of 4'-(cyclopropanecarboxamido)-3-fluoro-3'-methoxy-
[1,1'-biphenyl]-4-carboxylic acid, 2s 
 
 
 
Procedure 
(v) Compound of 1s-2 (0.50 g, 1.46 mmol) was dissolved in MeOH:THF (10 mL; 
1:1; v/v), followed by addition of LiOH (0.17 g, 7.28 mmol) in water (5 mL), 
and the reaction mixture was allowed to stir overnight. Upon reaction 
completion monitored by TLC, solvents were removed in vacuo. pH of the 
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resulting aqueous mixture wass adjusted to 2 with 10% HCl to obtain the desired 
product, 4'-(cyclopropanecarboxamido)-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-
carboxylic acid (2s) as white solid in 95% yield (0.45 g, 1.38 mmol), that was 
filtered and dried, used without further purification. Rf (EtOAc:Hex; 3:7; v/v) 
0.0. 1H NMR (400 MHz, CD3OH): δ  8.00 (d, J=8.3, 1H), 7.93 (t, J=7.8, 1H), 
7.51 (d, J=8.5, 1H), 7.45 (d, J=11.9, 1H), 7.29 (s, 1H), 7.24 (d, J=8.3, 1H), 
3.99 (s, 3H), 1.86 (m, 1H), 0.96-0.95 (m, 2H), 0.87-0.85 (m, 2H). 
 
4.3.5.9 Synthesis of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline, C3a 
 
 
 
Procedure 
(i) To a solution of 1,4-dioxane (15 mL) was added [1-1’-
bis(diphenylphosphino)ferrocene]dichloropalladium (Pd(dppf)Cl2) (0.21 g, 0.26 
mmol) and degassed for 10 minutes, followed by the addition of KOAc (0.52 g, 
5.26 mmol). 4-bromo-3-fluoroaniline (C3) (0.50 g, 2.63 mmol) and 
bis(pinacolato)diboron (1.00 g, 3.94 mmol) was added to the mixture, degassed 
for another 10 minutes and then refluxed at 80°C. The reaction mixture was 
filtered through celite and extracted with EtOAc (3x), washed with water, brine, 
dried over MgSO4 and concentrated to afford crude product, which afterwards 
purified by flash column chromatography with EtOAc:Hex (3:7; v/v) to yield 
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product of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (C3a) 
as light brown solid in 99% yield (0.62 g, 2.61 mmol). Rf (EtOAc:Hex; 3:7; v/v) 
0.3. 1H NMR (400 MHz, CDCl3): δ  7.15 (t, J=7.8, 1H), 6.36 (dd, J=2.7, 10.5, 
1H), 6.26 (dd, J=2.7, 8.8, 1H), 3.55 (bs, NH2), 1.25 (s, 12H). 
 
4.3.5.10 Synthesis of methyl 4'-amino-2',3-difluoro-[1,1'-biphenyl]-4-
carboxylate, 1t-1 
 
 
 
Procedure 
(ii) To a solution of 1,4-dioxane (15 mL) and water (5 mL), was added CS2CO3 
(1.58 g, 4.83 mmol), and left to stir bubbling (degassed) under N2 gas for 10 
minutes. Compound C3a (0.63 g, 2.66 mmol) and compound B2a (0.56 g, 2.42 
mmol) were then added to the mixture and allowed to dissolve completely 
followed by addition of Pd(PPh3)2Cl2 (0.20 g, 0.24 mmol) and stirring for an 
additional 10 minutes. The reaction mixture was set to reflux at 100°C for about 
4 hours. After completion of reaction monitored by TLC, 1,4-dioxane was 
removed in vacuo and extracted with EtOAc, washed with water, brine followed 
by drying over MgSO4 and concentration. The crude residue was then purified 
by column chromatography (EtOAc:Hex; 3:7; v/v) to afford desired product 
methyl 4'-amino-2',3-difluoro-[1,1'-biphenyl]-4-carboxylate (1t-1) as yellow 
solid in 63% (0.41 g, 1.54 mmol). Rf (EtOAc:Hex; 3:7; v/v) 0.2. 1H NMR (400 
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MHz, CD3OD): δ  7.90 (t, J=7.9, 1H), 7.38 (d, J=8.2, 1H), 7.31 (d, J=12.8, 
1H), 7.26 (t, J=8.5, 1H), 6.54 (dd, J=2.1, 6.4, 1H), 6.46 (dd, J=2.1, 11.8, 1H), 
3.89 (s, 3H). 
 
4.3.5.11 Synthesis of methyl 4'-(cyclopropanecarboxamido)-2',3-difluoro-
[1,1'-biphenyl]-4-carboxylate, 1t-2 
 
 
 
Procedure 
(iii) To a round bottom flask equipped with a magnetic stirrer was added compound 
1t-1 (0.37 g, 1.41 mmol), cyclopropanecarboxylic acid (B3) (0.11 mL, 1.41 
mmol), HATU (0.70 g, 1.82 mmol) and dissolved in DMF (6 mL) with stirring 
under N2 gas atmosphere. Afterwards, DiPEA (1 mL) was added to the mixture 
and reaction mixture was left to stir for 3 hours. Water (80 mL) was added to the 
reaction mixture, filtered and dried to afford methyl 4'-
(cyclopropanecarboxamido)-2',3-difluoro-[1,1'-biphenyl]-4-carboxylate (1t-2) as 
light yellow solid in 92% yield (0.43 g, 1.30 mmol)  which was then used 
without further purification. Rf (EtOAc:Hex; 1:1; v/v) 0.3. 1H NMR (400 MHz, 
CDCl3): δ  7.92 (t, J=8.0, 1H), 7.55 (d, J=12.9, 1H), 7.44 (s, 1H), 7.34-7.25 (m, 
3H overlap), 1.47-1.45 (m, 1H overlap), 1.08-1.04 (m, 2H), 0.86-0.81 (m, 2H). 
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4.3.5.12 Synthesis of 4'-(cyclopropanecarboxamido)-2',3-difluoro-[1,1'-
biphenyl]-4-carboxylic acid, 2t 
 
 
 
Procedure 
(iv) Compound 1t-2 (0.43 g, 1.30 mmol) was dissolved in THF (20 mL), followed 
by addition of LiOH (0.16 g, 6.49 mmol) in water (20 mL), and the reaction 
mixture was allowed to stir overnight. Upon reaction completion, solvents were 
removed in vacuo. pH of the resulting aqueous mixture was adjusted to 2 with 
10% HCl to obtain the desired product 4'-(cyclopropanecarboxamido)-2',3-
difluoro-[1,1'-biphenyl]-4-carboxylic acid (2t) as light yellow solid in 99% yield 
(0.41 g, 1.29 mmol). Rf (EtOAc:Hex; 1:1; v/v) 0.0. 1H NMR (400 MHz, 
DMSO-d6): δ  10.55 (s, NH), 7.92 (t, J=8.0, 1H), 7.72 (d, J=13.6, 1H), 7.57 (t, 
J=8.8, 1H), 7.48 (s, 1H), 7.45 (s, 1H), 7.40 (d, J=8.3, 1H), 1.79-1.76 (m, 1H), 
0.84-0.82 (m, 4H). 
 
Group 6 involves three compounds, 2r, 2s and 2t. Similar strategies as in preparation 
of previous compounds, involving Suzuki coupling, amide coupling and saponification 
were employed. However, slight differences for preparation of compounds, 2s and 2t 
were encountered, whereby their starting materials, 4-bromo-2-methoxyaniline (D1) 
104 
and 4-bromo-3-floroaniline (C3), were first subjected to the Miyaura borylation before 
the Suzuki coupling reaction, as shown in Scheme 4.12. 
 
 
Scheme 4.12. Synthetic strategy for compounds 2s and 2t. 
 
In summary, all of the side chain compounds were synthesised in good to excellent 
yield. Suzuki coupling reactions were used extensively in order to link carbon-carbon 
bond. 
 
 
4.4 Synthesis of Benzimidazole Derivatives 
 
Benzimidazole compounds serve a wide range of therapeutic effects, as described in 
the previous chapters. There is a plethora of organisations involved in the pursuit of 
benzimidazole as either PARP-1, or DHODH inhibitor (White et al., 2000; Zhu et al., 
2008; Penning et al., 2009; Tong et al., 2009; Romero-Castro et al., 2011). We 
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continued our study on benzimidazoles with carboxylic acid side chains as the starting 
materials as shown in the Scheme 4.13 below, and linking these compounds to obtain 
benzimidazole as PARP-1 and DHODH inhibitors. 
 
 
Scheme 4.13. General benzimidazole synthesis route. 
 
There are various ways to prepare benzimidazole compounds reported in the 
literature. Penning and co-workers described a convenient method in synthesising the 
scaffold, as illustrated in Scheme 4.14 (Penning et al., 2008, 2010). 
 
 
Scheme 4.14. Reagents and conditions: a) CDI, DMF, pyridine; b) AcOH, heat. 
Synthetic procedure reported by Penning and co-workers (Penning et al., 2008, 2010). 
 
Zhu and co-workers (Zhu et al., 2013) also reported a procedure to prepare a 
benzimidazole derivative where the benzene ring is substituted with a pyridine ring, as 
shown in Scheme 4.15. Here, they coupled the diaminonicotinamide with 3-pipecolinic 
acid and PyBOP or SOCl2, which then underwent cyclisation in acetic acid (Zhu et al., 
2013). 
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Scheme 4.15. Reagents and conditions: a) PyBOP, 3-pipecolinic acid, DiPEA, DMF, rt, 
12h; b) AcOH, 160oC, in an autoclave, 24h. Synthetic procedure reported by Zhu and 
co-workers (Zhu et al., 2013). 
 
 
In this work, four compounds, E1, E2, E3 and E4 were used, as shown in Table 4.2, 
as the starting materials for benzimidazole compounds. The general synthesis scheme is 
shown in Scheme 4.16. 
 
 
 
Scheme 4.16. General synthesis route for benzimidazole compounds. 
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4.4.1 Synthesis of Benzimidazole Derivatives via Route 1 
 
4.4.1.1  General procedure for synthesis of 5 
 
 
 
Procedure 
(i) To a round bottom flask equipped with a magnetic stir bar was added diamine 
benzoate (3; R2 = CH3; F) (1.00 mmol), carboxylic acid 2a-x (1.00 mmol), and 
HATU (1.30 mmol), dissolved in DMF (6 mL) and stirred under N2 gas. DiPEA 
(2 mL) was then added to the mixture and the reaction mixture was left to stir 
for 3 hours. Water (100 mL) was added to the reaction mixture, filtered and 
dried to afford 5, which was used without further purification. Rf (EtOAc:Hex; 
3:7; v/v) 0.3. 
 
4.4.1.2  General procedure for synthesis of 6 
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Procedure 
(ii) Compound 5 was dissolved in acetic acid (AcOH) (10 mL) and refluxed at 
130°C until reaction was fully completed under TLC analysis monitoring. Flash 
column chromatography with EtOAc:Hex (3:1; v/v) elution yielded purified 
compound 6. Rf (EtOAc:Hex; 3:1; v/v) 0.32.  
 
4.4.1.3  General procedure for synthesis of 7 
 
 
 
Procedure 
(iii) Compound 6 was dissolved in a mixture of MeOH:THF (1:1; v/v), followed by 
addition of LiOH.H2O (3-5 eq) and the reaction mixture was allowed to stir 
overnight. Upon reaction completion, solvents were removed in vacuo. pH of 
the resulting aqueous mixture was adjusted to 2 with 10% HCl to obtain the 
desired product 7, which was filtered, dried and used without further 
purification. Rf (EtOAc:Hex; 3:7; v/v) 0.0. 
 
4.4.1.4  General procedure for synthesis of 9, 10 and 11 
 
 
N
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Procedure 
(iv) To a solution of DMF (6 mL) was added EDCI.HCl (2 mmol), HOBt (2.00 
mmol), NH4Cl (5.00 mmol), and compound 7 (1.00 mmol) followed by DiPEA 
(1 mL), and was left to stir overnight until reaction was completed, judged by 
TLC analysis. Water (100 mL) was added to the reaction mixture after which the 
resulting product was filtered and dried to afford compound 9, 10 and 11. Rf 
(EtOAc:Hex; 3:7; v/v) 0.15. 
 
 
The carboxylic acids of 2a-x were subsequently coupled with diamine 3 and 4 to 
furnish compounds 5 and 8, respectively, as illustrated in Scheme 4.16. Two different 
routes were employed to prepare the benzimidazole compounds. The first route (route 
1) involves coupling of diamine 3 using standard 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) in 
dimethylformamide (DMF), and the presence of N,N-diisopropylethylamine (DiPEA) as 
base (Zhu et al., 2012) for the formation of 5. Subsequent thermal cyclisation of 5 in 
acetic acid (AcOH) gave the intermediate 6. Saponification of the ester 6 with lithium 
hydroxide (LiOH) provided the carboxylic acid derivatives 7a-g (Table 4.3), which 
were subsequently converted to the corresponding carboxamide benzimidazole 
derivatives 9a-j, 10a-h and 11a-e with hydroxybentzotriazole (HOBt) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI.HCl). 
 
 
 
 
 
110 
4.4.2 Synthesis of Benzimidazole Derivatives via Route 2 
 
4.4.2.1  General procedure for synthesis of 8 
 
 
 
Procedure 
(i) To a solution of DMF:pyridine (1:1; v/v) was added compound 2a-x (0.90 
mmol) and 1,1’-Carbonyldiimidazole (CDI) (0.90 mmol) and stirred at 60°C 
under N2 gas atmosphere for 3 hours. After the reaction mixture is cooled down 
to room temperature, 2,3-diaminobenzamide 4 (1.00 mmol) was added and left 
to stir overnight until the completion of the reaction, monitored by TLC 
analysis. Water (100 mL) was added and the resulting product of 8 was filtered 
and dried without further purification. Rf (EtOAc:Hex; 1:1; v/v) 0.3. 
 
4.4.2.2  General procedure for synthesis of 9, 10 and 11 
 
 
 
 
NH2
R2 NH2
O R1
2HCl
COOH
R3
R4
R5
NH2
N
H
O NH2
R3
R4
R5
O
i
4 
R1 = NH2; R2 = H
2a-x 8
8
ii
N
N
H
O NH2
R3 R4
R5
9, 10, 11
NH2
N
H
O NH2
R3
R4
R5
O
111 
Procedure 
(ii) Compound 8 was dissolved in acetic acid (AcOH) (10 mL) and refluxed at 
130°C until reaction was fully completed under TLC analysis monitoring. Flash 
column chromatography with EtOAc:Hex (3:1; v/v) elution yielded purified 
compound 9, 10 and 11. Rf (EtOAc 100%) 0.33. 
 
Compounds 9a-j, 10a-h and 11a-e (Table 4.4) could also be prepared via an 
alternative route (Route 2), as shown in Scheme 4.16. Reacting 2,3-diaminobenzamide 
4 with 1,1’-carbonyldiimidazole (CDI) in pyridine and dimethylformamide (DMF) (1:1, 
v/v) with 2a-x gave the amide 8, which could be then be cyclised to the benzimidazole 9 
by refluxing in AcOH, as reported by Penning and co-workers (Penning et al., 2009). 
 
 
Table 4.3. Chemical structures of synthesised benzimidazole carboxylic acid 
derivatives. 
Entry Compound Entry Compound 
7a 
 
7e 
 
7b 
 
7f 
 
7c 
 
7g 
 
7d 
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4.4.3 NMR Data for Compounds 7a-g (Refer to Appendix A2 for spectra) 
 
(i) 2-(2'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic 
acid, 7a 
 
 
 
1H NMR (270MHz, CD3OD): δ 8.03 (d, J=8.3, 2H), 7.84 (s, 1H), 7.53 (d, J=8.3, 
1H), 7.40 (d, J=8.3, 2H), 7.38 (d, J=5.9, 1H), 7.30-7.21 (m, 3H), 2.33 (s, 3H), 
1.88 (s, 3H). 13C NMR (67MHz, CD3OD): δ 172.44, 167.62, 154.55, 145.16, 
142.97, 138.17, 135.47, 133.25, 131.39, 130.50, 129.48, 128.58, 128.52, 128.46, 
127.96, 127.44, 124.14, 115.25, 22.92, 21.29. HRMS (ESI) calculated for 
C23H19N3O3 (M+H)+: 386.1504, found 386.1510 
 
(ii) 2-(3'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic 
acid, 7b 
 
 
 
1H NMR (270MHz, DMSO-d6): δ 10.08 (s, NH), 8.37 (d, J=8.1, 2H), 7.97 (s, 
1H), 7.76 (d, J=8.4, 2H), 7.70 (s, 1H), 7.65 (s, 1H), 7.60 (bs, 1H), 7.41 (s, 1H), 
7.39 (s, 1H), 2.46 (s, 3H), 2.07 (s, 3H). 13C NMR (67MHz, DMSO-d6): δ 
HN
O
N
N
H
OHO
HN
O
N
N
H
OHO
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168.67, 166.83, 152.52, 141.74, 140.04, 139.82, 129.53, 128.60, 128.12, 126.91, 
125.80, 121.57, 118.67, 117.32, 24.12, 21.02. HRMS (ESI) calculated for 
C23H19N3O3 (M+H)+: 386.1504, found 386.1502 
 
(iii) 2-(4'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic 
acid, 7c 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 10.28 (s, NH), 8.33 (d, J=8.3, 2H), 7.91 (d, 
J=8.0, 2H), 7.83 (s, 1H), 7.81 (s, 1H), 7.75 (d, J=9.0, 2H), 7.72 (d, J=8.8, 2H), 
2.50 (s, 3H), 2.06 (s, 3H). 13C NMR (100MHz, DMSO-d6): δ 169.10, 166.12, 
151.38, 143.58, 139.96, 135.99, 134.90, 133.14, 131.05, 129.69, 128.22, 127.49, 
126.71, 123.07, 119.71, 119.44, 117.08, 24.23, 21.12. HRMS (ESI) calculated 
for C23H19N3O3 (M+H)+: 386.1504, found 386.1499 
 
(iv) 2-(2-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic 
acid, 7d 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.52 (s, NH), 8.40 (s, 1H), 8.22 (d, J=7.8, 
1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.52 (d, J=8.1, 1H), 7.49-7.46 (m, 5H), 1.95 (s, 
NH
O
N
N
H
OHO
N
N
H
O OH
NH
O
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3H). 13C NMR (100MHz, DMSO-d6): δ 169.06, 166.51, 151.76, 139.21, 138.29, 
135.32, 132.22, 130.79, 128.66, 128.55, 127.73, 127.55, 127.05, 126.43, 125.49, 
116.10, 22.97, 20.98. HRMS (ESI) calculated for C23H19N3O3 (M+H)+: 
386.1504, found 386.1505 
 
(v) 2-(4'-((2-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-
benzimidazole-4-carboxylic acid, 7e 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.66 (s, NH), 8.40 (d, J=8.5, 2H), 7.96 (d, 
J=7.9, 2H), 7.89 (bs, 2H), 7.80 (d, J=8.5, 2H), 7.47 (d, J=7.3, 1H), 7.43 (d, 
J=7.9, 1H), 7.30 (t, J=7.9, 1H), 7.20 (t, J=7.3, 1H), 7.12 (d, J=8.5, 2H), 5.16 (s, 
2H), 2.54 (s, 3H), 2.07 (s, 3H). 13C NMR (100MHz, DMSO-d6): δ 168.71, 
165.65, 158.94, 150.77, 144.10, 135.75, 130.88, 130.76, 130.04, 129.97, 129.49, 
128.71, 128.33, 128.02, 126.44, 125.42, 125.30, 121.20, 118.51, 117.25, 115.50, 
66.24, 23.31, 20.87. HRMS (ESI) calculated for C30H25N3O4 (M+H)+: 492.1923, 
found 492.1929 
 
(vi) 2-(4'-((3-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-
benzimidazole-4-carboxylic acid, 7f 
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1H NMR (400MHz, DMSO-d6): δ 10.26 (s, NH), 8.40 (d, J=8.3, 2H), 7.89 (d, 
J=8.3, 2H), 7.84 (s, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.73 (d, J=8.5, 2H), 7.60 (d, 
J=8.0, 1H), 7.31 (t, J=7.8, 1H), 7.13 (d, J=10.2, 1H), 7.10 (d, J=8.8, 2H), 5.12 
(s, 2H), 2.51 (s, CH3), 2.09 (s, CH3). 13C NMR (100MHz, DMSO-d6): δ 168.66, 
165.72, 158.89, 150.65, 143.78, 139.67, 137.47, 135.24, 134.37, 130.83, 129.99, 
129.80, 128.86, 128.41, 128.23, 126.34, 122.19, 121.55, 118.62, 118.08, 117.09, 
115.46, 115.42, 69.42, 24.12, 20.96. HRMS (ESI) calculated for C30H25N3O4 
(M+H)+: 492.1923, found 492.1922 
 
(vii) 2-(4'-((4-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-
benzimidazole-4-carboxylic acid, 7g 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 10.30 (s, NH), 8.34 (d, J=8.5, 2H), 7.88 (d, 
J=8.5, 2H), 7.78 (bs, 2H), 7.75 (d, J=8.8, 2H), 7.60 (d, J=8.5, 2H), 7.38 (d, 
J=8.5, 2H), 7.12 (d, J=8.8, 2H), 5.09 (s, 2H), 2.03 (s, CH3). 13C NMR (100MHz, 
DMSO-d6): δ 168.41, 166.14, 158.77, 151.65, 143.06, 139.09, 133.69, 131.29, 
131.14, 129.11, 128.48, 128.14, 127.34, 126.37, 124.12, 120.01, 118.95, 116.60, 
115.50, 69.18, 24.11, 20.91. HRMS (ESI) calculated for C30H25N3O4 (M+H)+: 
492.1923, found 492.1928 
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Table 4.4a,b. Chemical structures of synthesised benzimidazole carboxamide 
derivatives. 
Entry Product Entry Product Entry Product 
9aa 
 
10aa 
 
11a 
 
9b 
 
10b 
 
11b 
 
9cb 
 
10c 
 
11c 
 
9d 
 
10da 
 
11d 
 
9eb 
 
10e 
 
11e 
 
9f 
 
10f 
 
  
9g 
 
10g 
 
  
9h 
 
10h 
 
  
9i 
 
    
9j 
 
    
      
aCompounds reported by Tong and group (Tong et al., 2009). 
bCompounds reported by White and group (White et al., 2000). 
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4.4.4 NMR Data for Compounds 9a-j, 10a-h and 11a-e (Refer to Appendix A3 for 
spectra) 
 
(i) 2-([1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide, 9a 
(Tong et al., 2009) 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.39 (s, NH), 8.32 (d, J=7.8, 2H), 7.90 (d, 
J=7.8, 3H overlap), 7.77 (d, J=7.8, 3H overlap), 7.51 (t, J=7.4, 2H), 7.41 (t, 
J=7.4, 1H), 7.35 (t, J=7.9, 1H). 13C NMR (100MHz, DMSO-d6): δ 166.44, 
151.17, 142.19, 141.66, 139.21, 135.51, 129.23, 128.23, 128.12, 127.60, 127.44, 
126, 89, 123.16, 122.58, 122.41, 115.22. HRMS (ESI) calculated for C20H15N3O 
(M+H)+: 314.1293, found 314.1294  
 
(ii) 2-([1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxamide, 9b 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.29 (s, CONH2), 9.34 (s, NH), 8.31 (d, 
J=7.1, 2H), 7.91 (d, J=8.1, 1H), 7.79 (d, J=7.8, 2H), 7.72 (s, 1H), 7.54 (s, 1H), 
7.51 (t, J=7.8, 2H), 7.43 (t, J=7.3, 1H). 13C NMR (100MHz, DMSO-d6): δ 
166.33, 151.19, 141.89, 139.83, 139.18, 135.76, 132.02, 129.14, 128.23, 128.11, 
N
N
H
O NH2
N
N
H
O NH2
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127.37, 127.33, 126.80, 124.39, 121.87, 114.82, 21.34. HRMS (ESI) calculated 
for C21H17N3O (M+H)+: 328.1449, found 328.1461  
 
(iii) 2-(4-methoxyphenyl)-1H-benzimidazole-4-carboxamide, 9c 
(White et al., 2000) 
 
 
 
1H NMR (270MHz, DMSO-d6): δ 13.25 (s, CONH2), 9.44 (s, NH), 8.21 (d, 
J=8.6, 2H), 7.89 (d, J=7.3, 1H), 7.73 (d, J=7.8, 1H), 7.34 (t, J=7.8, 1H), 7.16 (d, 
J=8.6, 2H), 3.87 (s, 3H). 13C NMR (67MHz, DMSO-d6): δ 166.41, 161.19, 
152.11, 141.66, 135.35, 128.59, 122.73, 122.09, 121.92, 121.56, 114.73, 114.55, 
55.41. HRMS (ESI) calculated for C15H13N3O2 (M+H)+: 268.1085, found 
268.1081  
 
(iv) 2-(4-methoxyphenyl)-6-methyl-1H-benzimidazole-4-carboxamide, 9d 
 
 
 
1H NMR (270MHz, DMSO-d6): δ 12.99 (s, CONH2), 9.28 (s, NH), 8.09 (d, 
J=8.9, 2H), 7.61 (s, 1H), 7.41 (s, 1H), 7.07 (d, J=8.9, 2H), 3.79 (s, 3H), 2.41 (s, 
3H). 13C NMR (67MHz, DMSO-d6): δ 166.33, 161.03, 151.59, 139.84, 135.63, 
N
N
H
O NH2
O
N
N
H
O NH2
O
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131.35, 128.39, 123.97, 121.72, 121.53, 114.52, 114.47, 55.41, 21.25. HRMS 
(ESI) calculated for C16H15N3O2 (M+H)+: 282.1242, found 282.1239 
  
(v) 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-4-carboxamide, 9e 
(White et al., 2000) 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.68 (s, CONH2), 9.28 (s, NH), 8.47 (d, 
J=8.1, 2H), 7.99 (d, J=7.8, 2H), 7.91 (d, J=7.6, 1H), 7.79 (d, J=8.1, 1H), 7.41 (t, 
J=7.8, 1H). 13C NMR (100MHz, DMSO-d6): δ 165.99, 150.43, 141.33, 135.50, 
132.92, 130.45, 130.06, 127.60, 126.10, 123.43, 123.02, 122.84, 115.33. HRMS 
(ESI) calculated for C15H10N3F3O (M+H)+: 306.0853, found 306.0855 
 
(vi) 6-methyl-2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-4-carboxamide, 9f 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.52 (bs, CONH2), 9.24 (s, NH), 8.44 (d, 
J=8.1, 2H), 7.96 (d, J=8.1, 2H), 7.74 (s, 1H), 7.57 (s, 1H), 2.47 (s, 3H). 13C 
NMR (100MHz, DMSO-d6): δ 166.09, 149.81, 139.51, 135.78, 133.10, 132.54, 
130.16, 129.84, 128.14, 127.42, 126.00, 122.72, 122.19, 115.19, 21.25. HRMS 
(ESI) calculated for C16H12N3F3O (M+H)+: 320.1010, found 320.1009  
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(vii) 2-(4-cyanophenyl)-6-methyl-1H-benzimidazole-4-carboxamide, 9g 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.45 (bs, CONH2), 9.29 (s, NH), 8.31 (d, 
J=9.7, 2H), 8.06 (d, J=7.3, 2H), 7.72 (d, J=1.8, 1H), 7.55 (d, J=1.7, 1H). 13C 
NMR (100MHz, DMSO-d6): δ 167.81, 166.67, 151.10, 140.12, 136.18, 135.99, 
132.81, 132.15, 128.72, 127.03, 125.12, 122.48, 115.45, 21.77. HRMS (ESI) 
calculated for C16H12N4O (M+H)+: 277.1089, found 277.1092 
 
(viii) 2-(2'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide, 9h 
 
 
 
1H NMR (270MHz, CD3OD): δ 8.19 (d, J=8.3, 2H), 7.92 (d, J=7.8, 1H), 7.68 (d, 
J=7.8, 1H), 7.52 (d, J=8.3, 2H), 7.48 (d, J=8.1, 1H), 7.36-7.30 (m, 3H), 7.22 (t, 
J=7.5, 1H), 1.98 (s, 3H). 13C NMR (67MHz, CD3OD): δ 172.54, 153.64, 143.00, 
138.24, 135.64, 131.40, 130.63, 129.55, 129.47, 128.45, 128.08, 127.97, 124.39, 
123.50, 123.27, 122.56, 118.58, 22.90. HRMS (ESI) calculated for C22H18N4O2 
(M+H)+: 371.1507, found 371.1505 
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(viii) 2-(3'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide, 9i 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.49 (s, CONH2), 10.10 (s, NH), 9.38 (s, 
NH), 8.33 (d, J=8.3, 2H), 7.99 (s, 1H), 7.88 (d, J=7.7, 1H), 7.83 (d, J=8.3, 2H), 
7.74 (d, J=7.8, 1H), 7.60 (s, 1H), 7.42 (d, J=4.8, 2H), 7.34 (t, J=7.8, 1H), 2.07 
(s, CH3). 13C NMR (100MHz, DMSO-d6): δ 168.56, 166.22, 151.60, 142.07, 
141.55, 140.02, 139.66, 135.41, 129.48, 128.17, 127.54, 127.26, 123.02, 122.42, 
121.54, 118.35, 117.28, 115.05, 24.07. HRMS (ESI) calculated for C22H18N4O2 
(M+H)+: 371.1507, found 371.1509 
 
(x) 2-(4'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide, 9j 
 
 
 
1H NMR (270MHz, DMSO-d6): δ 8.32 (d, J=8.4, 2H), 8.22 (d, J=7.8, 1H), 8.14 
(d, J=8.1, 1H), 7.93 (d, J=8.4, 2H), 7.75 (d, J=8.6, 2H), 7.69 (d, J=8.6, 2H), 7.54 
(bs, 1H), 2.21 (s, 3H). 13C NMR (100MHz, CD3OD): δ 168.98, 167.10, 153.10, 
142.02, 139.85, 133.94, 129.92, 129.04, 128.67, 127.79, 127.48, 126.84, 126.31, 
125.17, 122.55, 119.85, 116.65, 24.54. HRMS (ESI) calculated for C22H18N4O2 
(M+H)+: 371.1507, found 371.1508 
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(xi) 2-(4-(pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide, 10a 
(Tong et al., 2009) 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.51 (bs, CONH2), 9.37 (s, NH), 9.02 (s, 
1H), 8.63 (d, J=4.6, 1H), 8.38 (d, J=8.1, 2H), 8.21 (d, J=8.3, 1H), 8.00 (d, J=8.1, 
2H), 7.90 (d, J= 7.1, 1H), 7.80 (s, 1H), 7.77 (d, J=8.1, 1H), 7.55 (dd, J=4.8, 8.0, 
1H), 7.37 (t, J=7.6, 1H). 13C NMR (100MHz, DMSO-d6): δ 166.12, 151.38, 
149.01, 147.72, 142.78, 141.49, 138.97, 135.37, 134.61, 134.21, 128.72, 127.58, 
123.97, 123.04, 122.47, 115.03. HRMS (ESI) calculated for C19H14N4O 
(M+H)+: 315.1245, found 315.1234 
 
(xii) 2-(4-(6-aminopyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide, 10b 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.39 (s, CONH2), 9.39 (s, NH), 8.39 (s, 1H), 
8.27 (d, J=8.3, 2H), 7.88-7.79 (m, 4H), 7.74 (d, J=8.3, 1H), 7.35 (t, J=7.6, 1H), 
6.58 (d, J=8.7, 1H), 6.28 (s, NH2). 13C NMR (100MHz, DMSO-d6): δ 166.21, 
159.46, 151.83, 145.83, 141.58, 140.06, 135.48, 135.36, 127.46, 126.75, 125.65, 
122.89, 122.70, 122.28, 114.90, 108.16. HRMS (ESI) calculated for C19H15N5O 
(M+H)+: 330.1354, found 330.1348 
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(xiii) 2-(4-(6-acetamidopyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide, 10c 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.48 (s, CONH2), 10.67 (s, NH), 9.38 (s, 
NH), 8.77 (s, 1H), 8.34 (d, J=8.0, 2H), 8.21 (s, 2H), 7.97 (d, J=8.0, 2H), 7.89 (d, 
J=7.3, 1H), 7.81-7.75 (m, 1H), 7.36 (t, J=8.0, 1H), 2.13 (s, 3H). 13C NMR 
(100MHz, DMSO-d6): δ 169.96, 166.70, 152.32, 152, 03, 146.42, 142.03, 
139.24, 136.72, 135.88, 130.42, 128.63, 128.06, 127.39, 123.54, 122.91, 115.54, 
113.72, 24.46. HRMS (ESI) calculated for C21H17N5O2 (M+H)+: 372.1460, 
found 372.1461 
 
(xiv) 2-(4-(pyridin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide, 10d 
(Tong et al., 2009) 
 
 
 
1H NMR (270MHz, DMSO-d6): δ 9.37 (s, NH), 8.71 (d, J=3.8, 1H), 8.37 (d, 
J=8.4, 2H), 8.30 (d, J=8.6, 2H), 8.07 (d, J=8.1, 1H), 7.93 (dd, J=1.3, 7.5, 1H), 
7.87 (d, J=7.6, 1H), 7.76 (d, J=7.6, 1H), 7.40 (dd, J=4.6, 6.7, 1H), 7.32 (t, J=7.8, 
1H). 13C NMR (67MHz, DMSO-d6): δ 166.28, 155.02, 151.79, 149.72, 149.67, 
140.25, 137.42, 128.76, 127.22, 127.10, 123.14, 122.87, 122.29, 122.18, 120.61, 
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115.62. HRMS (ESI) calculated for C19H14N4O (M+H)+: 315.1245, found 
315.1251 
 
(xv) 2-(4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-
carboxamide, 10e 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.38 (bs, NH), 8.37 (d, J=8.4, 2H), 7.96 (d, 
J=8.4, 2H), 7.90 (d, J=7.2, 1H), 7.84 (d, J=8.4, 2H), 7.78 (d, J=8.0, 1H), 7.65 (d, 
J=8.0, 2H), 7.37 (t, J=7.2, 1H), 3.51-3.48 (m, 4H), 1.90-1.83 (m, 4H). 13C NMR 
(100MHz, DMSO-d6): δ 168.34, 166.79, 152.07, 141.63, 140.77, 137.14, 
128.99, 128.75, 128.43, 128.36, 128.08, 127.94, 127.16, 127.05, 123.48, 122.92, 
115.68, 49.10, 46.51, 26.53, 24.44. HRMS (ESI) calculated for C25H22N4O2 
(M+H)+: 411.1820, found 411.1817 
 
(xvi) 2-(4-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-
carboxamide, 10f 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.03 (bs, NH), 8.66 (bs, 1H), 8.37 (d, J=8.6, 
2H), 8.33 (s, 1H), 8.07 (d, J=8.6, 2H), 7.95 (d, J=7.7, 1H), 7.90 (d, J=8.1, 1H), 
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7.83 (bs, 1H), 7.53 (t, J=8.1, 1H), 3.62 (m, 2H), 3.49 (m, 2H), 1.82 (m, 4H). 13C 
NMR (100MHz, DMSO-d6): δ 166.90, 165.35, 153.71, 151.07, 146.51, 140.53, 
136.24, 134.03, 133.79, 129.98, 128.10, 125.30, 124.89, 124.25, 122.28, 117.00, 
49.02, 46.97, 26.53, 23.98. HRMS (ESI) calculated for C24H21N5O2 (M+H)+: 
412.1773, found 412.1761 
 
(xvii) 2-(4-(5-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-
carboxamide, 10g 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.22 (s, 1H), 8.90 (s, 1H), 8.80 (bs, NH), 8.71 
(s, 1H), 8.37 (d, J=8.1, 2H), 8.07 (d, J=8.1, 2H), 7.91 (d, J=7.7, 1H), 7.86 (d, 
J=8.6 ,1H), 7.47 (t, J=8.1, 1H), 3.48-3.43 (m, 4H), 1.82-1.79 (m, 4H). 13C NMR 
(100MHz, DMSO-d6): δ 167.20, 164.47, 150.96, 144.55, 143.21, 138.35, 
138.20, 136.65, 135.39, 134.44, 129.64, 128.42, 126.31, 124.98, 124.76, 122.06, 
117.21 49.18, 46.67, 26.19, 24.24. HRMS (ESI) calculated for C24H21N5O2 
(M+H)+: 412.1773, found 412.1765 
 
(xviii) 2-(4-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-
carboxamide, 10h 
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1H NMR (400MHz, CD3OD): δ 8.79 (s, 1H), 8.52 (s, 1H), 8.26 (d, J=8.3, 2H), 
8.15 (s, 1H), 7.92 (bd, 1H), 7.83 (d, J=8.3, 2H), 7.71, (bd, J=7.5, 1H), 3.84 (s, 
2H), 2.69 (bs, 4H), 1.87 (bs, 4H). 13C NMR (67MHz, CD3OD): δ 68.45, 57.61, 
55.03, 24.10, 22.13. HRMS (ESI) calculated for C24H23N5O (M+H)+: 398.1980, 
found 398.1989 
 
(xix) 2-(4'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-
carboxamide, 11a 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.61 (bs, CONH2), 9.42 (s, NH), 8.28 (d, 
J=7.5, 2H), 7.87 (d, J=6.8, 1H), 7.77 (d, J=8.3, 2H), 7.73 (d, J=7.5, 1H), 7.63 (d, 
J=8.3, 2H), 7.31 (t, J=7.5, 1H), 6.98 (d, J=8.3, 2H), 4.06 (t, J=5.3, 2H), 2.68 (t, 
J=5.3, 2H), 1.46 (t, J=5.3, 4H), 1.31 (bs, 2H). 13C NMR (100MHz, DMSO-d6): 
δ 166.88, 159.01, 152.30, 142.30, 135.97, 131.92, 130.43, 129.52, 128.37, 
128.01, 127.82, 127.38, 127.08, 126.86, 123.44, 122.78, 115.54, 65.75, 57.51, 
54.67, 25.66, 24.08, 21.74. HRMS (ESI) calculated for C27H28N4O2 (M+H)+: 
441.2290, found 441.2291 
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(xx) 2-(4'-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-
carboxamide, 11b 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 13.67 (s, CONH2), 9.39 (bs, NH), 8.33 (d, 
J=8.3, 1H), 7.96 (d, J=8.0, 2H), 7.85 (bs, 1H), 7.72 (d, J=8.0, 2H), 7.66 (d, 
J=8.3, 2H), 7.33 (bs, 1H), 7.03 (d, J=8.5, 2H), 4.09 (bs, 2H), 2.92 (bs, 2H), 2.11 
(bs, 2H), 1.70 (bs, 4H), 1.48 (bs, 2H) . 13C NMR (100MHz, DMSO-d6): δ 
167.35, 158.64, 143.68, 131.43, 129.95, 129.35, 128.12, 126.06, 115.05, 65.44, 
53.83, 52.57, 24.12, 23.27, 22.21. HRMS (ESI) calculated for C28H30N4O2 
(M+H)+: 455.2446, found 455.2441 
 
(xxi) 6-fluoro-2-(4'-propionamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-
carboxamide, 11c 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 10.03 (s, NH), 9.35 (s, NH), 8.27 (d, J=8.0, 
2H), 7.86 (d, J=8.3, 2H), 7.24 (bs, 4H), 7.59 (s, 1H), 7.57 (s, 1H), 2.34 (q, J=7.6, 
2H), 1.08 (t, J=7.6, 3H). 13C NMR (100MHz, DMSO-d6): δ 172.38, 165.20, 
158.47, 152.47, 141.81, 139.54, 133.45, 128.27, 127.58, 127.36, 127.16, 126.82, 
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125.98, 123.31, 119.53, 110.30, 101.68, 29.68, 9.75. HRMS (ESI) calculated for 
C23H19N4F1O2 (M+H)+: 403.1570, found 403.1575 
 
(xxii) 2-(4'-(cyclopropanecarboxamido)-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)-6-
fluoro-1H-benzimidazole-4-carboxamide, 11d 
 
 
 
1H NMR (400MHz, DMSO-d6): δ 9.53 (s, NH), 9.27 (s, NH), 8.33 (t, J=8.0, 
1H), 8.10 (d, J=8.3, 1H), 7.87 (d, J=12.9, 1H), 7.78 (dd, J=1.7, 8.3, 1H), 7.60 
(bm, 2H), 7.44 (s, 1H), 7.37 (dd, J=1.9, 8.5, 1H), 3.98 (s, 3H), 2.12 (m, 1H), 
0.80-0.76 (m, 4H). 13C NMR (100MHz, DMSO-d6): δ 172.08, 164.84, 160.48, 
158.06, 149.56, 148.05, 144.20, 137.53, 135.84, 133.15, 130.55, 128.27, 123.45, 
122.98, 121.81, 118.87, 115.17, 114.18, 110.60, 109.48, 101.92, 55.97, 14.26, 
7.44. HRMS (ESI) calculated for C25H20N4F2O3 (M+H)+: 463.1581, found 
463.1572 
 
(xxiii) 2-(4'-(cyclopropanecarboxamido)-2',3-difluoro-[1,1'-biphenyl]-4-yl)-6-fluoro-
1H-benzimidazole-4-carboxamide, 11e 
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1H NMR (400MHz, DMSO-d6): δ 10.60 (s, NH), 9.26 (s, NH), 8.35 (t, J=7.8, 1H), 
7.99-7.60 (m, 5H), 7.43 (s, 1H), 7.41 (s, 1H), 1.80-1.75 (m, 1H), 0.84-0.81 (m, 4H). 
13C NMR (100MHz, DMSO-d6): δ 172.46, 165.10, 160.45, 160.42, 158.00, 157.97, 
147.99, 141.44, 141.32, 138.44, 130.82, 130.50, 125.30, 124.05, 120.11, 116.39, 
115.77, 115.27, 110.78, 106.43, 102.10, 14.84, 7.75. HRMS (ESI) calculated for 
C24H17N4F3O2 (M+H)+: 451.1381, found 451.1378 
 
 
In conclusion, the methods employed were very convenient, easy and safe to handle. 
All compounds were obtained in high yield and purity. 
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CHAPTER 5: PARP-1 AND DHODH INHIBITION STUDIES 
 
5.1 Pharmacological evaluation 
 
Biological assay studies on PARP-1 and DHODH were carried out at Aurigene 
Discovery Technologies Ltd. (Malaysia). These assays were independently done on 
PARP colometric assay and DHODH enzymatic assay.  
 
5.1.1 Poly (ADP-ribose) Polymerase (PARP) Colorimetric Assay 
 
Inhibitory effects of compounds 7a-g, 9a-j, 10a-h and 11a-e on PARP-1 activity 
were measured using HT Universal Colorimetric PARP assay kit Histone-coated Strip 
Wells, Trevigen, Gaithersburg, MD, USA. The assays were carried out by quantifying 
the incorporation of biotinylated poly (ADP-ribose) onto histone proteins in 96-well 
plates. In brief, 10 µL of PARP-1 enzyme (0.25 U) was pre-incubated with 15 µL of 
tested compounds in rehydrated histone-coated wells, followed by addition of 25 µL of 
PARP cocktail mixture containing 2 µL of 10x PARP cocktail, 2 µL of 10x activated 
DNA and 21 µL of 1x PARP buffer into the wells. After 60 minutes of incubation, the 
wells were washed twice with 1x PBS + 0.1% Triton X-100, followed by 1x PBS. 50 
µL of 1x Strep-HRP was then added and incubated for 60 minutes. The wells were 
washed again as in the previous step. 50 µL of pre-warmed TACS-Sapphire substrate 
was added and the mixture incubated for 15 minutes in dark. The reactions were 
terminated with 50 µL of 0.2 M HCl. The absorbance readings were taken at 450 nm 
using VICTORTM X5, Multimode Plate Reader. IC50 values were determined by fitting 
the activity data at different concentrations of the compounds to sigmoidal dose-
response curve fitting program, using GraphPad Prism software version 6.00. 
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5.1.2 Dihydroorotate Dehydrogenase (DHODH) Enzymatic Assay 
 
Compounds 7a-g, 9a-j, 10a-h and 11a-e were evaluated for their potency to inhibit 
DHODH in a coupled enzymatic spectrophotometric assay. The assay is based on the 
decrease in absorbance at 610 nm, resulting from the oxidation of L-dihydroorotic acid 
(L-DHO), facilitated by the reduction of 2,6-dichloroindophenol (DCIP) and 
decylclubiquinone (DUQ) (Baldwin et al., 2005). The decrease in absorbance at 610 nm 
is proportional to the reduction of DCIP. The assay buffer was 50 mM TrisHcl, 150 mM 
MKCL and 0.8% Triton, pH 8.0. 100 µL reaction mixture was used in 96-well plates at 
room temperature. A mixture of 82 µL of enzyme (25 ng) in buffer and 5 µL of test 
compounds were pre-incubated for 30 minutes, and the reaction was started by adding 
13 µL of substrate mixture (20 mM of L-DHO, 2 mM of DuQ and 2 mM of DCIP). The 
final concentration of DMSO used was 1%. Lastly, the absorbance of mixture in each 
well was measured at 610 nm, using a VICTOR X5 (Waltham, MA, USA) at every 10 
minutes for 1 hour. IC50 values were determined from the dose response plot using 
GraphPad Prism software version 6.00. 
 
Preliminary activities for both PARP and DHODH assay were measured at 10 µM 
concentrations of the synthesized compounds (7a-g, 9a-j, 10a-h and 11a-e) with 
veliparib and brequinar as reference inhibitors (Table 5.1). The biological assay results 
tabulated in Table 5.1 show a number of compounds with good inhibitory activity either 
in PARP-1, or DHODH assay, in correlation with the functional groups attached to the 
compound. 
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Table 5.1. PARP-1 and DHODH inhibition by benzimidazole derivatives. The activity 
is expressed as percent inhibition at 10 µM or IC50 values. 
 
 
Entry R1 R2 R3 R4 R5 
PARP DHODH 
IC50 (µM) / % 
Inhibition at 10 µM 
IC50 (µM) / % 
Inhibition at 10 µM 
Veliparib 
(ABT-888)  
0.005 - 
Brequinar 
 
- 0.012 
9aa NH2 H H H 
 
0.714 9.80 
9b NH2 CH3 H H 28% 7.80 
9cb NH2 H H H 
-OCH3 
N.A N.A 
9d NH2 CH3 H H N.A N.A 
9eb NH2 H H H 
-CF3 
N.A N.A 
9f NH2 CH3 H H N.A N.A 
9g NH2 CH3 H H -CN N.A N.A 
9h NH2 H H H 
 
0.14 51% 
9i NH2 H H H 
 
0.46 42% 
9j NH2 H H H 
 
16% 56% 
10aa NH2 H H H 
 
0.022 19% 
10b NH2 H H H 
 
0.032 20% 
10c NH2 H H H 
 
0.049 46% 
10da NH2 H H H 
 
0.083 28% 
10e NH2 H H H 
 
0.31 20% 
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Table 5.1 continued  
10f NH2 H H H 
 
0.12 26% 
10g NH2 H H H 
 
0.29 28% 
10h NH2 H H H 
 
0.061 55% 
11a NH2 H H H 
 
0.72 31% 
11b NH2 CH3 H H 
 
2.28 N.A 
11c NH2 F H H 
 
1.72 12% 
11d NH2 F F H 
 
0.98 23% 
11e NH2 F F H 
 
0.084 48% 
7a OH CH3 H H 
 
N.A 32% 
7b OH CH3 H H 
 
N.A 1.38 
7c OH CH3 H H 
 
N.A 0.21 
7d OH CH3 H NHAc  
N.A 47% 
7e OH CH3 H H 
 
10.63 0.30 
7f OH CH3 H H 
 
N.A 0.028 
7g OH CH3 H H 
 
44% 0.013 
*N.A. – Not active 
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A library of diversified compounds (as shown in Table 5.1) were designed and 
synthesised by substituting various electron-donating and electron-withdrawing groups 
on the benzimidazole scaffold and their biological activities were evaluated for the two 
targets, PARP-1 and DHODH. The objective was to develop an inhibitor that is active 
towards both on PARP-1 and DHODH enzymes. The designed compounds were docked 
onto PARP-1 (pdb ID: 4HHZ) and DHODH (pdb ID: 4IGH) enzymes, and their 
interactions with the active site residues of both enzymes were analyzed in order to 
understand their activities with the two targets.  
 
Compound I1 (Figure 5.1) was reported by Thunuguntla and co-workers to inhibit 
DHODH (Thunuguntla et al., 2010) activity with an IC50 value of 0.75 µM. Replacing 
the carboxylic acid substituent at C-4 position of the benzimidazole ring in compound 
I1 with amide functionality as in compound 9a resulted in an improved activity with 
PARP-1 enzyme (IC50 value of 0.71 µM). However, at the same time, the potency of 
compound 9a towards DHODH enzyme was observed to decrease to 9% inhibition at 
10 µM. This seemes to indicate that the -COOH group at C-4 position is required for 
DHODH activity, while the -CONH2 substituent is needed for PARP-1 activity.   
 
 
Figure 5.1. (A) shows the docking mode of compound I1 on DHODH enzyme (pdb ID: 
4IGH). (B) shows the docking mode of compound 9a docked on PARP-1 enzyme (pdb 
ID: 4HHZ). Figures were generated with PyMol. 
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5.2 Biological Evaluation of Synthesised Compounds  
 
5.2.1   Biological Evaluation of Synthesised Compounds on PARP-1 Enzyme  
 
The parent benzimidazole compound, 9a (Figure 5.2) showed activity towards 
PARP-1 at IC50 value of 0.71 µM.  
 
 
Figure 5.2. Compound 9a. 
 
To test possible hydrophobic site for interaction at the active pocket, the hydrogen at 
C-6 of the benzimidazole head-group was substituted with a methyl group (compound 
9b). This change led to a reduction in activity by about 28% compared to compound 9a. 
 
Investigation on the influence of substituents in the tail of the benzimidazole 
compound, using compound 9a as the parent template were carried out. The biphenyl 
group in 9a was replaced with the 4-methoxyphenyl and 4-triflourophenyl to give 
compounds 9c and 9e, respectively. No activity was observed with both compounds on 
PARP-1 enzyme. Two other compounds, 9d and 9f (Figure 5.3) were tested on PARP-1 
enzyme assay. Neither compound showed any activity activities towards the PARP-1 
enzyme. Another compound, 9g (Figure 5.3), with methyl substituent on C-6 of the 
head-group and 4-cynophenyl at the tail-end was tested for PARP-1 activity and 
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similarly, no activity was observed. Thus, it can be concluded that the C-6 position of 
the head-group must not be a methyl, and that the biphenyl group is necessary at the 
tail-end. 
 
 
Figure 5.3. Compounds 9c, 9d, 9e, 9f and 9g. 
 
Three compounds, 9h, 9i and 9j, with an acetamide functionality at the ortho, meta 
and para-positions of the second phenyl ring in the biphenyl tail-end of the 
benzimidazole were synthesized and screened, as shown in Figure 5.4.   
 
 
Figure 5.4. Compounds 9h, 9i and 9j. 
 
Compound 9h gave an IC50 value of 0.14 µM in PARP-1 activity, while compound 
9i showed a decreased in activity against PARP-1 with an IC50 value of 0.46 µM. Both 
compounds 9h and 9i showed better inhibitory activity towards PARP-1 compared to 
compound 9a. However, compound 9j, with the acetamide at the para-position of the 
biphenyl ring, displayed poorer PARP-1 activity with only 16% inhibition at 10 µM. 
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The presence of an electron-donating acetamide group seems to increase the PARP-1 
activity, in the first instance, as seen with compounds 9h and 9i. 
 
As shown in the surface model (Figure 5.5, A), compound 9h fits exactly into the 
active pocket of the enzyme. This would enable good interactions between functional 
groups of the ligand with the active site of the PARP-1 enzyme. Two hydrogen-bond 
interactions were observed between compound 9h, with Ser-243 (C=O to O-H Ser, 2.2 
Å) and Gly-202 (N-H to C=O Gly, 2.1 Å). Intramolecular hydrogen-bond interaction 
between the -NH of the carboxamide group with the imidazole nitrogen helped to put 
the carboxamide group in place for a good interaction between this group and the Ser-
243 and Gly-202 residues. In addition, a water-mediated hydrogen bonding interaction 
between the acetamide group of the site of the ligand with the Arg-217 (C=O to H-O-H, 
2.4 Å to N-H Arg, 2.4 Å) residue of the enzyme was also observed, as shown in Figure 
5.5 (B).  
 
 
Figure 5.5. (A) shows the ligand interaction of compound 9h towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
(B) illustrates the docking mode of compound 9h on PARP-1 enzyme (pdb ID: 4HHZ). 
Hydrogen bonds are highlighted in yellow dash. Figures were generated with PyMol. 
 
For compound 9i, the ligand seems to still fit into the active pocket of the enzyme. 
The lower activity observed with 9i compare to 9h, presumably is due to the lost of 
some interactions between the ligand and the residues in the active pocket of the 
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enzyme. The H-bond interactions between the carboxamide head-group with Ser-243 
and Gly-202 are still observed with compound 9i, as shown in Figure 5.6. However, 
unlike in compound 9h, there is no H-bond interaction between the amide functionality 
at the tail-end of the ligand (compound 9i) with Arg-217. This may be the cause of the 
reduced activity observed between compound 9i and PARP-1 enzyme. 
 
 
Figure 5.6. (A) shows the ligand interaction of compound 9i towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
(B) illustrates the docking mode of compound 9i on PARP-1 enzyme (pdb ID: 4HHZ). 
Hydrogen bonds are highlighted in yellow dash. Figures were generated with PyMol. 
 
 
Figure 5.7. (A) shows the ligand interaction of compound 9j towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
(B) illustrates the docking mode of compound 9j on PARP-1 enzyme (pdb ID: 4HHZ). 
Hydrogen bonds are highlighted in yellow dash. Figures were generated with PyMol. 
 
A drastic lost in activity, however, was observed with compound 9j, although similar 
H-bond interactions were observed between the carboxamide head-group of 9j with Ser-
243 and Gly-202. As seen in the model shown in Figure 5.7, the tail-end of this ligand is 
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linear rather than “bent” as in compounds 9h and 9i. The linear tail-end of compound 9j 
seems to be pushed out of the cavity of the active pocket of the enzyme, as shown in 
Figure 5.7, possibly affecting the activity of the compound against PARP-1 enzyme. 
 
Thus, it can be conclude that the position of amide at the tail-end of the ligand is 
important for activity. When it is in the ortho-position, it was able to form added 
interaction with Arg-271. However, in the meta-position, the amide group is distant 
from the Arg-217 residue, and is not enable to form any H-bond interaction. This is 
more distinctly observed in the case where the amide group is placed in the para-
position. 
 
It has been reported by Tong and co-workers that replacing the second benzene ring 
with a pyridine showed increase in activity, compared to compound 9a. Compound 10a 
(Tong et al., 2009) was reported to inhibit the PARP-1 enzyme activity with a Ki value 
of 0.95 nM. Thus, extension of this study was done by introducing heteroaromatic 
moiety to replace the second benzene ring at the tail-end of the benzimidazole structure. 
Using compound 10a as reference, compounds 10b and 10c were synthesised and tested 
for activity with PARP-1 enzyme (Figure 5.8).   
 
 
Figure 5.8. Compounds 9a, 10a, 10b and 10c. 
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The activity of compound 10a with PARP-1 was observed to give an IC50 value of 
0.022 µM. This is an increase of approximately 14-folds in activity for compound 10a, 
compared to that of compound 9a (IC50 = 0.71 µM). Presumably, the more polar 
pyridinyl group in compound 10a led to repulsion between the residues Tyr-49, Ala-
101, Asp-105, Ala-219 and Ala-223, pushing the ligand more inwards into the active 
pocket of PARP-1 (Figure 5.9). This resulted in a stronger H-bond interaction between 
the carboxamide head-group with Ser-243 and Gly-202 of PARP-1 enzyme (Compound 
10a H-bonds length, C=O to H-O Ser, 1.7 Å; C=O to N-H Gly, 1.7 Å and N-H to C=O 
Gly, 1.7 Å. Compound 9a H-bonds length, C=O to H-O Ser, 1.6 Å; C=O to N-H Gly, 
2.1 Å and N-H to C=O Gly, 1.7 Å) (Figure 5.10). 
 
Adding an amino group on the pyridinyl ring as in compound 10b resulted in slight 
reduction of activity observed with PARP-1 enzyme (IC50 = 0.032 µM). Examination of 
the model as shown in Figure 5.11 revealed the amino group to be outside the cavity of 
the active pocket of the enzyme. This also plausibly affected the H-bond interaction 
between the carboxamide head-group and the residues Ser-243 (C=O to H-O Ser, 2.0 Å) 
and Gly-202 (C=O to N-H Gly, 2.1 Å; N-H to C=O Gly, 1.8 Å) of the PARP-1 enzyme. 
 
 
Figure 5.9. (A) shows the hydrophobic interactions of compound 10a on PARP-1 
enzyme (pdb ID: 4HHZ). Red color indicates hydrophobic surface. (B) illustrates the 
docking mode of compound 10a on PARP-1 enzyme (pdb ID: 4HHZ). Hydrogen bonds 
are highlighted as yellow dash. Figures were generated with PyMol. 
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Figure 5.10. Superposition of compounds 9a and 10a on PARP-1 enzyme (pdb ID: 
4HHZ). Figure was generated with PyMol. 
 
 
Figure 5.11. (A) shows the hydrophobic interactions of compound 10b on PARP-1 
enzyme (pdb ID: 4HHZ). Red color indicates hydrophobic surface. (B) illustrates the 
docking mode of compound 10b on PARP-1 enzyme (pdb ID: 4HHZ). Hydrogen bonds 
are highlighted as yellow dash. Figures were generated with PyMol. 
 
For compound 10c, where the amino group (in compound 10b) was replaced with an 
acetamide group, the PARP-1 activity was observed with an IC50 value of 0.049 µM. 
The acetamide group was observed to reside outside the cavity of the active pocket of 
the PARP-1 enzyme (Figure 5.12, A). Furthermore, the hydrophobic interactions at the 
tail-end of the compound occurred with different residues than that of all previous 
compounds studied (Figure 5.12, B). Here, the interactions of the tail-end group of the 
ligand were observed with the residues Ile-45, Leu-108, Asp-109, Gly-233, Ile-234, 
instead of the usual Gln-98, Ala-101, Glu-102, Pro-224, Lys-232 and Ile-258. In 
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addition, poorer H-bond interactions were observed between the carboxamide head-
group with Ser-243 (C=O to H-O Ser, 2.1 Å) and Gly-202 (N-H to C=O Gly, 2.4 Å).   
 
 
Figure 5.12. (A) shows the hydrophobic interactions of compound 10c on PARP-1 
enzyme (pdb ID: 4HHZ). Red color indicates hydrophobic surface. (B) illustrates the 
docking mode of compound 10c on PARP-1 enzyme (pdb ID: 4HHZ). Hydrogen bonds 
are highlighted as yellow dash. Figures were generated with PyMol. 
 
Compounds 10a, 10b and 10c all contained the pyridinyl ring in the tail-end group 
with the nitrogen atom in the 3rd position. Investigation on the importance of the 
nitrogen atom position in the pyridinyl ring for PARP-1 activity was carried out. 
Compound 10d was prepared with the nitrogen atom of pyridinyl ring at the 2nd position 
(Figure 5.13). Biological assay of compound 10d indicated a 4-fold reduction in activity 
compared to compound 10a. 
 
 
Figure 5.13. Compounds 10a and 10d. 
 
However, docking studies did not indicate much difference to explain the significant 
difference that was observed in the assay. Extra hydrophobic interactions between 
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compound 10a and the amino acid residues of PARP-1 were observed compared to 
those of compound 10d (Figure 5.14). Table 5.2 shows the amino acids that interacted 
with compounds 10a and 10d. Perhaps it is these added interactions that resulted in 
better activity observed for compound 10a.   
 
 
Figure 5.14. (A) and (B) illustrates the docked pose of compounds 10a and 10d on 
PARP-1 enzyme, respectively. Hydrogen bonds are highlighted as yellow dash. (C) 
shows the superposition of compounds 10a and 10d on PARP-1 enzyme (pdb ID: 
4HHZ). Figures were generated with PyMol. 
 
Table 5.2. Ligand-amino acid interactions (close contact) in the active pocket of PARP-
1 enzyme for compounds 10a and 10d. 
 
 10a 10d 
Amino Acids 
(Found) 
Ala-101 
Ala-219 
Ala-223 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
Phe-236 
Pro-220 
Pro-224 
Ser-203 
Thr-226 
Trp-200 
Tyr-228 
Ala-101 
Ala-219 
Ala-223 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
Phe-236 
Pro-220 
Pro-224 
Ser-203 
Thr-226 
Trp-200 
Tyr-228 
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Table 5.2 continued 
 
Amino Acids 
(Found) 
His-201 
Lys-232 
Lys-242 
Tyr-235 
Tyr-246 
Tyr-49 
His-201 
Lys-232 
Lys-242 
Tyr-235 
Tyr-246 
Tyr-49 
 
*Gln-98 
 *Ile-218  
*Glu-102 
*Ile-258 
  
*Additional amino acid residue interaction. 
 
 
In addition, the hydrogen bond length calculated for compound 10d (1.6 Å C=O to 
H-O Ser-243, 2.1 Å C=O to N-H Gly-202 and 2.1 Å N-H to C=O Gly-202) were longer 
compared to compound 10a (1.7 Å C=O to H-O Ser-243, 1.7 Å C=O to N-H Gly-202 
and 1.7 Å N-H to C=O Gly-202). The intramolecular hydrogen bond length between the 
two compounds was found to be identical at 2.0 Å. Lesser number of contacts between 
10d with amino acid residues in the active pocket of PARP-1 was observed, which 
resulted in lower interactions towards these hydrophobic residues. In addition, longer 
hydrogen bond length was observed between the head group of the compound 10d with 
Ser-243 and Gly-202. These findings could potentially be the major factor for activity 
reduction in compound 10d compared to compound 10a.   
 
Investigation on another group of compounds involving pyrrolidinone substituents at 
the tail-end of the benzimidazole compound were carried out. These compounds are 
shown in Figure 5.15. 
 
Compound 10e exhibited an IC50 value of 0.31 µM in PARP-1 activity. This is an 
increase in activity for PARP-1 inhibition compared to that observed with compound 9a 
(IC50 = 0.71 µM). As shown in Figure 5.16, the interactions between the enzyme and the 
head-group of compound 10e are similar to that of compound 9a, as well as all other 
ligands described earlier. However, the tail-end of compound 10e is longer than that of 
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compound 9a, as shown in Figure 5.17. Presumably, the extra length of compound 10e 
(observed in the model in Figure 5.17) led to added hydrophobic interactions between 
10e and the enzyme, which may explain the better activity observed in 10e compared to 
compound 9a (Figure 5.18). 
 
 
Figure 5.15. Compounds 10e, 10f, 10g and 10h. 
 
 
Figure 5.16. Docked pose of compound 10e on PARP-1 enzyme (pdb ID: 4HHZ). 
Hydrogen bonds are highlighted in yellow dash. Figure was generated with PyMol. 
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Figure 5.17. Ligand interaction of compounds 9a and 10e towards hydrophobicity 
surface. Red color shows the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
Figure was generated with PyMol. 
 
 
Figure 5.18. (A) and (B) shows the ligand interactions on PARP-1 enzyme with 
compounds 9a and 10e, respectively (pdb ID: 4HHZ). Red circle indicates negative 
charged residues, cyan indicates polar residues, green indicates hydrophobic residues, 
purple indicates positive charged residues. Cutoff was at 4.00 Å. Figures were generated 
with Maestro Schrodinger software. 
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Compound 10f showed an IC50 value of 0.12 µM. This is an almost 3-fold increase in 
activity compared to compound 10e. The difference between compound 10f and 10e lies 
in the tail-end where the second aryl group is a pyridinyl ring instead of a phenyl ring 
(Figure 5.19). This increase in activity is expected, as similar increase in activity was 
observed with compound 10a (described above) when the second phenyl ring was 
replaced with a pyridinyl ring. In addition, 10f fits better into the cavity of the active 
pocket of the enzyme compared to 10e. However, this increase in activity is not as 
significant compared to that of 10a. Presumably, poorer fit of compound 10f into the 
active site of the enzyme compared to 10a due to the extra pyrrolidinone group affected 
the activity of compound 10f (Figure 5.20).  
 
 
Figure 5.19. Ligand interaction of compounds 10e and 10f towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
Figure was generated with PyMol. 
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Figure 5.20. Ligand interaction of compounds 10a and 10f towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
Figure was generated with PyMol. 
 
 
 
Figure 5.21. Docked pose of compound 10g on PARP-1 enzyme (pdb ID: 4HHZ). 
Hydrogen bonds are highlighted in yellow dash. Figure was generated with PyMol. 
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Figure 5.22. Ligand interaction of compounds 10f and 10g towards hydrophobicity 
surface. Red color indicates the hydrophobic surface of the enzyme (pdb ID: 4HHZ). 
Figure was generated with PyMol. 
 
 
Figure 5.23. (A) and (B) shows the ligand interactions on PARP-1 enzyme with 
compounds 10f and 10g, respectively (pdb ID: 4HHZ). Red circle indicates negative 
charged residues, cyan indicates polar residues, green indicates hydrophobic residues, 
purple indicates positive charged residues. Cutoff was at 4.00 Å. Figures were generated 
with Maestro Schrodinger software. 
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Changing the pyrrolidinone group with a methylpyrrolidine group, as in compound 
10h, resulted in a significant increase in activity compared to compound 10g. The IC50 
value observed for compound 10h was 0.061 µM. Perhaps, by removing the carbonyl 
group, there is an increase in hydrophobic interaction between the ligand and the active 
site of the enzyme (Figure 5.24). In addition, as shown in Figure 5.25, an additional 
ionic interaction between the nitrogen of the pyrrolidine and the residue Asp-109 is 
observed. Perhaps this led to the better activity observed with 10h. 
 
Figure 5.24. (A) illustrates the docking mode of compound 10h on PARP-1 enzyme 
(pdb ID: 4HHZ). Hydrogen bonds are highlighted in yellow dash. (B) shows the ligand 
interaction of compound 10h towards hydrophobicity surface. Red color indicates the 
hydrophobic surface of the enzyme (pdb ID: 4HHZ). Figures were generated with 
PyMol. 
 
 
Figure 5.25. Ligand interaction of compound 10h on PARP-1 enzyme (pdb ID: 4HHZ). 
Red circle indicates negative charged residues, cyan indicates polar residues, green 
indicates hydrophobic residues, purple indicates positive charged residues. Cutoff was 
at 4.00 Å. Figure was generated with Maestro Schrodinger software. 
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Table 5.3 shows a summary of the ligand-protein of compounds 10e, 10f, 10g and 
10h towards the amino acid residues in the active pocket of the PARP-1 enzyme. 
 
Table 5.3. Ligand-amino acid interactions (close contact) in active pocket of PARP-1 
enzyme for compounds 10e, 10f, 10g and 10h. 
 
Amino 
Acids 
(Found) 
10e 10f 10g 10h 
Ala-219 
Ala-223 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
His-201 
Ile-218 
Leu-108 
Lys-242 
Phe-236 
Pro-220 
Thr-226 
Trp-200 
Tyr-228 
Tyr-235 
Tyr-246 
Tyr-49 
Ala-219 
Ala-223 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
His-201 
Ile-218 
Leu-108 
Lys-242 
Phe-236 
Pro-220 
Thr-226 
Trp-200 
Tyr-228 
Tyr-235 
Tyr-246 
Tyr-49 
Ala-219 
- 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
His-201 
Ile-218 
Leu-108 
Lys-242 
Phe-236 
Pro-220 
Thr-226 
Trp-200 
Tyr-228 
Tyr-235 
Tyr-246 
Tyr-49 
Ala-219 
- 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
His-201 
Ile-218 
Leu-108 
Lys-242 
Phe-236 
Pro-220 
Thr-226 
Trp-200 
Tyr-228 
Tyr-235 
Tyr-246 
Tyr-49 
  
*Asp-109 
*Ser-203 
**Asp-109 
*Ser-203 
* Additional amino acid residue interaction. 
** Ionic interaction of compound 10h with amino acid residue. 
 
In order to probe other possible interactions outside the cavity of the active pocket, 
compounds with longer substituent on the C-4’ position of the biphenyl tail-end were 
prepared. Compounds 11a and 11b (Figure 5.26) were synthesised and screened for 
PARP-1 enzyme inhibitory activities. Results observed were as anticipated with 
compound 11a, giving an IC50 value at 0.72 µM, while compound 11b showed poor 
IC50 value at 2.28 µM.  
 
Figure 5.26. Compounds of 11a and 11b. 
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Adding an alkane piperidine substituent to the benzimidazole compound with an 
ether linkage seems to be unfavorable for PARP-1 activity. Our model showed this 
group to be entirely exposed towards the solvent site, which could presumably reduce 
the activity of the compound (Figure 5.27).    
 
 
Figure 5.27. (A) and (B) illustrates the superposition of compounds 11a and 11b on 
PARP-1 enzyme, respectively, with hydrophobic interaction (pdb ID: 4HHZ). Red color 
indicates hydrophobic surface. Figures were generated with PyMol. 
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Fluorine and cyclopropane are bioisosteres for hydrogen and aromatic hydrocarbon, 
respectively. Many compounds have shown better activity when these isoteres were 
incorporated into the molecule. The unique properties of fluorine in a molecule often 
resulted in significant effect towards the bioactivity of the molecule. In such molecules, 
the hydrophobic interaction between the fluorinated ligand and the enzyme is enhanced, 
since the Van de Waals radius of hydrogen compared to fluorine increases from 1.20 to 
1.35 Å. In addition, the high electronegativity of fluorine causes the carbon-fluorine 
bond to be polarized, which could affect the pose of the ligand in the active site of the 
enzyme.   
 
Cyclopropane could also act as an isostere for an aryl group. Cyclopropane ring has a 
low molecular weight, and is low in lipophilicity. Thus, its presence in a molecule could 
presumably contribute to the potency of the molecule by enhancing its ADMET 
(adsorption, distribution, metabolism, excretion and toxicity) properties. In this work, 
cyclopropane was incorporated as cyclopropanecarboxamide in the hoping that the 
amido functionality could serve as a hydrogen bond donor and/or acceptor. 
 
It would therefore be useful to investigate and study the effect of compounds with 
such functionality towards the PARP-1 inhibitory activity.  Thus, compounds 11c, 11d 
and 11e (Figure 5.28) were prepared by incorporating fluorine(s) and cyclopropane ring 
at various positions in the molecule. 
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Figure 5.28. Compounds 11c, 11d and 11e. 
  
Fluoro group were placed at the C-6 position of the benzimidazole scaffold and a 
propionamide group were connected at the para-position of the biphenyl, as depicted in 
Figure 5.28 for compound 11c. However, poor activity was observed for this compound 
at an IC50 value of 1.72 µM.  From the model (Figure 5.29), it seemed that compound 
11c did not fit into the cavity as well as compound 10e. The propionamide group 
seemed to be pushed into the lower surface of the cavity, possibly creating a high 
repulsion between the ligand and the surface of the cavity. Compound 10e fitted better 
in the sense that it fits nicely within the hole of the cavity (Figure 5.29) 
 
In compound 11d, there is an additional fluoro substituent at the C-2 of the first 
phenyl ring of the biphenyl substituent in benzimidazole and a methoxy group at the C-
3’ position of the same biphenyl substituent. A much better activity, albeit still low, was 
observed for this compound (IC50 = 0.98 µM) (Figure 5.28). 
 
The F-H bond (2.0 Å) between the amide hydrogen and the fluorine substituent on 
the phenyl ring helped to lock the conformation of the benzimidazole tail. This resulted 
in the cyclopropionamide group to be pushed away from the surface, fitting into the 
hole of the cavity better, as in compound 10e (Figure 5.30). 
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Putting two fluoro groups into the molecule, such as in compound 11e, resulted in an 
improved activity for compound 11e with the IC50 value observed at 0.084 µM. The 
model in Figure 5.31 showed compound 11e to fit nicely into the hole of the cavity. In 
addition, there were added hydrophobic interactions at the sites where both the fluoro 
substituents were placed 
 
 
Figure 5.29. Superposition of compounds 10e and 11c on PARP-1 with hydrophobic 
interaction (pdb ID: 4HHZ). Red color indicates hydrophobic surface. Figure was 
generated with PyMol. 
 
As for compounds 7a-g, the docking mode of each compound on PARP-1 enzyme 
can be found in appendix B. 
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Figure 5.30. (A) illustrates the superposition of compounds 10e, 11c and 11d on PARP-
1 enzyme with hydrophobic interaction. (B) shows the tail-end group of the 
superimposed compounds 11c and 11d located at the cavity entrance of PARP-1 
enzyme (pdb ID: 4HHZ). Red color indicates hydrophobic surface. Figures were 
generated with PyMol. 
 
 
Figure 5.31. (A) illustrates the docked pose of compound 11e on PARP-1 enzyme. (B) 
shows compound 11e with hydrophobic interaction (pdb ID: 4HHZ). Red color 
indicates hydrophobic surface. Figures were generated with PyMol. 
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5.2.2   Biological Evaluation of Synthesised Compounds on DHODH Enzyme 
 
The same synthesised compounds (Table 5.1) were then tested onto the second 
target, the DHODH enzyme. Liu and co-workers reported the brequinar analogue to 
have high affinity for human DHODH (Liu et al., 2000). Co-crystallised brequinar 
analogue (Figure 5.32) in human DHODH showed an IC50 value of 0.007 µM (pdb ID: 
1D3G).  
 
 
Figure 5.32. Structure of brequinar analogue. 
 
Liu ascribed the high affinity in human DHODH observed with brequinar analogue 
to possibly be due to the interactions between the ligand and the enzyme. The 
fluoroquinoline carboxylate head-group of the analogue were observed to be buried 
deep inside the polar region of the active site of DHODH, while the two aromatic rings 
were in the hydrophobic region. The carboxylate form of the brequinar analogue formed 
hydrogen-bonding interactions with the residues Arg-136 and Gln-47 of DHODH. In 
addition, a water-mediated hydrogen bond between this carboxylate ligand and Thr-360 
was also observed.  
 
In addition, the fluorine group at C-6 position of the brequinar analogue interacted 
closely with the C-7 methyl of the FMN, while the quinoline ring formed a π-π stack 
with His-56 (Figure 5.33) (Liu et al., 2000). 
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Figure 5.33. Brequinar analogue co-crystallised with DHODH (pdb ID: 1D3G). 
Hydrogen bonds are highlighted as yellow dash. Red and white sphere dots represents 
water molecules. Figure was generated with PyMol. 
 
Compounds in Table 5.1, first evaluated against PARP-1 enzyme, were then 
subjected towards DHODH enzyme since the objective is to design a compound that 
could act as a dual inhibitor, towards PARP-1 and towards DHODH. 
 
Evaluation of compounds 9a-g (Figure 5.34) against DHODH enzyme was carried 
out. In this series (9a-g), the best activity observed was with compound 9b with 
inhibition at an IC50 value of 9.80 µM. Compound 9a showed 9% inhibition at 10 µM, 
while compounds 9c, 9f and 9g showed 1%, 11% and 5% inhibition at 10 µM, 
respectively, and considered to be inactive. However, compounds 9d and 9e were found 
to be inactive towards the enzyme. 
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Figure 5.34. Compounds 9a-g. 
 
Compounds 9h, 9i and 9j showed slight improvement in percent inhibition with 
values of 51%, 42% and 56% inhibition at 10 µM, respectively (Figure 5.35).  
 
 
Figure 5.35. Compounds 9h, 9i and 9j. 
 
In order to understand the problem, we studied the co-crystallised structure of 
brequinar analogue with the DHODH enzyme (pdb ID: 1D3G) and compared this with 
the model of compounds 9h, 9i and 9j docked onto DHODH enzyme (Figure 5.36), 
since these three compounds showed the best activities amongst the 9-series of 
compounds. 
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Figure 5.36. (A), (B), (C) and (D) illustrates the docked pose of compounds 9h, 9i, 9j 
and brequinar analogue on DHODH enzyme (pdb ID: 4IGH), respectively. Hydrogen 
bonds are highlighted as yellow dash. Figures were generated with PyMol. 
 
Several dissimilarities were observed between the interactions of compounds 9h, 9i 
and 9j and the brequinar analogue. For compounds 9h, 9i and 9j, the carbonyl oxygen 
of the carboxamide group of the ligand formed hydrogen-bonding with Arg-136. With 
the brequinar analogue, two hydrogen-bonding interactions were observed between the 
Arg-136 with the carboxylate group of the brequinar analogue. In addition, the amino 
hydrogen in the Gln-47 residue formed one hydrogen-bond with one of the carboxylate 
in the brequinar analogue. In the 9h, 9i, and 9j models, this hydrogen-bond occurs 
between carbonyl oxygen of the Gln-47 residue and the amino hydrogen of the 
carboxamide head-group of the compound 9h (Figure 5.37, A), but no H-bond 
interaction was observed with compounds 9i (Figure 5.37, B) and 9j (Figure 5.37, C) 
with Gln-47. This is shown (schematic diagram) in Figure 5.37.    
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Figure 5.37. (A), (B), (C) and (D) illustrates the head-group of compounds 9h, 9i, 9j 
and brequinar analogue interactions with DHODH enzyme, respectively. Hydrogen 
bonds are highlighted as red dash (pdb ID: 4IGH). 
 
Unlike what is seen in the brequinar analogue-DHODH structure, no water-mediated 
H-bond was observed between compounds 9h, 9i and 9j and Thr-360. Instead, the 
hydrogen bonding occurred between the amino hydrogen of the carboxamide and the 
carbonyl oxygen group of Thr-360 (Figure 5.38). The water molecule within the 
DHODH cavity is conserved and lies deep within the active pocket. It seems to play a 
crucial role in enhancing the activity of the ligand toward DHODH enzyme (Figure 
5.39) (Liu et al., 2000). The loss of this interaction with the compounds 9h, 9i and 9j 
(as well as all the other 9-series compounds) would therefore contribute to the loss in 
activities, observed with these compounds. 
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Figure 5.38. (A), (B), (C) and (D) illustrates the head-group of compounds 9h, 9i, 9j 
and brequinar analogue interactions with DHODH enzyme, respectively. Hydrogen 
bonds to amino acid residues are highlighted as red dash. Hydrogen bond to a conserved 
water molecule is highlighted as green dash (pdb ID: 4IGH). 
 
 
Figure 5.39. A conserved water molecule found deep inside the active site of DHODH 
enzyme (pdb ID: 4IGH). Figure was generated with PyMol. 
 
Compounds 10a-h (called the 10-series) and compounds 11a-e (called the 11-series) 
were also tested as listed in Table 5.1. All the models for these compounds displayed 
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similar hydrogen bonding interactions as observed with the 9-series compounds. All of 
them showed similarly poor activity, at approximately 10-55% inhibition at 10 µM. The 
pictures of the models for all these compounds are shown in the appendix C. 
 
Since the activities of benzimidazole carboxamide towards DHODH were observed 
to be very poor activity, consideration by replacing the carboxamide group at the C-3 
position of the benzimidazole derivatives with a carboxyl substituent were made. This is 
to imitate the brequinar analogue where there is a good interaction between the 
carboxylate functionality with the important amino acid residues of DHODH. With this 
substituent, the compounds are expected to give better inhibitory activities towards 
DHODH. In addition, a methyl group was added at the C-6 position of the 
benzimidazole derivatives. The methyl substituent was placed at C-6 position to serve 
as a substituent for the fluorine in the brequinar analogue. By doing so, gaining some 
insights onto the interactions between the fluorine (in brequinar analogue) and FMN of 
the DHODH enzyme is hope to be observed. Compounds 7a-g (7-series), were 
synthesised and tested for bioactivity with DHODH enzyme. Figure 5.40 shows the 
structure and bioactivity results for the compounds 7a-g. 
 
Figure 5.40. Compounds 7a-g. 
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Of all the compounds in the 7-series, the best activities were observed with 
compounds 7f and 7g with IC50 values at 0.028 µM and 0.013 µM, respectively. All 
compounds in the 7-series displayed similar head-group interactions, where the 
carboxylate on the benzimidazole compounds interacted with the amino acid residues, 
Arg-136 and Gln-47 in DHODH (see appendix C). In addition, this carboxylate group 
formed a water-mediated H-bonding with the hydroxyl of Thr-360 moiety (Figure 
5.41).   
 
The difference in interaction between the compounds in this 7-series and DHODH 
enzymes lies in the tail-end of the molecule, presumably causing the difference in 
activities observed in these compounds. For 7f, there is an added π-π interaction 
between the third phenyl ring of the ligand and the amino acid Tyr-38 of the DHODH 
enzyme, while compound 7g has an additional H-bonding interaction between the 
amide group on the third ring of the tail-end of the benzimidazole derivative and Asp-34 
of the DHODH enzyme as well as compound 7f. These interactions are shown in Figure 
5.42. Presumably, these additional interactions observed in 7f and 7g (but not with the 
other compounds) led to better activities observed with DHODH, compared to all other 
compounds in the 7-series. 
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Figure 5.41. General head-group interactions for compounds 7a-g (7-series) on 
DHODH enzyme. Hydrogen bond interactions are highlighted as yellow dash. Figure 
was generated with PyMol. 
 
 
Figure 5.42. (A) and (B) illustrate interactions of compounds 7f and 7g on DHODH 
enzyme respectively (pdb ID: 4IGH). Hydrogen bonds are in pink arrow. π-π 
interactions are in green arrow. Red circle indicates negative charged residues, cyan 
indicates polar residues, green indicates hydrophobic residues, purple indicates positive 
charged residues. Cutoff was at 4.00 Å. Figures were generated with Maestro 
Schrodinger software. 
 
Since aim of study is to search for a compound with dual inhibitory properties, 
towards both PARP-1 and DHODH enzymes, activity of the 7-series compounds 
towards PARP-1 were carried out.   
 
From Table 5.1, compound 7e is the only compound that indicated fair activities 
towards both DHODH and PARP-1with IC50 values of 10.63 µM for PARP-1, and 0.30 
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µM for DHODH. Compound 7e comprised a carboxylate group at the C-3 position and 
a methyl substituent at the C-6 position of the benzimidazole scaffold. In addition, there 
is an acetamide group at the ortho-position of the third phenyl ring at the tail-end group 
compound (Figure 5.43). In comparison, the acetamide group in 7f and 7g is at the 
meta- and para-position of the compound, respectively. The activities for these two 
compounds, as discussed earlier, were good for DHODH, but not for PARP-1 enzyme 
(Figure 5.43). 
 
 
Figure 5.43. Compounds 7e, 7f and 7g. 
  
Model study of compound 7e, docked into the PARP-1 enzyme indicated the 
carboxylate head-group of the benzimidazole scaffold to form a hydrogen-bonding 
interaction with Ser-203. In addition, the –NH of the acetamide group at the tail-end of 
this compound formed a hydrogen-bond with the carbonyl oxygen of Ile-218 (Figure 
5.44). However, although same interactions were observed with the head-group of 
compounds 7f and 7g and Ser-203, no such H-bonds were observed at the tail-end with 
Ile-218. The H-bond interactions between tail-end of compound 7e with Ile-218 in 
PARP-1 presumably played some role in increasing the activity of this compound 
towards PARP-1. 
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Figure 5.44. (A) shows the docked pose of compound 7e on PARP-1 enzyme. 
Hydrogen bonds are highlighted as yellow dash. (B) illustrates compound 7e on PARP-
1 enzyme with hydrophobic surface interactions. Red color indicates hydrophobic 
surface (pdb ID: 4HHZ). Figures were generated with PyMol. 
  
While good activities were observed with compounds 7f and 7g with DHODH giving 
IC50 values of 0.028 and 0.013 µM, respectively (Figure 5.43), compound 7e did not 
show such good activity with an IC50 value of 0.30 µM. The head-group interactions of 
all the three compounds (7e, 7f and 7g) are the same where the carboxylate head-group 
formed hydrogen-bond interactions with Arg-136 and Gln-47, in addition to a water-
mediated H-bond interaction with hydroxyl group of Thr-360 (Figure 5.45, A).  
 
The difference between compound 7e and compounds 7f and 7g lie in the tail-end 
interaction of these compounds with the DHODH enzyme where the amido group forms 
hydrogen-bonding interaction with Tyr-38 in compound 7e while for compounds 7f and 
7g, this hydrogen-bonding occurred with Asp-34 (Figure 5.42). Presumably, the 
hydrogen-bonding interaction with Asp-34 has some role to play in the activity of 
DHODH. Unfortunately, the findings could not be confirmed during this work.  
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Figure 5.45. (A) shows the docked pose of compound 7e on DHODH enzyme. 
Hydrogen bonds are highlighted as yellow dash. (B) illustrates superimposed of 
compounds 7e, 7f and 7g on DHODH enzyme with hydrophobic surface interactions. 
Red color indicates hydrophobic surface (pdb ID: 4IGH). Figures were generated with 
PyMol. 
 
Reviewing the activities for both PARP-1 and DHODH on all compounds tested 
revealed several compounds with relatively good activity values. These compounds are 
listed in Table 5.4 for PARP-1 and Table 5.5 for DHODH. 
 
Table 5.4. Selected compounds with good activity for PARP-1 enzyme, and their 
ligand-amino acid interactions in the active pocket. 
 
PARP-1 
enzyme 
7e 
(IC50 = 10.63 µM ) 
9h 
(IC50 = 0.14 µM) 
10h 
(IC50 = 0.061 µM) 
11e 
(IC50 = 0.084 µM) 
Head-group 
interactions 
Gly-202 
Ser-243 
Gly-202 
Ser-243 
Gly-202 
Ser-243 
Gly-202 
Ser-243 
Tail-end 
interactions 
Ile-218 - 
Asp-109 
(ionic interaction) 
Tyr-49 
Close 
contacts 
Ala-219 
Ala-237 
Arg-217 
Glu-327 
His-201 
Ile-333 
Leu-108 
Lys-242 
 
Pro-220 
Thr-226 
Asp-105 
Tyr-235 
Tyr-246 
Tyr-49 
Tyr228 
 
 
Ala-219 
Ala-237 
Arg-217 
Asn-106 
Asn-207 
Asp-105 
Asp-109 
Glu-327 
His-201 
Ile-211 
Leu-108 
Lys-242 
Pro-220 
Ser-203 
Thr-226 
Tyr-235 
Tyr-246 
Tyr-49 
Ala-219 
Ala-237 
Arg-217 
Asp-105 
Glu-327 
His-201 
Ile-218 
Leu-108 
Lys-242 
Phe-236 
Pro-220 
Ser-203 
Thr-226 
Trp-200 
Tyr-228 
Tyr-235 
Tyr-246 
Tyr-49 
Ala-219 
Arg-217 
Asp-105 
His-201 
Leu-108 
Lys-242 
 
 
 
Pro-220 
Ser-203 
Thr-226 
Tyr-228 
Tyr-235 
Tyr-246 
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Table 5.5. Selected compounds with good activity for DHODH enzyme, and their 
ligand-amino acid interactions in the active pocket. 
 
DHODH 
enzyme 
7e 
(IC50 = 0.30 µM) 
9h 
(51% at 10 µM) 
10h 
(55% at 10 µM) 
11e 
(48% at 10 µM) 
Head-group 
interactions 
Gln-47 
Arg-136 
Gln-47 
Arg-136 
Thr-360 
Gln-47 
Arg-136 
Thr-360 
Gln-47 
Arg-136 
Thr-360 
Tail-end 
interactions 
Tyr-38 Tyr-38 Tyr-38 Leu-67 
Close 
contacts 
Ala-55 
Ala-59 
Asp-34 
His-56 
Leu-42 
Leu-46 
Leu-67 
Leu-68 
Leu359 
Met-43 
Phe-62 
Phe-98 
Pro-364 
Pro-52 
Pro-69 
Tyr-147 
Tyr-356 
Tyr-38 
Val-134 
Val-143 
Ala-55 
Ala-59 
His-56 
Leu-42 
Leu-46 
Leu-50 
Leu-58 
Leu-67 
Leu-68 
Met-111 
Met-43 
Phe-62 
Phe-98 
Pro-364 
Pro-52 
Thr-63 
Tyr-356 
Tyr-38 
Val 134 
Val-143 
Pro-52 
Val-134 
Tyr356 
Val-143 
Phe-98 
His-56 
Ala-55 
Met-43 
Leu-46 
Phe-62 
Tyr-38 
Leu-42 
Ala-59 
Leu-58 
Pro-364 
Phe-37 
Ala-55 
Ala-59 
His-56 
Leu-42 
Leu-46 
Leu-67 
Leu-68 
Met-43 
Phe-62 
Phe-98 
Pro-364 
Pro-52 
Tyr-356 
Tyr-38 
p-p  
interactions 
Tyr-38 
Phe-62 
Phe-62 Phe-62 
Tyr-38 
Phe-62 
Other 
interactions 
H-O-H – Thr-360 - - - 
 
 
Out of these compounds, three compounds indicated good inhibitory activities for 
both PARP-1 and DHODH. These compounds are 7e, 10h and 11e. Unfortunately, there 
was no relationship that we could identify to connect these compounds with the 
relatively good activities observed for both enzymes. For PARP-1, the carboxamide at 
C-3 and hydrogen and/or fluorine at C-6 in the head-group of the benzimidazole 
scaffold are essential for good activity. For good DHODH activity, on the other hand, a 
carboxylic acid head-group at the C-3 and a methyl group at the C-6 position of the 
head-group of the benzimidazole scaffold are required. However, a methyl substituent at 
C-6 of the benzimidazole scaffold is detrimental for PARP-1 activity.  
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The biphenyl ring at the tail end of the benzimidazole scaffold is equally important 
for both PARP-1 and DHODH inhibitory activity.  However, it seemed that the 
determining functionality for both PARP-1 and DHODH activities lie in the head-group 
of the benzimidazole scaffold. Compounds 7e, 10h and 11e seemed to exhibit relatively 
good activities for both enzymes, and could potentially be used as a template to further 
search for a lead compound with dual properties.   
 
A diagram summarizing the important functionalities in the benzimidazole scaffold 
for both PARP-1 and DHODH enzyme activities is shown in Figure 5.46. 
 
 
Figure 5.46. Summary of the SAR (structural-activity relationship) points for possible 
dual inhibition of PARP-1 and DHODH enzymes. 
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CHAPTER 6: CONCLUSION AND FUTURE WORK 
 
6.1 Conclusion 
 
Studies of various benzimidazole derivatives as prospective inhibitors for both 
PARP-1 and DHODH enzymes were conducted. All the benzimidazole compounds 
have been synthesized in good to excellent yields. These benzimidazole compounds 
have been tested for inhibitory activities against PARP-1 and DHODH enzymes. 
 
Compounds 9h, 10b, 10c, 10f, 10h and 11e, were observed to give good activities 
with PARP-1 enzyme while compounds 7b, 7e, 7f and 7g showed good activities with 
DHODH enzymes. 
 
SAR and bioactivity results indicated that carboxamide group on C-3 and hydrogen 
and/or fluorine at C-6 of the benzimidazole scaffold are important for PARP-1 enzyme 
inhibitory activity, while carboxylate group on C-3 and methyl group at C-6 of the same 
benzimidazole scaffold are important functionalities for DHODH enzyme activities. 
However, at the tail-end of the benzimidazole scaffold, the biphenyl ring is observed to 
play an essential role for enhancing bioactivities in both PARP-1 and DHODH 
enzymes. The results also indicated that the interactions of the head-group of the 
benzimidazole ligand are more important in influencing the activity of both enzymes.  
 
There are, however, some indications of dual inhibitions observed with some 
compounds, such as compounds 9h, 10h, and 11e, although they show much better 
activity with PARP-1 enzyme than with DHODH. Compound 7e also indicated 
activities towards both PARP-1 and DHODH enzymes. However, unlike compounds 
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9h, 10h and 11e, compound 7e showed better activity towards DHODH than PARP-1.  
These compounds could then be used to assist in designing other molecules with dual 
inhibition properties towards PARP-1 and DHODH. 
 
 
6.2 Future Work 
 
For the results obtained in the study, compounds 7e, 9h, 10h and 11e indicated dual 
activities towards PARP-1 and DHODH. These compounds could be used as template 
to design other molecules, which may show better activities towards both enzymes.   
 
As discussed, one of the essential groups for activity towards PARP-1 could be the 
C-6 fluorine on the benzimidazole scaffold. It was also observed that a fluorine group at 
this position could interact with the C-7 methyl group of the FMN in the DHODH 
enzyme. So, perhaps, putting fluorine on compounds, such as 7e, 9h and 10h could help 
to increase the activities of these compounds towards DHODH.   
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As for compound 11e, perhaps by substituting the cyclopropane of the 
cyclopropionamide to a isoxazole, a cyano hydroxyl, hydroxamic acid groups and other 
potential functional groups could possibly help to enhance the activities towards both 
PARP-1 and DHODH enzymes.  
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